JPS61268265A - Syringe apparatus - Google Patents
Syringe apparatusInfo
- Publication number
- JPS61268265A JPS61268265A JP61051627A JP5162786A JPS61268265A JP S61268265 A JPS61268265 A JP S61268265A JP 61051627 A JP61051627 A JP 61051627A JP 5162786 A JP5162786 A JP 5162786A JP S61268265 A JPS61268265 A JP S61268265A
- Authority
- JP
- Japan
- Prior art keywords
- injection
- firing pin
- plunger
- injection device
- ampoule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/30—Syringes for injection by jet action, without needle, e.g. for use with replaceable ampoules or carpules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
- A61M5/2053—Media being expelled from injector by pressurised fluid or vacuum
Landscapes
- Health & Medical Sciences (AREA)
- Vascular Medicine (AREA)
- Engineering & Computer Science (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Abstract
(57)【要約】本公報は電子出願前の出願データであるた
め要約のデータは記録されません。(57) [Summary] This bulletin contains application data before electronic filing, so abstract data is not recorded.
Description
【発明の詳細な説明】
（産業上の利用分野）
本発明は皮下注射用の注射装置に係り、より詳細にはプ
ランジャに支持されて往復運動するアンプルと、駆動装
置とを有し、注射針を用いることなく、筋肉内又は皮下
への注射を行うための注射器に関する。DETAILED DESCRIPTION OF THE INVENTION (Industrial Application Field) The present invention relates to an injection device for hypodermic injection, and more specifically, it has an ampoule that is supported by a plunger and moves back and forth, and a drive device, and has an injection needle. This invention relates to a syringe for intramuscular or subcutaneous injection without using a syringe.
（従来技術及び問題点）
現用の注射針を使用しない皮下注射用注射器は、分離さ
れて独立に交換されるアンプルと、炭酸ガスが充填され
たカートリッジを含む駆動装置とを有する。この種の注
射器は米国特許第３，６８８．７６５号（特許権者 ガ
サウェイ（Ｇａｓａｗａｙ ）、１９７２年９月５日付
）に例示されている。この特許で開示された注射器は中
央部に本体を有し、この本体の一方の端部にほぼ円筒形
の空とプランジャとを有し、その一方の端部は他方の端
部に設りられたノズルから離間している。上記プランジ
ャの上記ノズルの反対側の端部にはピストンの端部が隣
接し、このピストンは通路を通って上記本体の反対側の
端部まで延びる。加圧ガスのカートリッジは上記本体の
反対側の端部に取り付けられ破断されるシール部を有し
、このシール部は上記本体の中央部から挿入される。撃
針は、ばねが取り付けられ、このばねの作用で突き出さ
れ、上記炭酸ガスカートリッジに刺突してこのカートリ
ッジの中の高圧の炭酸ガスを円筒部に導くために中空で
あり、この中空部に上記プランジャ駆動型のピストンが
収められる。従って上記ピストンは上記プランジャを上
記ノズルに向けて押し出し、アンプル中の注射液を押し
出す。(Prior Art and Problems) Current needleless hypodermic syringes have an ampoule that can be separated and replaced independently, and a drive device that includes a cartridge filled with carbon dioxide gas. A syringe of this type is illustrated in US Pat. No. 3,688,765 (Gasaway, September 5, 1972). The syringe disclosed in this patent has a central body with a generally cylindrical cavity and a plunger at one end of the body; It is separated from the nozzle. Adjacent to the end of the plunger opposite the nozzle is the end of a piston that extends through the passageway to the opposite end of the body. The pressurized gas cartridge has a breakable seal attached to the opposite end of the body, the seal being inserted through the center of the body. The firing pin has a spring attached to it, is pushed out by the action of the spring, and is hollow in order to pierce the carbon dioxide gas cartridge and guide the high-pressure carbon dioxide gas in the cartridge to the cylindrical portion. Contains a plunger-driven piston. The piston therefore pushes the plunger towards the nozzle and forces out the injection liquid in the ampoule.
このような注射器では、加圧ガスカートリッジと注射液
を入れたアンプルを別々に装填しなければならず、上記
注射器を注射できる状態にするためには上記カートリッ
ジとアンプルを相対的に回転さ・せて、軸線方向に引き
放さなければならない。In such a syringe, a pressurized gas cartridge and an ampoule containing injection liquid must be loaded separately, and the cartridge and ampoule must be rotated relative to each other in order to get the syringe ready for injection. and then pull it away in the axial direction.
さらにプランジャ駆動型ピストンは、注射液を射出させ
る時に、アンプルを変える間、空気にさらされる。それ
故このような注射器を患者に対して使用する時には、患
者その他の医療関係者が行なわなければならない処置が
著しく多い。また、上記注射器ではアンプルがノズル又
はプランジャで汚される危険もある。In addition, the plunger-driven piston is exposed to air during changing ampules when ejecting the injection solution. Therefore, when using such a syringe on a patient, there is a significant number of procedures that must be performed by the patient or other medical personnel. Furthermore, with the syringe described above, there is a risk that the ampoule may be contaminated by the nozzle or plunger.
他のタイプの無針型皮下注射用注射器を米国特許第４，
０８９，３３４号（特許権者 シュウニベル（Ｓｃｈｗ
ｅｂｅｌ ）他）が開示した。この特許の注射器は火薬
を詰めた蓋を使用し、この火薬の爆発生成ガスで注射液
を注射器の一方の端部の注射用の孔から噴射する。この
タイプの注射器には実用上多くの欠点がある。その欠点
のひとつは、患者に危害を及ぼし、又は少なくとも患者
にそのような危険を感じさせるおそれがある点である。Another type of needleless hypodermic syringe is disclosed in U.S. Pat.
No. 089,334 (patent holder: Schw
disclosed by Ebel et al.). The syringe of this patent uses a cap filled with gunpowder, and the gas produced by the explosion of the gunpowder injects the injection solution through an injection hole at one end of the syringe. This type of syringe has many practical drawbacks. One of its disadvantages is that it may pose a risk to the patient, or at least make the patient feel at risk.
このような危険又は危険な感じを与えるので上記注射器
を、人体の組織の柔かい部分、たとえば口部に使用し得
ない場合が多い。その理由は、火薬を詰めた装置を口部
等に使用することを患者がこわがるからである。Because of this danger or sense of danger, such syringes often cannot be used in soft tissue areas of the human body, such as the mouth. The reason for this is that patients are afraid of using devices filled with gunpowder in their mouths.
そこで本発明は、広義には上記すでに提案された従来技
術に基づく注射器の欠点を除去し、制約を解消すること
を目的とする。より詳細には、本発明の目的は次のとお
りである。ツなわら、（１） 駆動力源、プランジャ、
及び注射液アンプルを含むアンプル装置を使用し、この
アンプル装置を１個だけ取り換えるだけで注射できる構
造の無針型皮下注射装置を提供することにより、く２〉
このような注射器を使用するだめの経験又は訓練をほ
とんど有しない者でも操作できる上記注射装置を提供す
ることにあり、
（３） 使用の都度、自動的に再使用できる状態になる
上記注射装置を提供することにあり、（４） ？０数
の構成部材を有するが、この構成部材は適正にかつ充分
に組立てられる限り、操作する必要のない上記注射装置
を提供することにあり、
（５） 使用中の騒音及び注射時の爆発生成ガスの発生
階を最少にすることにより、人体の組織の柔かい部分、
たとえば口部に極めて接近させて使用できる上記注射装
置を提供することにあり、（６） 注射した注射液がで
きるだけ早く血流中に入るように、その注射液を舌部に
注射できる上記注射装置を提供することにあり、
（７） 構造が簡単で、容易かつ安価に製造及び組立て
を行うことができ、従って反′ｇ１使用品としても使い
捨て品としても市販できる上記注（ト）装置を提供する
ことにある。SUMMARY OF THE INVENTION In a broad sense, the present invention aims to eliminate the drawbacks and overcome the limitations of the previously proposed syringes based on the prior art. More specifically, the objectives of the invention are as follows. (1) Driving power source, plunger,
By providing a needleless hypodermic injection device that uses an ampoule device containing an ampoule and an injection solution ampoule and can inject by simply replacing one ampoule device,
The object of the present invention is to provide the above-mentioned injection device that can be operated even by a person who has little experience or training in using such a syringe, and (3) the above-mentioned injection device is automatically ready for reuse each time it is used. (4) ? The object of the present invention is to provide the above-mentioned injection device, which has zero component parts, which do not need to be operated as long as the components are assembled properly and sufficiently; (5) Noise during use and generation of explosion during injection. By minimizing the generation of gas, the soft parts of human body tissue,
For example, the purpose is to provide the above-mentioned injection device that can be used in close proximity to the mouth, and (6) the above-mentioned injection device that can inject the injection solution into the tongue so that the injection solution enters the bloodstream as quickly as possible. (7) To provide the above-mentioned device which has a simple structure, can be easily and inexpensively manufactured and assembled, and can therefore be sold as a disposable product or as a disposable product. It's about doing.
上記目的は、次の圧力作動型皮下注射装置によって達成
される。すなわちこの注）１装置は細長ｌ／１外殻と、
プランジャと、加圧ガスカートリッジと、本体と、アク
チュエータとを含み、上記外殻は、内壁面の所定の長さ
の部分の断面形状が均一であり、一方の端部に隣接する
注射薬噴射孔を有し、上記プランジャは上記外殻の断面
形状が均一な部分の中に摺動できるように装着され、上
記注射液噴射孔からの距離が異なる注射待機位置と注射
済み位置との間を交互に移動し、上記カートリッジは上
記プランジャに装着されてこのプランジャと共に移動す
ると共にガス噴出装置を有し、このガス噴出装置は上記
注射薬噴射孔とは反対の方向を向き、上記本体は上記外
殻の反対側の端部に装着され、上記アクチュエータは上
記本体に取り付けられ、手動操作により上記ガス噴出装
置を作動させて上記プランジャを上記注射待機位置から
注射済み位置の方に駆動する。上記外殻及びプランジャ
は、プランジャが注射待機位置にある時に、注射薬を入
れるアンプル室を形成する。The above objects are achieved by the following pressure actuated hypodermic injection device. In other words, this Note) 1 device has an elongated l/1 outer shell,
The outer shell includes a plunger, a pressurized gas cartridge, a main body, and an actuator, and the outer shell has a uniform cross-sectional shape over a predetermined length of the inner wall surface, and an injection injection hole adjacent to one end. The plunger is slidably mounted in a portion of the outer shell having a uniform cross-sectional shape, and alternately moves between an injection standby position and an injected position having different distances from the injection liquid injection hole. the cartridge is attached to and moves with the plunger and has a gas ejection device, the gas ejection device facing in a direction opposite to the injection injection hole, and the main body is connected to the outer shell. and the actuator is attached to the body and manually actuates the gas ejection device to drive the plunger from the injection standby position toward the injected position. The shell and plunger form an ampoule chamber for receiving the injection drug when the plunger is in the injection ready position.
上記ガス噴出装置は通常、破断すべき部分を含み、上記
アクチュエータは通常、往復運動する撃針を含み、この
撃針の一方の端部が上記破断すべき部分に接触してこれ
を破断し得る形状である。The gas ejection device typically includes a portion to be ruptured, and the actuator typically includes a reciprocating firing pin, one end of which is shaped to contact and rupture the portion to be ruptured. be.
従って上記注射装置は、作動時に、撃針が上記破断ずべ
き部分を破断し、それにより上記ガスが噴出してカート
リッジ及びこのカートリッジに取り付けられたプランジ
ャを上記注射薬噴射孔の方に移動させて、注射器の注射
薬を上記注（ト）薬噴剣孔から患者に注入する。Accordingly, when the injection device is activated, the firing pin breaks the portion that should be broken, thereby causing the gas to blow out and move the cartridge and the plunger attached to the cartridge toward the injection injection hole, Inject the drug from the syringe into the patient through the injection hole mentioned above.
また、上記注射装置は通常、上記撃針の支持と安全解除
とを選択的に行うことにより、注射する時だけ上記撃針
の安全解除を行ない、注射が斉めば上記撃針を次の注射
のために自動的に始動位置に戻して安全装置をかける。In addition, the injection device normally selectively supports and releases the safety of the firing pin, so that the safety of the firing pin is released only when injecting, and once the injections are performed simultaneously, the firing pin is released for the next injection. Automatically returns to the starting position and engages the safety device.
（実施例）
以下、本発明の好ましい実施例を図を用いて詳細に説明
する。各図において、本発明に基づく注射針を使用しな
い皮下シール用の注射装置の全体を符号１０で表わす。(Example) Hereinafter, preferred examples of the present invention will be described in detail with reference to the drawings. In the figures, an injection device for subcutaneous sealing without a needle according to the invention is designated as a whole by 10.
前記注射装置１０は気泡的に本体１２と、この本体に一
部取外しができるように装着できるアンプル装置１４と
、上記本体の外部に装着されて摺動するカラー１６と、
アクチュエータ１８よりなる。アンプル装置１４は外殻
２０を含み、この外１２０は加圧ガスを含むカートリッ
ジ２２を有し、一方の端部にプランジャ２４が装着され
る。プランジャ２４は図の実施例では１．５８８ｍｍ（
１／１６インチ）のＯリング２５を含み、このＯリング
２５は上記プランジャと外殻２０の内壁との間を適当に
シールする。アンプル装置１４の前端部には通常、直径
が約０．０１３ｍｍ（１／２ミル）の孔がある。カート
リッジ２２には通常、［ｉガスを充填するがこの炭酸ガ
スを他のガスに代えることもできる。カートリッジのシ
ール部材２８は破断てきるものであり、通常、ポリウレ
タンその他の適当な素材で作られ、カートリッジ２２を
加圧下でシールする構造であり、このシール部材はアク
チュエータ１８によって破断される。The injection device 10 includes a main body 12 in the form of a bubble, an ampoule device 14 that can be attached to the main body in a partially removable manner, and a collar 16 that is attached to the outside of the main body and slides.
It consists of an actuator 18. Ampoule device 14 includes an outer shell 20 having a cartridge 22 containing pressurized gas and having a plunger 24 mounted at one end. The plunger 24 is 1.588 mm (1.588 mm) in the illustrated embodiment.
1/16 inch) O-ring 25 which provides a suitable seal between the plunger and the inner wall of shell 20. The front end of ampoule device 14 typically has a hole approximately 1/2 mil in diameter. The cartridge 22 is normally filled with [i-gas, but the carbon dioxide gas may be replaced with other gas. The cartridge seal member 28 is rupturable, typically made of polyurethane or other suitable material, and is constructed to seal the cartridge 22 under pressure and is ruptured by the actuator 18.
第１０図に示すように、アンプル装置１４は外殻２０の
後端部の一対の長穴２３の近傍に装着され、この長穴２
３は一対のアンプル装置係合用のビン２７を受け入れ得
る形状であり、このビン２７は本体から延びる。上記注
射装置には、アンプル１４ど本体１２を適当に係合させ
るだけでなく、上記アンプル装置が本体に完全に係合し
ている限り、注射装置１０からの注射薬の漏洩を防ぐ装
置が設けられる。このお射ちを第９図に示す。As shown in FIG. 10, the ampoule device 14 is attached near the pair of elongated holes 23 at the rear end of the outer shell 20.
3 has a shape capable of receiving a pair of bottles 27 for engaging an ampoule device, and the bottles 27 extend from the main body. The injection device is provided with a device that not only properly engages the ampoule 14 with the body 12, but also prevents leakage of the injection drug from the injection device 10 as long as the ampoule device is fully engaged with the body. It will be done. This shot is shown in Figure 9.
この装置はカラーの一対のピン３０を含み、このピン３
０は本体１２に設けられた対応する一対の長穴又は切欠
き部３２を通って内側に延びる。上記外殻２０が押され
て本体１２の中を進むと、まず、アンプル装置係合用の
ビン２７が長穴２３の長手方向に延びる部分２３ａの中
に摺動移動し、次に横断方向の部分２３ｂの中に摺動移
動する。The device includes a pair of pins 30 in the collar;
0 extends inwardly through a pair of corresponding elongated holes or notches 32 provided in the body 12. When the outer shell 20 is pushed and advances through the main body 12, the ampoule device engaging bottle 27 first slides into the longitudinally extending portion 23a of the elongated hole 23, and then the transverse portion. 23b.
アンプル係合用のピン２７が上記横断方向の部分２３ｂ
の端部に接触した時だけ、上記長手方向の部分２３ａが
カラーのピン３０の長手方向と整列する。いかにさらに
詳細に説明するように、カラー１６は、上記整列が行な
われた時だけ、前方に摺動して上記注射装置から注射液
を噴射させることができる。The pin 27 for engaging the ampoule is in the transverse direction portion 23b.
Only when it contacts the end of the collar is the longitudinal portion 23a aligned with the longitudinal direction of the pin 30 of the collar. As will be explained in further detail, the collar 16 can only be slid forward to cause injection fluid to be ejected from the injection device once the alignment has been achieved.
アクチュエータ１８は、往復運動する部分、たとえば、
図に示ず撃針３４を含み、この撃針は前端部にシール部
材に刺突するためのとがった部分３６を有し、中央部に
対称形の環状の溝３８を有し、端部に後向きに設けられ
たばねの座４０を有する。ばねの座４０は撃針支持部材
４２に取り付けられ、この撃針支持部材４２は撃針のば
ね４４を方向づ（プると共にこの撃針のばね４４を支持
する。The actuator 18 has a reciprocating portion, e.g.
It includes a firing pin 34 (not shown) having a pointed portion 36 at its forward end for piercing the seal member, a symmetrical annular groove 38 at its center, and a rearwardly extending groove 38 at its end. It has a spring seat 40 provided therein. The spring seat 40 is attached to a firing pin support member 42 which directs and supports the firing pin spring 44.
第３図乃至第６図に示すように、複数の撃針支持部材す
なわち支持ローラーは、たとえば球４８゜４８・・・よ
り成り、アクチュエータの中で撃針３４に選択的に係合
すると共に環状の溝３８で上記撃針３４の拘束を解除す
る。この球４８は、アクチュエータのスリーブ５０によ
って長手方向すなわち軸線方向に保持され、この支持ロ
ーラーの何かに撃針３４が摺動できるように取り付けら
れる。As shown in FIGS. 3 through 6, a plurality of firing pin support members or support rollers are formed, for example, of balls 48, 48, etc., which selectively engage the firing pin 34 in the actuator and have an annular groove. At step 38, the firing pin 34 is released. The ball 48 is held longitudinally or axially by an actuator sleeve 50, to which the firing pin 34 is slidably mounted.
この球４８は支持部材（その全体を符号５２で表わす）
によって撃針３４に対向するように保持される。この球
支持部材５２を、水明ｌｉｔ書では内側壁という。この
内側壁５２には狭いレース５４及び広いレース５６を有
し、狭いレース５４は、球４８を環状の溝３８の中に接
触させながら保持する寸法である。幅の広いレース５６
は球４８を、撃針３４の残余の部分とこのレースとの間
に保ち得る寸法である。This ball 48 is a support member (the entirety is represented by the reference numeral 52).
It is held opposite the firing pin 34 by. This ball support member 52 is called an inner wall in the Suimei lit book. The inner wall 52 has a narrow race 54 and a wide race 56 sized to retain the ball 48 in contact with the annular groove 38 . wide lace 56
is sized to keep ball 48 between the remainder of firing pin 34 and this race.
図に示す実施例では、撃針の環状溝３８はこれを取り囲
む壁を含み、この壁は球４８の外周に対応する形状であ
る。この形状は、実施例によっては上記法の形状に充分
合う限り先細りの形であっても差し支えない。それ故、
球４８が環状溝３８に係合し、狭いレース５４によって
この環状溝の中に保持される時には、撃針３４は外殻２
０の内部圧力の作用を受けても、又は撃針のばね４４に
押されても、軸線方向に動かない。幅の広いレース５６
が球４８に隣接する位置にある時には、撃針４４が偏位
して球４８を環状溝３８の外に押すので、撃針３４が軸
線方向にアンプル装置１４に向けて前進する。In the illustrated embodiment, firing pin annular groove 38 includes a surrounding wall that is shaped to correspond to the outer circumference of ball 48 . Depending on the embodiment, this shape may be tapered as long as it is sufficiently compatible with the shape of the method described above. Therefore,
When the ball 48 engages the annular groove 38 and is retained therein by the narrow race 54, the firing pin 34 is inserted into the outer shell 2.
It does not move axially when subjected to zero internal pressure or when pushed by the firing pin spring 44. wide lace 56
When is in position adjacent ball 48, firing pin 44 is deflected and forces ball 48 out of annular groove 38, thereby advancing firing pin 34 axially toward ampoule device 14.
球支持部材５２は球支持ばね５８によって接方に偏移さ
れ、この球支持ばねはアクチュエータ５０の環状溝６０
の中にある。上記球支持部材５２の後端部は一対の差込
みビン６２に接触し、この差込みビン６２は！！！動す
るカラー１６から内側に延びる。差込みビン６２の後端
部に対向するように内側のばね６４があり、摺動するカ
ラー１６は上記内側のばね６４によって前方に押される
と共に球支持ばね５８によって後方に押される。The ball support member 52 is tangentially biased by a ball support spring 58 which is in contact with the annular groove 60 of the actuator 50.
It's inside. The rear end of the ball support member 52 contacts a pair of insert pins 62, and the insert pins 62! ! ! Extending inwardly from the movable collar 16. Opposed to the rear end of the insert pin 62 is an inner spring 64, and the sliding collar 16 is pushed forward by the inner spring 64 and rearward by the ball support spring 58.
球支持部材５２が第３図乃至第５図に示す位置にある時
には、球支持ばね５８の力は内側のばね６４の力より大
きくなる。この理由についてさらに説明する。When ball support member 52 is in the position shown in FIGS. 3-5, the force of ball support spring 58 is greater than the force of inner spring 64. The reason for this will be further explained.
ブリード孔７０は本体１２を貴き、アンプル装置１４を
本体１２に適当に係合するような位置にあり、第３図乃
至第６図に示すように長穴２３に整合する。安全のため
にディテントの長穴７６゜７６を第８図及び第９図に示
す。この対向する一対の長穴７６は、第８図及び第９図
には１個のみ記載したが、実際には上記２個の差込みビ
ン６２を受け入れ得るように設けられる。第３図乃至第
９図に示すように、長穴７６は撃針の安全解除装ｆｆ１
８０及び手動アーミング部８２を含み、上記安゛全解除
装置８０はアクチュエータ１８に上記注射器から注射液
を押し出す作用をさけ、手動アーミング装置１８は、上
記注射液押出し前に、上記アクチュエータを始動位置に
保持する。中央に設けられたディテント部８４はカラー
１６が偶発的に回転するのを防止する。これは球支持ば
ね５８の力が内側のばね６４の力より強いので、差込み
ビン６２を各ディテント部８４に保持するためである。Bleed hole 70 is positioned to open body 12 and properly engage ampoule device 14 therein, and is aligned with slot 23 as shown in FIGS. 3-6. For safety purposes, the elongated holes 76° 76 in the detent are shown in FIGS. 8 and 9. Although only one pair of long holes 76 facing each other is shown in FIGS. 8 and 9, they are actually provided so as to be able to receive the two insertion bottles 62. As shown in FIGS. 3 to 9, the elongated hole 76 is the firing pin safety release device ff1.
80 and a manual arming portion 82, the safety release device 80 prevents the actuator 18 from forcing the injection solution out of the syringe, and the manual arming device 18 moves the actuator to the starting position before extruding the injection solution. Hold. A centrally located detent 84 prevents accidental rotation of the collar 16. This is because the force of the ball support spring 58 is stronger than the force of the inner spring 64, so that the insert bottle 62 is held in each detent portion 84.
以上説明した注射装置は作用は次のとおりである。The operation of the injection device described above is as follows.
上記注射装置を使用するためには、先ずアクチュエータ
１８を始動位置に保持する。この動作は、通常、前回の
注射の直後に自動的に行なわれるが、手動で行うことも
できる。この手動操作を行う場合には、カラー１６を少
し回転させて後に引く。To use the injection device, first the actuator 18 is held in the starting position. This action is usually performed automatically immediately after the previous injection, but can also be performed manually. When performing this manual operation, the collar 16 is slightly rotated and pulled back.
この後退は、差込みビン６２が安全用のディテント長穴
７６のアーミング装置８２を完全に通過するまで行なう
。差込みビン６２がカラー１６と共に後退すると、この
差込みビンとカラーが撃針のばね４２の下側に接触し、
これによって撃針３４が第３図に示す始動位置まで後退
する。This retraction is performed until the insert pin 62 completely passes through the arming device 82 of the safety detent elongated hole 76. When the bayonet pin 62 is retracted with the collar 16, the bayonet and collar contact the underside of the firing pin spring 42;
This causes the firing pin 34 to retract to the starting position shown in FIG.
アクチュエータ１８が始動位置まで完全に移動すると、
前回の注射に使用されて空になったアンプル装置１４（
もしあれば）が取り除かれ、アンプル装置を交換する装
置が注射薬の入っている新しいアンプル装置を装填し、
シール部材と、ガスを充填した７Ｊ −ｔ−リッジ２２
とを上記位置に取り付ける。この作動は外殻２０を本体
１２に挿入するだけで完了し、この動作によってアンプ
ル装置係合ビン２７が長穴２３の長手方向に延びる部分
２３ａを貫いて摺動する。次に外殻２ｏが第９図に示す
位置まで回転し、この位置でアンプル装置係合ビン２７
が横断方向部分２３ｂの端部に接触する。第９図に示す
ように、この位置で外殻２゜がカラーのビン３０を長手
方向の部分２３ａに整列させるので、カラーは自由に前
進して注射装置から注射薬を噴出させることができる。Once the actuator 18 has fully moved to the starting position,
Ampoule device 14 (empty from the previous injection)
) is removed, the device for replacing the ampoule device loads a new ampoule device containing the injection drug, and
7J-t-ridge 22 filled with sealing member and gas
Attach it to the above position. This operation is completed by simply inserting the outer shell 20 into the main body 12, which causes the ampoule device engaging pin 27 to slide through the longitudinally extending portion 23a of the elongated hole 23. Next, the outer shell 2o is rotated to the position shown in FIG.
contacts the end of the transverse portion 23b. In this position, the outer shell 2° aligns the collar bottle 30 with the longitudinal portion 23a, as shown in FIG. 9, so that the collar is free to advance and eject the injection from the injection device.
外殻２０が何等かの原因で回転せず、固定された侭であ
る場合には、上記整列は行なわれない。If the outer shell 20 does not rotate for some reason and remains fixed, the above alignment will not be performed.
上記注射装置を用いて注射を行なう時には、この注射装
置を患者の皮膚に直接当てる。図に示す注射装置は、患
者の舌に対して注射を行なう場合に特に有用であり効果
的である。従来の無針型注射器は通常、患者の口部に注
射するためには余りにも大型であり、操作が極めて難し
く、また余りにも人世の爆発の廃棄を患者の口の中に排
出する。When performing an injection using the injection device, the injection device is directly applied to the patient's skin. The illustrated injection device is particularly useful and effective when injecting into a patient's tongue. Conventional needleless syringes are usually too large and difficult to operate for injection into the patient's mouth, and eject too much explosive waste into the patient's mouth.
そのために患者は注射時に非常に苦痛を覚えるので舌を
動かし易く、そのために舌に裂傷を与える危険がある。This causes the patient to experience great pain during the injection, making it easy to move the tongue, thereby risking lacerations to the tongue.
舌の血管の性質から見て、上記裂傷は極めて危険である
。舌に血管が細かく分布しているということは、舌に直
接注射するという観点からすれば極めて有利である。注
ＯＡ後何秒も経たないうちに注射液を血流中に入れるこ
とができ、このことは多くの場合、極めて重要である。Given the nature of the blood vessels in the tongue, such lacerations are extremely dangerous. The fine distribution of blood vessels in the tongue is extremely advantageous from the standpoint of direct injection into the tongue. Injection fluid can enter the bloodstream within seconds after injection OA, which is often critical.
第３図に注射準備完了状態の注射装置を示す。FIG. 3 shows the injection device ready for injection.
この状態では、支持部材５２の狭いレース５４は球４８
を撃針３４の環状溝３８の中に保持する。In this condition, the narrow race 54 of the support member 52 is connected to the ball 48.
is retained in the annular groove 38 of the firing pin 34.
この状態では、撃針３４は撃針のばね４４が偏位しても
前に送り出されない。In this condition, the firing pin 34 will not be advanced even if the firing pin spring 44 is deflected.
上記注射装置で注射を行なうためには、カラー１６を少
し前に漬らせて差込みビン７８を撃針始動装置８０の端
部に向番プる。この時にも、アンプル装置１４が完全に
所定の位置に入らず、長穴２３の長手方向の部分２３ａ
がカラーのビン３０に整列しない限り、上記カラー１６
を前進させることができない、カラー１６を前進させる
と、支持部材５２は球支持はね５８に押されて前進し、
支持部材５２の幅の広いレース５６を球４８に隣接さｌ
る。撃針のばね４４は偏位して球４８を環状１１ｆｆ３
８から半径方向外側に、幅の広いレース５６に接触する
まで移動させ、これによって拘束を解かれた撃針３４は
撃針のばね４４の作用で軸線方向に８動する。この状態
で撃針３４の前端部の突出部３２は、第４図に示すよう
に、＊酸ガスカートリッジ２２の後端部のシール２８を
刺突してこれを破る。To perform an injection with the injection device, the collar 16 is slightly dipped and the insert bottle 78 is inserted into the end of the firing pin starter 80. At this time as well, the ampoule device 14 does not completely enter the predetermined position, and the longitudinal portion 23a of the elongated hole 23
unless the color 16 is aligned with the color's bin 30.
When the collar 16 is advanced, the support member 52 is pushed forward by the ball support spring 58,
The wide race 56 of the support member 52 is placed adjacent the ball 48.
Ru. The firing pin spring 44 deflects the ball 48 into an annular shape 11ff3.
The firing pin 34 is moved radially outwardly from 8 until it contacts the wide race 56, thereby causing the unrestrained firing pin 34 to move axially 8 under the action of the firing pin spring 44. In this state, the protrusion 32 at the front end of the firing pin 34 pierces and breaks the seal 28 at the rear end of the acid gas cartridge 22, as shown in FIG.
カートリッジ２２の中の加圧ガスは後方に自由に吹ぎ出
すので、上記カートリッジ２２及びプランジャ２４はい
わゆる「注射待機」の位置から前に押し出され、その力
で注射液の全量が注射孔２６から押し出されで注射され
、プランジｐ２４は第５図に示すようにシェル２０の＠
前端部に来る。この時点でカートリッジ２２及びプラン
ジャ２４は、いわゆる「注射済み」の状態になる。この
位置にあるプランジャ２４によって、シェル２０の内部
圧力は約２８ 、１２Ｋｇ／ｃｍ （約４００ｐｓｉ
）である。この値はカートリッジ２２の圧力が約５６．
２５ｆ（ｇ／ｃｊ ＜約８００ｐｓｉ）の場合の値であ
る。次に上記２８ 、１２Ｋｇ／ｃｍ （約４００ｐｓ
ｉ ）の圧ツノはカートリッジのシール部材２８に加わ
り、撃針のばね４４の作用に逆らっで撃針３４を後退さ
せる。このばね４４の力は注射液が注射薬噴射孔２６か
ら噴出する時の抵抗力より大ぎいので、この注射薬が噴
射されている間、カートリッジのシール部材２８は固定
された侭でいる。Since the pressurized gas in the cartridge 22 is freely blown out backwards, the cartridge 22 and the plunger 24 are pushed forward from the so-called "injection standby" position, and this force causes the entire amount of the injection solution to be released from the injection hole 26. Injected by extrusion, the plunge p24 is inserted into the shell 20 as shown in FIG.
Come to the front end. At this point, cartridge 22 and plunger 24 are in a so-called "injected" state. With plunger 24 in this position, the internal pressure of shell 20 is approximately 28,12 kg/cm (approximately 400 psi).
). This value indicates that the pressure of the cartridge 22 is approximately 56.
This value is for 25f (g/cj < about 800psi). Next, the above 28, 12Kg/cm (approximately 400ps
The pressure point of i) applies to the sealing member 28 of the cartridge and retracts the firing pin 34 against the action of the firing pin spring 44. Since the force of this spring 44 is greater than the resistance force when the injection solution is ejected from the injection injection hole 26, the sealing member 28 of the cartridge remains fixed while the injection solution is being ejected.
しかしながら上記力は、プランジャ２４がその注射待機
位置から第５図に示す位置まで移動した後は、撃針を所
定の位置に保持するのに必要な力よりはやや弱くなる。However, this force is somewhat less than that required to hold the firing pin in place after plunger 24 has moved from its injection standby position to the position shown in FIG.
従って、カートリッジのシール２８に加えられる上記２
８．１２７（ｇ／ｃｉ（約４００ｐｓｉ）の作用で撃針
が第６図に示す位置まで押し戻され、アクチュエータ１
８が自動的に始動位置に来る。カートリッジのシール部
材２８が撃針のばね４４に邪魔されてすぐに移動しない
時には、注射装＠１０を患者の体から放すまで、通常、
上記カートリッジのシール部材を完全に移動させない。Therefore, the above-mentioned two added to the seal 28 of the cartridge
8.127 (g/ci (approximately 400 psi)) pushes the firing pin back to the position shown in Figure 6, and actuator 1
8 automatically comes to the starting position. If the cartridge sealing member 28 is blocked by the firing pin spring 44 and does not move immediately, it will normally remain closed until the injection device 10 is released from the patient's body.
Do not completely move the seal member of the cartridge.
撃針３４が撃発位置に戻されれば、外殻２０の高圧ガス
は外殻２０の長穴２３及び本体１２のブリード穴７０を
通りまた、カラー１６と本体１２との間に形成される間
隙を通って妨げられることなく大気中に散逸する。When the firing pin 34 is returned to the firing position, the high pressure gas in the outer shell 20 passes through the elongated hole 23 in the outer shell 20 and the bleed hole 70 in the body 12, and also through the gap formed between the collar 16 and the body 12. and dissipate unhindered into the atmosphere.
このようにして上記注射装置は自動的に次の注射のため
の始動状態になる。次にアンプル装置１４を取り出し、
次の注射に使用する新しいカートリッジ及び新しく注射
薬を入れたアンプル装置を装填する。In this way, the injection device is automatically activated for the next injection. Next, take out the ampoule device 14,
Load a new cartridge for the next injection and an ampoule device containing a fresh injection.
以上、本発明を好ましい実施例によって詳細に説明した
が、他の形態への変更及び細部の変更は本願特許請求の
範囲に含まれるものである。Although the present invention has been described above in detail with reference to preferred embodiments, modifications to other forms and changes in details are included within the scope of the claims of the present application.
第１図は本発明に基くアンプル装置を含む皮下注射装置
の側部立面斜視図、第２図は第１図の注射装置の右側部
端面図、第３図は第２図の注射装置の注射待機位置にあ
る時の線３−６に沿う側面断面図、第４図は上記注射装
置が作動開始直後、カー１−リッジの破断される部分に
撃針が刺突され、このカートリッジからガスが噴出する
前の状態における上記注射装置の第３図の線３−６に沿
う側面断面図、第５図はカートリッジからガスが噴出し
、カートリッジ及びプランジＶが注射済み位置の移動し
た直後の状態にあることを除けば第３図及び第４図と同
じである注射装置の第２図の線３−６に沿う側両立面断
面図、第６図は第３図乃至第５図に対応し、カートリッ
ジ及びプランジャが注射済み位置まで移動し、アンプル
装置に入った上記ガスが撃針をその初期位置まで移動さ
せて始動待機状態にしたことだけが異なる注射装置の第
２図の線３−６に沿う側両立面断面図、第７図は上記注
射装置を９０°回転させた状態の、第６図の線７−７に
沿う立面図、第８図はディテント式安全機構の一部破断
部分断面図、第９図は上記注ｒＪＪ装置の一部破断側両
立面図、第１０図は第９図の注射装置のアンプル装置の
側面立面図である。
１０・・・注射装置、１２・・・本体、１４・・・アン
プル装置、１６・・・カラー、２０・・・外殻、２２・
・・カー１−リッジ、２４・・・プランジャ、２５・・
・０リング、２６・・・注射液噴射孔、２７・・・アン
プル装置係合ピン、２８・・・アクチュエータ、３４・
・・撃針、３６・・・突出部、３８・・・満、４４・・
・撃針駆動ばね、４８・・・球、５２・・・支持部材、
５４．５６・・・レース、６２・・・差込みピン、７０
・・・逃気孔、７６・・・長穴、８０・・・安全解除装
置、８２・・・手動アーミング部、８４・・・ディテン
ト部。
出願人代理人 佐 藤 −雄
手続補 正 書 （方式）
昭和６１年６月７２日
特許庁長官 宇 賀 道 部 殿
１４事件の表示
昭和６１年 特許願 第５１６２７号
２、発明の名称
注射装置
３、補正をする者
事件との関係 特許出願人
バイオジエクト、インコーホレーテッド４、代 理 人
（郵便番号１００）
昭和６１年５月７日
（発送日 昭和６１年５月２７日）
６、補正の対象
図面（第７図）
７、補正の内容
ＦＩＧ ？1 is a side elevational perspective view of a hypodermic injection device including an ampoule device according to the present invention, FIG. 2 is a right side end view of the injection device of FIG. 1, and FIG. 3 is a side elevational view of the injection device of FIG. FIG. 4 is a side cross-sectional view taken along line 3-6 when the injection device is in the injection standby position. Immediately after the injection device starts operating, the firing pin is pierced into the broken part of the cartridge 1-ridge, and gas is discharged from the cartridge. A side sectional view taken along line 3-6 in FIG. 3 of the injection device in the state before ejection, and FIG. 5 shows the state immediately after gas has ejected from the cartridge and the cartridge and plunge V have moved to the injected position. FIG. 6 corresponds to FIGS. 3-5; The injection device is along line 3-6 of FIG. 2, the only difference being that the cartridge and plunger have moved to the injected position and said gases entering the ampoule device have moved the firing pin to its initial position and ready to start. 7 is an elevational view taken along line 7-7 in FIG. 6 with the injection device rotated 90 degrees; FIG. 8 is a partially cutaway cross-section of the detent-type safety mechanism. 9 is a partially cut-away side elevational view of the injection device described above, and FIG. 10 is a side elevational view of the ampoule device of the injection device of FIG. 9. DESCRIPTION OF SYMBOLS 10... Injection device, 12... Main body, 14... Ampoule device, 16... Collar, 20... Outer shell, 22...
...Car 1-ridge, 24...plunger, 25...
・0 ring, 26... injection liquid injection hole, 27... ampoule device engagement pin, 28... actuator, 34...
... firing pin, 36... protrusion, 38... full, 44...
- Firing pin drive spring, 48... ball, 52... support member,
54.56...lace, 62...insertion pin, 70
...Breath hole, 76...Elongated hole, 80...Safety release device, 82...Manual arming part, 84...Detent part. Applicant's agent: Sato-Oo procedural amendment (formality) June 72, 1985 Director General of the Patent Office Michibe Uga 14 Indication of case 1986 Patent application No. 51627 2, title of invention Injection device 3 , Relationship with the case of the person making the amendment Patent applicant Biogeect, Incorporated 4, Agent (zip code 100) May 7, 1985 (Shipping date: May 27, 1986) 6. Amendment Target drawing (Figure 7) 7. Contents of correction FIG?
Claims (1)
注射薬を噴出させ得る交換可能のアンプル装置とを含み
、皮下注射に使用され、圧力で作動する注射装置におい
て、上記注射装置は細長い外殻を有し、この外殻は内壁
面がこの外殻の所定の長さの部分に沿つてほぼ同一の断
面形状を有し、上記外殻は前端部に隣接する注射薬噴射
孔を有し、上記注射装置はプランジャを有し、このプラ
ンジャは上記外殻の上記所定の長さの部分の中に摺動で
きるようにシール装着され、上記注射薬噴射孔から後方
に或る距離離れた注射待機位置と上記注射待機位置より
も前方にあり上記注射薬噴射孔に近い位置にある注射済
み位置との間を移動することができ、上記外殻及びプラ
ンジャはこのプランジャが上記注射待機位置にある時に
アンプル室を形成し、このアンプル室は注射液を入れる
ことができ、上記注射装置は圧縮ガスを充填したカート
リッジを有し、このカートリッジは上記アクチュエータ
が作動した時に上記プランジャを上記注射待機位置から
上記注射済み位置まで移動させることを特徴とする注射
装置。 ２、上記アンプル装置のカートリッジは、上記アクチュ
エータが作動した時に、上記カートリッジに充填されて
いるガスを後方に噴出させる装置を含むことを特徴とす
る特許請求の範囲第１項に記載の注射装置。 ３、上記カートリッジは破断される部材を有し、この部
材は上記アクチュエータの作動によつて破断されること
を特徴とする特許請求の範囲第２項に記載の注射装置。 ４、上記カートリッジは上記外殻の中の上記プランジャ
に装着され、上記プランジャと共に、上記注射待機位置
と上記注射済み位置との間を摺動することを特徴とする
特許請求の範囲第２項に記載の注射装置。 ５、上記注射装置に回転できるように取り付けられた装
置と、上記アンプル装置が上記注射装置の中で回転され
ない限り上記アクチュエータの作動及び上記プランジャ
の移動を防止する安全装置とを有し、この安全装置は長
手方向に延びる凹部を有し、この凹部は上記注射装置の
作動時に上記アクチュエータの上記おブラケット凹凸相
補う形の延長部を受け入れるために上記外殻に設けられ
、上記凹部は上記アンプル装置が上記注射装置の中で回
転されない時だけ上記凹部が回転して上記延長部材と整
列することを特徴とする特許請求の範囲第１項に記載の
注射装置。 ６、皮下注射に使用される圧力作動方式の注射装置にお
いて、上記注射装置は細長い外殻を有し、この外殻はそ
の所定の長さの部分に沿つて内壁面の断面形状がほぼ同
一であり、上記外殻は一方の端部に隣接する注射薬噴射
孔を有し、上記注射装置はプランジャを有し、このプラ
ンジャは上記外殻の上記所定の長さの部分の中に摺動で
きるようにシール装着され、上記注射薬噴射孔から或る
距離離れている注射待機位置から、上記注射待機位置よ
りも上記注射液噴射孔に近い注射済み位置まで移動する
ことができ、上記外殻及びプランジャは、上記プランジ
ャが上記注射待機位置にある時にアンプル室を形成し、
このアンプル室は注射薬を入れることができ、上記注射
装置は加圧ガスのカートリッジを有し、このカートリッ
ジは上記プランジャと共に移動できるようにこのプラン
ジャに取り付けられ、上記注射薬噴射孔とは反対の方向
を向くガス噴出装置を有し、上記注射装置は本体を有し
、この本体は上記外殻の他方の端部に着脱できるように
シール装着され、上記注射装置はアクチュエータを有し
、このアクチュエータは上記本体に取り付けられ、手動
操作により上記ガス噴出装置を作動させて上記プランジ
ャを上記注射待機位置から注射済み位置まで移動させる
ことを特徴とする注射装置。 ７、上記アクチュエータは往復運動する部分を含み、こ
の部分は後退した位置を延長した位置との間を移動し得
ることを特徴とする特許請求の範囲第６項に記載の注射
装置。 ８、上記往復運動する部分は往復運動する撃針を含み、
この撃針の一方の端部は上記ガス噴出装置に対面し、上
記がはが上記延長部まで移動した時に上記ガス噴出装置
に接触することを特徴とする特許請求の範囲第７項に記
載の注射装置。 ９、上記ガス噴出装置は破断される部分を有し、上記往
復運動する撃針の上記一方の上記破断される部分に接触
してこれを破断することを特徴とする特許請求の範囲第
８項に記載の注射装置。 １０、上記撃針は環状の溝を有し、上記アクチュエータ
は複数の支持ローラーを含み、この支持ローラーは上記
撃針の環状の溝の中に選択的に係合し、この環状の溝は
上記支持ローラーを上記環状の溝に選択的に係合保持さ
せるための狭いレース及び幅の広いレースに対面する内
面を有し、この内面が上記各支持ローラーを上記環状の
溝の外に出るように移動させて保持し、次に上記撃針を
安全解除することができることを特徴とする特許請求の
範囲第８項に記載の注射装置。 １１、皮下注射に使用される注射装置において、上記注
射装置は圧力により作動し、アンプル装置を有し、この
アンプル装置は細長い外殻を有し、この外殻の壁は内部
に室を形成すると共にこの壁の一方の端部に隣接する注
射薬噴射孔を有し、上記注射装置はプランジャを有し、
このプランジャは上記室の中に設けられ、上記注射薬噴
射孔から或る距離離間した注射待機位置と上記注射待機
位置よりも上記注射薬噴射孔に近い注射済み位置との間
で摺動できるようにシール装着され、上記注射装置は加
圧ガスカートリッジを有し、このカートリッジは上記外
殻の中に摺動できるように取り付けられると共に、上記
プランジャの上記注射薬噴射孔とは反対の側に固定され
、上記カートリッジは上記注射薬噴射孔の反対の側に破
断されるシール部材を有し、このシール部材は上記外殻
の上記他方の端部から挿入することができ、上記注射装
置は細長い本体を有し、この本体の一方の端部は上記ア
ンプル装置の上記外殻の他方の端部に取外しできるよう
にシールされ固定されて結合し、上記本体は細長い通路
を有し、この通路は上記カートリッジのシール部材に隣
接して開口し、上記注射装置は撃針を有し、この撃針は
上記通路の中に設けられ、この撃針のシール部材破断用
の端部は上記通路の一方の開口部に隣接するように配置
され、上記撃針は上記アンプル装置が上記プランジャと
共に上記本体部に取り付けられて注射待機位置にある時
に、上記シール部材から離れた始動可能位置から射出位
置まで移動して上記撃針の上記一方の端部が上記シール
部材を貫くように延び、上記注射装置は撃針を偏位させ
る装置を有し、この撃針偏位装置は上記本体に取り付け
られ、上記撃針を上記始動可能位置から上記射出位置の
方に押されるように上記撃針に取り付けられ、上記注射
装置は上記撃針を上記始動可能位置に位置させるための
アーミング装置と、上記撃針を上記始動可能位置に支持
するため及び上記撃針を上記射出位置の方に選択的に送
り出すための引金装置とを有することを特徴とする注射
装置。 １２、上記本体は軸線方向に移動する内面部を有し、上
記引金装置は上記撃針に形成された環状の溝と、複数の
撃針支持部材とを有し、この撃針支持部材は上記撃針の
環状の溝の中に選択的に係合できるように位置及び寸法
が決められ、上記撃針支持部材は上記本体の内面部に接
触し、上記本体の内面部は上記撃針支持部材を上記環状
の溝の中に係合するように保持するための狭いレースと
、上記撃針支持部材を上記環状の溝から移動させるため
の幅の広いレースとを有し、上記注射装置は上記撃針支
持部材の軸線方向の移動を防止する装置を有し、この装
置によつて上記撃針は上記撃針支持部材が上記環状の溝
に係合している時に上記始動可能位置からの移動が防止
されると共に、上記撃針支持部材が上記撃針を安全解除
した時に上記撃針が上記射出位置の方に移動できるよう
になることを特徴とする特許請求の範囲第１１項に記載
の注射装置。 １３、上記環状の溝は中央部が細く上記撃針支持部材に
傾斜接合する面を有し、この傾斜接合面は、上記撃針支
持部材が上記狭いレースによつて上記環状の溝に係合保
持されない時に、上記ばねの作用で上記撃針支持部材を
上記傾斜接合面に沿つて、上記撃針が上記射出位置の方
に自由に移動できるようになるまで、外側に向けて移動
させることを特徴とする特許請求の範囲第１２項に記載
の注射装置。 １４、上記撃針支持部材はほぼ球形のロー ラーを有することを特徴とする特許請求の範囲第１３項
に記載の注射装置。 １５、上記幅の広いレースは上記アンプル装置から上記
狭いレースより離れた位置に設けられて上記レースを上
記アンプル装置から遠ざけるように押し出すレース偏位
装置を有し、上記アーミング装置はカラーを含み、この
カラーは上記本体に摺動できるように取り付けられ、こ
のカラーは上記本体の内面部に接触してこの内面部が上
記レース偏位装置の押圧作用に抗して移動できるように
し、これにより上記撃針支持部材の作動を制御できるよ
うにすることを特徴とする特許請求の範囲第１４項に記
載の注射装置。 １６、上記撃針は上記撃針が上記始動可能位置にある時
に上記破断されるシール部に係合するための装置を含み
、上記撃針偏位位置は上記撃針を上記始動可能位置の方
に押し、この撃針を押す力は上記外殻の中で上記シール
部が破断され上記プランジャが上記注射済み位置に移さ
れた後の力より小さく、そのために上記プランジャが上
記注射済み位置まで移動された後に、上記破断されるシ
ール部及び撃針が上記始動可能位置の方に駆動され、上
記引金は上記撃針が上記始動可能位置まで駆動された後
に上記撃針に再係合するための装置を含むことを特徴と
する特許請求の範囲第１１項に記載の注射装置。 １７、上記撃針を再係合させる装置は上記撃針支持部材
を有することを特徴とする特許請求の範囲第１６項に記
載の注射装置。 １８、患者の舌部に注射薬を注射するために圧力で作動
し、注射針のない皮下注射用の注射装置において、上記
注射装置は注射薬を噴出させるアンプル装置を有し、こ
のアンプル装置は細長い外殻を有し、この外殻は前端部
に隣接する注射薬噴射孔を有し、上記注射装置はプラン
ジャを有し、このプランジャは上記外殻の中にシールさ
れ摺動できるように装着され、このプランジャは上記注
射薬噴射孔から或る距離離間した注射待機位置と、この
注射待機位置よりも上記注射薬噴射孔に近い注射済み位
置との間で移動することができ、上記外殻とプランジャ
はこのプランジャが上記注射待機位置にある時にアンプ
ル室を形成し、このアンプル室は注射薬を入れることが
でき、上記注射装置はプランジャ駆動装置を有し、この
プランジャ駆動装置は上記プランジャと協働して上記プ
ランジャを上記注射待機位置から上記注射済み位置の方
に駆動し、上記注射装置は上記アンプル装置を手動で患
者の舌部に接触させるための手動操作装置を有し、この
手動操作装置は上記アンプル装置に取り付けられて上記
プランジャを上記注射待機位置から上記注射済み位置の
方に駆動するように上記プランジャ駆動装置を選択的に
作動させる作用をすることができることを特徴とする注
射装置。 １９、上記プランジャ駆動装置は圧縮ガスを充填したカ
ートリッジを有し、上記注射装置のアクチュエータを作
動させた時にその影響を受けて上記プランジャを上記注
射待機位置から注射済み位置の方に駆動することを特徴
とする特許請求の範囲第１８項に記載の注射装置。[Claims] 1. A main body, an actuator attached to the main body,
and a replaceable ampoule device capable of ejecting an injectable drug, the injection device is used for subcutaneous injection and is pressure-actuated, the injection device having an elongated outer shell, the outer shell having an inner wall surface that is in contact with the outer shell. having a substantially uniform cross-sectional shape along a predetermined length of the shell, the shell having a syringe injection aperture adjacent a forward end, the injection device having a plunger, the plunger having a substantially uniform cross-sectional shape along a predetermined length of the shell; an injection standby position which is slidably sealed within the predetermined length of the shell and which is a certain distance rearwardly from the injection injection hole; and an injection standby position which is forward of the injection standby position; The shell and the plunger are movable between an injection position proximate to the injection hole, and the shell and the plunger form an ampoule chamber when the plunger is in the injection standby position, and the ampoule chamber contains the injection liquid. The injection device is characterized in that the injection device has a cartridge filled with compressed gas, and the cartridge moves the plunger from the injection standby position to the injection completed position when the actuator is actuated. 2. The injection device according to claim 1, wherein the cartridge of the ampoule device includes a device that blows out the gas filled in the cartridge backward when the actuator is activated. 3. The injection device according to claim 2, wherein the cartridge has a breakable member, and this member is broken by the actuation of the actuator. 4. The cartridge is attached to the plunger in the outer shell and slides together with the plunger between the injection standby position and the injection completed position. Injection device as described. 5. a device rotatably attached to the injection device; a safety device for preventing actuation of the actuator and movement of the plunger unless the ampoule device is rotated within the injection device; The device has a longitudinally extending recess provided in the shell for receiving a complementary extension of the bracket of the actuator during actuation of the injection device; 2. The injection device of claim 1, wherein the recess rotates into alignment with the extension member only when the injection device is not rotated within the injection device. 6. In a pressure-operated injection device used for subcutaneous injection, the injection device has an elongated outer shell, and the inner wall surface of the outer shell has a substantially uniform cross-sectional shape along a predetermined length of the outer shell. and the outer shell has a syringe injection hole adjacent one end, and the injection device has a plunger that is slidable within the predetermined length of the outer shell. The outer shell and a plunger forming an ampoule chamber when the plunger is in the injection standby position;
The ampoule chamber is capable of containing an injection drug, and the injection device has a cartridge of pressurized gas, the cartridge being mounted on the plunger for movement therewith and opposite the injection hole. the injection device has a body removably seal-mounted to the other end of the shell; the injection device has an actuator; the injection device has an actuator; is attached to the main body, and the gas ejecting device is operated by manual operation to move the plunger from the injection standby position to the injection completed position. 7. The injection device according to claim 6, wherein the actuator includes a reciprocating portion, which portion is movable between a retracted position and an extended position. 8. The reciprocating part includes a reciprocating firing pin,
An injection according to claim 7, wherein one end of the firing pin faces the gas ejection device and contacts the gas ejection device when the firing pin moves to the extension. Device. 9. According to claim 8, the gas ejecting device has a breakable portion, and the gas ejection device contacts and breaks the breakable portion of one of the reciprocating firing pins. Injection device as described. 10. The firing pin has an annular groove, the actuator includes a plurality of support rollers that selectively engage within the annular groove of the firing pin, and the annular groove is in contact with the support roller. an inner surface facing the narrow race and the wide race for selectively engaging and holding the support rollers in the annular groove; 9. The injection device of claim 8, wherein the firing pin can then be released. 11. An injection device used for hypodermic injection, said injection device being actuated by pressure and having an ampoule device, said ampoule device having an elongated outer shell, the walls of said outer shell forming a chamber inside. and an injection injection hole adjacent one end of the wall, the injection device having a plunger;
The plunger is disposed within the chamber and is slidable between an injection standby position spaced a certain distance from the injection nozzle and an injected position closer to the injection nozzle than the injection standby position. the injection device having a pressurized gas cartridge slidably mounted within the shell and secured to a side of the plunger opposite the injection hole; the cartridge has a breakable sealing member opposite the injection injection hole, the sealing member being insertable from the other end of the outer shell, and the injection device having an elongated body. one end of the body is removably sealed and fixedly coupled to the other end of the outer shell of the ampoule device, the body having an elongated passageway, the passageway having an elongated passageway connected to the shell of the ampoule device. The injection device has a firing pin opening adjacent the sealing member of the cartridge, the firing pin being disposed within the passageway, and a sealing member-rupturing end of the firing pin in one opening of the passageway. are arranged adjacent to each other, and the firing pin moves from an actuation position away from the sealing member to an ejection position when the ampoule device is attached to the main body with the plunger and in an injection standby position, and the firing pin moves from the actuation position away from the seal member to the ejection position. the one end extending through the seal member, the injection device having a firing pin deflection device attached to the body to move the firing pin away from the actuation position. attached to the firing pin to be pushed toward the ejection position, the injection device includes an arming device for positioning the firing pin in the actuation position, and an arming device for supporting the firing pin in the actuation position; and a trigger device for selectively delivering the injection toward the injection position. 12. The main body has an inner surface that moves in the axial direction, and the trigger device has an annular groove formed in the firing pin and a plurality of firing pin support members, the firing pin support members supporting the firing pin. The firing pin support member is positioned and dimensioned for selective engagement within the annular groove, the firing pin support member contacting an interior surface of the body, and the interior surface of the body guides the firing pin support member into the annular groove. a narrow race for retaining the firing pin support member in engagement with the annular groove, and a wide race for displacing the firing pin support member from the annular groove; a device for preventing movement of the firing pin from the starting position when the firing pin support member is engaged in the annular groove; 12. The injection device of claim 11, wherein the firing pin is movable toward the firing position when a member disengages the firing pin. 13. The annular groove is narrow in the center and has a surface that is inclinedly joined to the firing pin support member, and this inclined joint surface prevents the firing pin support member from being engaged and retained in the annular groove by the narrow race. sometimes, the action of the spring causes the firing pin support member to move outwardly along the inclined mating surface until the firing pin is free to move toward the firing position. The injection device according to claim 12. 14. The injection device of claim 13, wherein the firing pin support member includes a generally spherical roller. 15. The wide race has a race deflection device located farther from the ampoule device than the narrow race to push the race away from the ampoule device, and the arming device includes a collar; The collar is slidably attached to the body, and the collar contacts the inner surface of the body to allow the inner surface to move against the biasing action of the race deflector, thereby 15. The injection device according to claim 14, wherein the firing pin support member is controllable. 16. The firing pin includes a device for engaging the ruptured seal when the firing pin is in the ready-to-start position, and the firing pin deflection position pushes the firing pin toward the ready-to-start position, The force pushing the firing pin is less than the force after the seal is broken within the shell and the plunger is moved to the injected position, so that after the plunger is moved to the injected position, The seal to be ruptured and the firing pin are driven toward the ready-to-start position, and the trigger includes a device for re-engaging the firing pin after the firing pin has been driven to the ready-to-start position. An injection device according to claim 11. 17. The injection device of claim 16, wherein the firing pin re-engaging device includes the firing pin support member. 18. An injection device for hypodermic injection without a needle and operated by pressure for injecting an injection drug into the patient's tongue, the injection device having an ampoule device for squirting the injection drug, the ampoule device comprising: the injection device has an elongated outer shell having a syringe injection hole adjacent a forward end, the injection device having a plunger sealed and slidably mounted within the outer shell; the plunger is movable between an injection standby position spaced a certain distance from the injection nozzle and an injected position closer to the injection nozzle than the injection standby position; and the plunger form an ampoule chamber when the plunger is in the injection standby position, the ampoule chamber can contain an injection drug, and the injection device has a plunger drive, which plunger drive is connected to the plunger. cooperatively driving the plunger from the injection standby position towards the injected position, the injection device having a manual operating device for manually bringing the ampoule device into contact with the patient's tongue; An injection device, wherein an operating device is attached to the ampoule device and is operable to selectively actuate the plunger drive device to drive the plunger from the injection standby position toward the injected position. Device. 19. The plunger driving device has a cartridge filled with compressed gas, and when the actuator of the injection device is actuated, the plunger is driven from the injection standby position to the injection completed position under the influence of the actuator of the injection device. An injection device according to claim 18.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/715,930 US4596556A (en) | 1985-03-25 | 1985-03-25 | Hypodermic injection apparatus |
| US715930 | 1991-06-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPS61268265A true JPS61268265A (en) | 1986-11-27 |
Family
ID=24876044
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP61051627A Pending JPS61268265A (en) | 1985-03-25 | 1986-03-11 | Syringe apparatus |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US4596556A (en) |
| EP (1) | EP0197625A1 (en) |
| JP (1) | JPS61268265A (en) |
| CA (1) | CA1232807A (en) |
Families Citing this family (1000)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4680027A (en) * | 1985-12-12 | 1987-07-14 | Injet Medical Products, Inc. | Needleless hypodermic injection device |
| CA1283827C (en) * | 1986-12-18 | 1991-05-07 | Giorgio Cirelli | Appliance for injection of liquid formulations |
| US4790824A (en) * | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US4940460A (en) * | 1987-06-19 | 1990-07-10 | Bioject, Inc. | Patient-fillable and non-invasive hypodermic injection device assembly |
| US4941880A (en) * | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| EP0317298A3 (en) * | 1987-11-16 | 1989-10-18 | Sy-Quest International Limited | Improved apparatus for hypodermic injection of liquids |
| US4913699A (en) * | 1988-03-14 | 1990-04-03 | Parsons James S | Disposable needleless injection system |
| US5024656A (en) * | 1988-08-30 | 1991-06-18 | Injet Medical Products, Inc. | Gas-pressure-regulated needleless injection system |
| US5312335A (en) * | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5064413A (en) * | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5062830A (en) * | 1990-04-04 | 1991-11-05 | Derata Corporation | Dry disposable nozzle assembly for medical jet injector |
| GB9118204D0 (en) * | 1991-08-23 | 1991-10-09 | Weston Terence E | Needle-less injector |
| US5383851A (en) * | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| US7001759B1 (en) | 1993-01-26 | 2006-02-21 | The Trustees Of The University Of Pennsylvania | Compositions and methods for delivery of genetic material |
| US5981505A (en) * | 1993-01-26 | 1999-11-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods for delivery of genetic material |
| AU675702B2 (en) * | 1993-01-26 | 1997-02-13 | Leslie R. Coney | Compositions and methods for delivery of genetic material |
| US5746714A (en) * | 1993-04-05 | 1998-05-05 | P.A.T.H. | Air powered needleless hypodermic injector |
| TW360548B (en) * | 1993-04-08 | 1999-06-11 | Powderject Res Ltd | Products for therapeutic use |
| DE69426390T2 (en) * | 1993-07-31 | 2001-04-12 | Weston Medical Ltd | NEEDLE-FREE INJECTOR |
| FR2718357B1 (en) | 1994-04-06 | 1997-10-03 | Defarges Alain Moreau | Improvements made to a needleless jet injection device. |
| US5899880A (en) * | 1994-04-08 | 1999-05-04 | Powderject Research Limited | Needleless syringe using supersonic gas flow for particle delivery |
| GB9416663D0 (en) | 1994-08-17 | 1994-10-12 | Oxford Bioscience Limited | Particle delivery |
| GB9426379D0 (en) | 1994-12-23 | 1995-03-01 | Oxford Biosciences Ltd | Particle delivery |
| US5599302A (en) | 1995-01-09 | 1997-02-04 | Medi-Ject Corporation | Medical injection system and method, gas spring thereof and launching device using gas spring |
| AU4494196A (en) * | 1995-02-06 | 1996-08-27 | Weston Medical Limited | Needle-less injector |
| GB9502879D0 (en) * | 1995-02-14 | 1995-04-05 | Oxford Biosciences Ltd | Particle delivery |
| US5503628A (en) * | 1995-03-15 | 1996-04-02 | Jettek, Inc. | Patient-fillable hypodermic jet injector |
| DE29507987U1 (en) * | 1995-05-15 | 1996-09-19 | Ferton Holding, Delemont | Ejection device for high pressure ejection of a liquid |
| US5730723A (en) * | 1995-10-10 | 1998-03-24 | Visionary Medical Products Corporation, Inc. | Gas pressured needle-less injection device and method |
| US6013050A (en) * | 1995-10-20 | 2000-01-11 | Powderject Research Limited | Particle delivery |
| US5899879A (en) * | 1995-12-19 | 1999-05-04 | Genesis Medical Technologies, Inc. | Spring-actuated needleless injector |
| US5800388A (en) | 1996-02-29 | 1998-09-01 | Medi-Ject Corporation | Plunger/ram assembly adapted for a fluid injector |
| US5921967A (en) | 1996-02-29 | 1999-07-13 | Medi-Ject Corporation | Plunger for nozzle assembly |
| US5722953A (en) | 1996-02-29 | 1998-03-03 | Medi-Ject Corporation | Nozzle assembly for injection device |
| US5643211A (en) | 1996-02-29 | 1997-07-01 | Medi-Ject Corporation | Nozzle assembly having a frangible plunger |
| US5865795A (en) | 1996-02-29 | 1999-02-02 | Medi-Ject Corporation | Safety mechanism for injection devices |
| US5697917A (en) | 1996-02-29 | 1997-12-16 | Medi-Ject Corporation | Nozzle assembly with adjustable plunger travel gap |
| GB9607549D0 (en) * | 1996-04-11 | 1996-06-12 | Weston Medical Ltd | Spring-powered dispensing device |
| US5875976A (en) | 1996-12-24 | 1999-03-02 | Medi-Ject Corporation | Locking mechanism for nozzle assembly |
| EP0955947B1 (en) | 1997-01-24 | 2003-01-02 | MetaMorphix International, Inc. | Pharmaceutical delivery system |
| US6261281B1 (en) * | 1997-04-03 | 2001-07-17 | Electrofect As | Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells |
| US5993412A (en) * | 1997-05-19 | 1999-11-30 | Bioject, Inc. | Injection apparatus |
| US5947928A (en) * | 1997-06-19 | 1999-09-07 | Mile Creek Capital, Llc | Drug delivery system |
| US6610042B2 (en) | 1997-12-05 | 2003-08-26 | Felton Medical, Inc. | Disposable unit-dose jet-injection syringe for pre-filled and/or transfilled liquid injectable medical drug or vaccine products and method thereof |
| US6541606B2 (en) * | 1997-12-31 | 2003-04-01 | Altus Biologics Inc. | Stabilized protein crystals formulations containing them and methods of making them |
| GB9802508D0 (en) | 1998-02-05 | 1998-04-01 | Boc Group Plc | Needleless medical device |
| US6369201B1 (en) | 1998-02-19 | 2002-04-09 | Metamorphix International, Inc. | Myostatin multimers |
| AU3489499A (en) | 1998-04-14 | 1999-11-01 | Merck & Co., Inc. | Needleless administration of polynucleotide formulations |
| US6063054A (en) * | 1998-05-13 | 2000-05-16 | Mark L. Anderson | Injector pump |
| JP2002521147A (en) * | 1998-07-27 | 2002-07-16 | メディ−ジェクト コーポレイション | Loading mechanism for use in medical syringe assemblies |
| CN1651103A (en) * | 1998-07-27 | 2005-08-10 | 安塔雷斯药品公司 | Injection device |
| GB9818110D0 (en) * | 1998-08-19 | 1998-10-14 | Weston Medical Ltd | Needleless injectors and other devices |
| US6783509B1 (en) | 1998-11-18 | 2004-08-31 | Bioject Inc. | Single-use needle-less hypodermic jet injection apparatus and method |
| US6689093B2 (en) | 1998-11-18 | 2004-02-10 | Bioject, Inc. | Single-use needle-less hypodermic jet injection apparatus and method |
| US6264629B1 (en) | 1998-11-18 | 2001-07-24 | Bioject, Inc. | Single-use needle-less hypodermic jet injection apparatus and method |
| US6406455B1 (en) * | 1998-12-18 | 2002-06-18 | Biovalve Technologies, Inc. | Injection devices |
| WO2000064514A1 (en) * | 1999-04-22 | 2000-11-02 | Gilbert Garitano | Needleless permanent makeup and tattoo device |
| US6689103B1 (en) | 1999-05-07 | 2004-02-10 | Scimed Life System, Inc. | Injection array apparatus and method |
| US6319230B1 (en) | 1999-05-07 | 2001-11-20 | Scimed Life Systems, Inc. | Lateral needle injection apparatus and method |
| US7192713B1 (en) | 1999-05-18 | 2007-03-20 | President And Fellows Of Harvard College | Stabilized compounds having secondary structure motifs |
| EP1792991A1 (en) | 1999-08-24 | 2007-06-06 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| CA2387326A1 (en) | 1999-10-11 | 2001-04-19 | Needleless Ventures, Inc. | Universal anti-infectious protector for needleless injectors |
| US7074210B2 (en) * | 1999-10-11 | 2006-07-11 | Felton International, Inc. | Universal protector cap with auto-disable features for needle-free injectors |
| US6776776B2 (en) | 1999-10-14 | 2004-08-17 | Becton, Dickinson And Company | Prefillable intradermal delivery device |
| US6569143B2 (en) | 1999-10-14 | 2003-05-27 | Becton, Dickinson And Company | Method of intradermally injecting substances |
| US6494865B1 (en) | 1999-10-14 | 2002-12-17 | Becton Dickinson And Company | Intradermal delivery device including a needle assembly |
| US6843781B2 (en) * | 1999-10-14 | 2005-01-18 | Becton, Dickinson And Company | Intradermal needle |
| US6569123B2 (en) | 1999-10-14 | 2003-05-27 | Becton, Dickinson And Company | Prefillable intradermal injector |
| US20020193740A1 (en) | 1999-10-14 | 2002-12-19 | Alchas Paul G. | Method of intradermally injecting substances |
| US7887506B1 (en) | 1999-11-23 | 2011-02-15 | Pulse Needlefree Systems, Inc. | Safety mechanism to prevent accidental patient injection and methods of same |
| US6770054B1 (en) | 1999-11-23 | 2004-08-03 | Felton International, Inc. | Injector assembly with driving means and locking means |
| US7029457B2 (en) * | 1999-11-23 | 2006-04-18 | Felton International, Inc. | Jet injector with hand piece |
| US6613026B1 (en) | 1999-12-08 | 2003-09-02 | Scimed Life Systems, Inc. | Lateral needle-less injection apparatus and method |
| US6344027B1 (en) | 1999-12-08 | 2002-02-05 | Scimed Life Systems, Inc. | Needle-less injection apparatus and method |
| AU782443B2 (en) * | 1999-12-23 | 2005-07-28 | Tecpharma Licensing Ag | Injection device and propulsion system therefor |
| ATE501751T1 (en) * | 2000-01-07 | 2011-04-15 | Valeritas Inc | INJECTION DEVICE |
| US6210359B1 (en) | 2000-01-21 | 2001-04-03 | Jet Medica, L.L.C. | Needleless syringe |
| US7137968B1 (en) * | 2000-03-13 | 2006-11-21 | Nucryst Pharmaceuticals Corp. | Transcutaneous medical device dressings and method of use |
| US6719987B2 (en) | 2000-04-17 | 2004-04-13 | Nucryst Pharmaceuticals Corp. | Antimicrobial bioabsorbable materials |
| AU2001271950A1 (en) * | 2000-07-10 | 2002-01-21 | Peter M. Wild | Woody plant injection method and apparatus |
| US20040191329A1 (en) * | 2000-07-27 | 2004-09-30 | Burrell Robert E. | Compositions and methods of metal-containing materials |
| DE60107253T2 (en) | 2000-07-27 | 2005-12-01 | Nucryst Pharmaceuticals Corp., Fort Saskatchewan | USE OF PRECIOUS METALS FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF HYPERPROLIFERATIVE SKIN DISEASES AND DISEASES |
| US7001617B2 (en) | 2001-04-23 | 2006-02-21 | Nueryst Pharmaceuticals Corp. | Method of induction of apoptosis and inhibition of matrix metalloproteinases using antimicrobial metals |
| US20030185901A1 (en) | 2000-07-27 | 2003-10-02 | Burrell Robert E. | Methods of treating conditions with a metal-containing material |
| US6989157B2 (en) * | 2000-07-27 | 2006-01-24 | Nucryst Pharmaceuticals Corp. | Dry powders of metal-containing compounds |
| US7427416B2 (en) * | 2000-07-27 | 2008-09-23 | Nucryst Pharmaceuticals Corp. | Methods of treating conditions using metal-containing materials |
| US20030206966A1 (en) * | 2000-07-27 | 2003-11-06 | Burrell Robert E. | Methods of inducing apoptosis and modulating metalloproteinases |
| US7008647B2 (en) * | 2001-04-23 | 2006-03-07 | Nucryst Pharmaceuticals Corp. | Treatment of acne |
| US7255881B2 (en) * | 2000-07-27 | 2007-08-14 | Nucryst Pharmaceuticals Corp. | Metal-containing materials |
| US20030180379A1 (en) * | 2000-07-27 | 2003-09-25 | Burrell Robert E. | Solutions and aerosols of metal-containing compounds |
| GB0022742D0 (en) | 2000-09-15 | 2000-11-01 | Smithkline Beecham Biolog | Vaccine |
| PT2266603E (en) | 2000-10-18 | 2012-11-02 | Glaxosmithkline Biolog Sa | Tumour vaccines |
| EP1339442A4 (en) * | 2000-11-30 | 2006-12-27 | Biovalve Technologies Inc | Injection systems |
| AU2002222371A1 (en) | 2000-12-21 | 2002-07-01 | Arnold Neracher | Injection device with re-usable pressure generating means. |
| BR0206312A (en) | 2001-01-04 | 2004-02-17 | Univ Saskatchewan | Vaccine composition, use of enteroemorrhagic escherichia coli cell culture supernatant (ehec), and methods for generating an immune response in a mammal against a secreted enteroemorrhagic escherichia coli (ehec) antigen, and enteroemorrhagic 0157: h7 (ehec 0157) : h7) secreted, and for reduction of colonization of enteroemorrhagic escherichia coli (ehec) in a ruminant |
| GB0100756D0 (en) | 2001-01-11 | 2001-02-21 | Powderject Res Ltd | Needleless syringe |
| WO2002074336A2 (en) | 2001-02-23 | 2002-09-26 | Glaxosmithkline Biologicals S.A. | Influenza vaccine formulations for intradermal delivery |
| US6645170B2 (en) | 2001-03-05 | 2003-11-11 | Bioject Medical Technologies, Inc. | Simplified disposable needle-free injection apparatus and method |
| US6471669B2 (en) | 2001-03-05 | 2002-10-29 | Bioject Medical Technologies Inc. | Disposable needle-free injection apparatus and method |
| US6500239B2 (en) | 2001-03-14 | 2002-12-31 | Penjet Corporation | System and method for removing dissolved gas from a solution |
| GB0109297D0 (en) | 2001-04-12 | 2001-05-30 | Glaxosmithkline Biolog Sa | Vaccine |
| US7795218B2 (en) | 2001-04-12 | 2010-09-14 | Bioaxone Therapeutique Inc. | ADP-ribosyl transferase fusion variant proteins |
| US20050192530A1 (en) * | 2001-04-13 | 2005-09-01 | Penjet Corporation | Method and apparatus for needle-less injection with a degassed fluid |
| US6613010B2 (en) | 2001-04-13 | 2003-09-02 | Penjet Corporation | Modular gas-pressured needle-less injector |
| ES2261659T3 (en) * | 2001-04-23 | 2006-11-16 | Nucryst Pharmaceuticals Corp. | A MEDICINAL OR PREPARATION CONTAINING A METAL SUCH AS SILVER, GOLD, PLATINUM OR PALADIO AS AN ANTIMICROBIAL AGENT AND ITS USE FOR THE TREATMENT OF INFLAMMATORY STATES OF THE SKIN. |
| EP1427463A2 (en) | 2001-04-27 | 2004-06-16 | PenJet Corporation | Method and apparatus for filling or refilling a needle-less injector |
| TWI228420B (en) | 2001-05-30 | 2005-03-01 | Smithkline Beecham Pharma Gmbh | Novel vaccine composition |
| US20100221284A1 (en) | 2001-05-30 | 2010-09-02 | Saech-Sisches Serumwerk Dresden | Novel vaccine composition |
| US6752781B2 (en) * | 2001-06-08 | 2004-06-22 | Sergio Landau | Durable hypodermic jet injector apparatus and method |
| US20060018877A1 (en) * | 2001-06-29 | 2006-01-26 | Mikszta John A | Intradermal delivery of vacccines and therapeutic agents |
| CN1253220C (en) * | 2001-06-29 | 2006-04-26 | 贝克顿迪肯森公司 | Intradermal delivery of vaccines and gene therapeutic agents via microcannula |
| US8061006B2 (en) * | 2001-07-26 | 2011-11-22 | Powderject Research Limited | Particle cassette, method and kit therefor |
| US6824526B2 (en) | 2001-10-22 | 2004-11-30 | Penjet Corporation | Engine and diffuser for use with a needle-less injector |
| US6607510B2 (en) | 2001-11-09 | 2003-08-19 | Bioject Medical Technologies Inc. | Disposable needle-free injection apparatus and method |
| IL162844A0 (en) * | 2002-01-18 | 2005-11-20 | Inovio As | Use of an expression vector for preparing pharmaceutical compositions |
| GB0206560D0 (en) * | 2002-03-20 | 2002-05-01 | Glaxo Group Ltd | Novel device |
| JP4594623B2 (en) | 2002-04-12 | 2010-12-08 | シェーリング コーポレイション | G protein-coupled receptor ligand and method |
| US20040025420A1 (en) * | 2002-05-09 | 2004-02-12 | Peter M. Wild | Injection needle for injecting woody plants |
| KR101086533B1 (en) | 2002-05-24 | 2011-11-23 | 쉐링 코포레이션 | Neutralizing human anti-IGFR antibody, a method for producing it and a composition comprising it |
| US6942638B1 (en) * | 2002-05-30 | 2005-09-13 | Kerry Quinn | Needleless injector and ampule system |
| US7238167B2 (en) * | 2002-06-04 | 2007-07-03 | Bioject Inc. | Needle-free injection system |
| US7156823B2 (en) * | 2002-06-04 | 2007-01-02 | Bioject Inc. | High workload needle-free injection system |
| US6676630B2 (en) | 2002-06-04 | 2004-01-13 | Bioject Medical Technologies, Inc. | Needle-free injection system |
| US20030229308A1 (en) * | 2002-06-05 | 2003-12-11 | Israil Tsals | Injector adapter and combination thereof |
| DE10226537A1 (en) * | 2002-06-14 | 2004-01-08 | Peter Eichhorst | pre-injection device |
| WO2004004443A2 (en) * | 2002-07-03 | 2004-01-15 | Wild Peter M | Plant injection method and apparatus |
| US20040132058A1 (en) | 2002-07-19 | 2004-07-08 | Schering Corporation | NPC1L1 (NPC3) and methods of use thereof |
| US6883222B2 (en) * | 2002-10-16 | 2005-04-26 | Bioject Inc. | Drug cartridge assembly and method of manufacture |
| EP3284753B1 (en) | 2002-10-17 | 2019-06-05 | Genmab A/S | Human monoclonal antibodies against cd20 for use in the treatment of multiple sclerosis |
| JP2006509738A (en) * | 2002-10-22 | 2006-03-23 | ニュクリスト ファーマシューティカルズ コーポレーション | Prophylactic treatment |
| US7018356B2 (en) | 2002-10-31 | 2006-03-28 | Wise Roger R | Method and apparatus for adjusting the contents of a needle-less injector |
| EP1587907B1 (en) | 2003-01-07 | 2011-03-02 | Dyax Corporation | Kunitz domain library |
| US6935384B2 (en) * | 2003-02-19 | 2005-08-30 | Bioject Inc. | Needle-free injection system |
| CA2559330A1 (en) * | 2003-04-21 | 2004-11-04 | Stratagent Life Sciences | Apparatus and methods for repetitive microjet drug delivery |
| US20060184101A1 (en) * | 2003-04-21 | 2006-08-17 | Ravi Srinivasan | Microjet devices and methods for drug delivery |
| ES2368737T3 (en) | 2003-04-23 | 2011-11-21 | Medarex, Inc. | HUMANIZED ANTIBODIES AGAINST THE ALFA 1 INTERFER RECEIVER (IFNAR-1). |
| BRPI0410562B8 (en) | 2003-05-22 | 2021-05-25 | Fralunhofer Usa Inc | carrier protein and its production method in a plant, isolated nucleic acid, expression vector and host cell |
| JP4621664B2 (en) * | 2003-06-20 | 2011-01-26 | アラーガン、インコーポレイテッド | Needleless injector |
| WO2005014642A2 (en) | 2003-07-21 | 2005-02-17 | Transgene S.A. | Novel multifunctional cytokines |
| HU225252B1 (en) * | 2003-08-21 | 2006-08-28 | S Istvan Lindmayer | Needleless injection apparatus |
| AU2003270473A1 (en) * | 2003-09-09 | 2005-04-27 | University Of Florida | Desferrithiocin derivatives and their use as iron chelators |
| US7131961B2 (en) * | 2003-10-01 | 2006-11-07 | Bioject, Inc. | Needle-free injection system |
| GB0325836D0 (en) * | 2003-11-05 | 2003-12-10 | Celltech R&D Ltd | Biological products |
| EP1983000B1 (en) | 2003-11-21 | 2015-09-02 | UCB Biopharma SPRL | Method for the treatment of multiple sclerosis by inhibiting IL-17 activity |
| US7776007B2 (en) | 2003-12-05 | 2010-08-17 | Zogenix, Inc. | Device for readying a needle free injector for delivery |
| JP4942487B2 (en) | 2003-12-10 | 2012-05-30 | メダレックス インコーポレーティッド | IP-10 antibody and use thereof |
| PT1711207E (en) | 2003-12-10 | 2013-02-13 | Medarex Inc | Interferon alpha antibodies and their uses |
| US8147426B2 (en) * | 2003-12-31 | 2012-04-03 | Nipro Diagnostics, Inc. | Integrated diagnostic test system |
| EP2816351A3 (en) * | 2004-01-27 | 2015-03-25 | Compugen Ltd. | Methods and systems for annotating biomolecular sequences |
| US20050209553A1 (en) * | 2004-03-19 | 2005-09-22 | Sergio Landau | Needle-free single-use cartridge and injection system |
| US20050209554A1 (en) * | 2004-03-19 | 2005-09-22 | Sergio Landau | Needle-free single-use cartridge and injection system |
| DE102004024617A1 (en) | 2004-05-18 | 2005-12-29 | Ganymed Pharmaceuticals Ag | Differentially expressed in tumors gene products and their use |
| EP1753458A4 (en) * | 2004-05-19 | 2009-07-22 | Wyeth Corp | Modulation of immunoglobulin production and atopic disorders |
| US7717874B2 (en) * | 2004-05-28 | 2010-05-18 | Bioject, Inc. | Needle-free injection system |
| AU2005258077C1 (en) | 2004-06-21 | 2012-10-25 | E. R. Squibb & Sons, L.L.C. | Interferon alpha receptor 1 antibodies and their uses |
| WO2006017538A2 (en) | 2004-08-03 | 2006-02-16 | Dyax Corp. | Hk1-binding proteins |
| GB0417852D0 (en) | 2004-08-11 | 2004-09-15 | Biotica Tech Ltd | Production of polyketides and other natural products |
| CA2478458A1 (en) * | 2004-08-20 | 2006-02-20 | Michael Panzara | Treatment of pediatric multiple sclerosis |
| CN102657855B (en) | 2004-09-22 | 2015-12-09 | 葛兰素史密丝克莱恩生物有限公司 | For carrying out the immunogenic composition of staphylococcus inoculation |
| US20060089593A1 (en) * | 2004-10-26 | 2006-04-27 | Sergio Landau | Needle-free injection device for individual users |
| US20060089594A1 (en) * | 2004-10-26 | 2006-04-27 | Sergio Landau | Needle-free injection device |
| US9492400B2 (en) | 2004-11-04 | 2016-11-15 | Massachusetts Institute Of Technology | Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals |
| CA2585719A1 (en) | 2004-11-08 | 2006-05-18 | Schering Corporation | Tumor association of mdl-1 and methods |
| CA2629751A1 (en) | 2004-11-12 | 2006-05-18 | The University Of British Columbia | Antimicrobial peptides |
| EP2808033A1 (en) | 2004-11-19 | 2014-12-03 | Biogen Idec MA Inc. | Treatment for multiple sclerosis |
| US7648483B2 (en) | 2004-11-22 | 2010-01-19 | Intelliject, Inc. | Devices, systems and methods for medicament delivery |
| WO2006057636A1 (en) | 2004-11-22 | 2006-06-01 | Intelliject, Llc | Devices, systems, and methods for medicament delivery |
| US10737028B2 (en) | 2004-11-22 | 2020-08-11 | Kaleo, Inc. | Devices, systems and methods for medicament delivery |
| US7947017B2 (en) | 2004-11-22 | 2011-05-24 | Intelliject, Inc. | Devices, systems and methods for medicament delivery |
| US11590286B2 (en) | 2004-11-22 | 2023-02-28 | Kaleo, Inc. | Devices, systems and methods for medicament delivery |
| US7648482B2 (en) | 2004-11-22 | 2010-01-19 | Intelliject, Inc. | Devices, systems, and methods for medicament delivery |
| DK2532378T3 (en) * | 2004-12-01 | 2016-07-25 | Acushot Inc | needleless injector |
| MX2007006640A (en) | 2004-12-03 | 2007-06-19 | Schering Corp | Biomarkers for pre-selection of patients for anti-igf1r therapy. |
| EP1833509A4 (en) * | 2004-12-03 | 2008-12-03 | Biogen Idec Inc | Delaying or preventing onset of multiple sclerosis |
| US20060183893A1 (en) * | 2005-01-25 | 2006-08-17 | North Don A | Nucleic acids for apoptosis of cancer cells |
| DE602005014148D1 (en) * | 2005-01-25 | 2009-06-04 | Sky Genetics Inc | NUCLEIC ACIDS FOR THE APOPTOSIS OF CANCER CELLS |
| GB2440039A (en) | 2005-02-01 | 2008-01-16 | Intelliject Llc | Devices, systems and methods for medicament delivery |
| US8206360B2 (en) | 2005-02-01 | 2012-06-26 | Intelliject, Inc. | Devices, systems and methods for medicament delivery |
| US7731686B2 (en) * | 2005-02-01 | 2010-06-08 | Intelliject, Inc. | Devices, systems and methods for medicament delivery |
| US8361026B2 (en) | 2005-02-01 | 2013-01-29 | Intelliject, Inc. | Apparatus and methods for self-administration of vaccines and other medicaments |
| US8231573B2 (en) | 2005-02-01 | 2012-07-31 | Intelliject, Inc. | Medicament delivery device having an electronic circuit system |
| US9022980B2 (en) | 2005-02-01 | 2015-05-05 | Kaleo, Inc. | Medical injector simulation device |
| DK2529619T3 (en) | 2005-02-17 | 2016-01-11 | Biogen Ma Inc | Treatment of neurological disorders |
| WO2006089232A2 (en) | 2005-02-18 | 2006-08-24 | Medarex, Inc. | Monoclonal antibodies against cd30 lacking fucosyl residues |
| US20100061994A1 (en) * | 2005-03-11 | 2010-03-11 | Rose Mary Sheridan | Medical uses of 39-desmethoxyrapamycin and analogues thereof |
| GB0504994D0 (en) * | 2005-03-11 | 2005-04-20 | Biotica Tech Ltd | Novel compounds |
| WO2006100111A1 (en) | 2005-03-23 | 2006-09-28 | Glaxosmithkline Biologicals S.A. | Composition |
| CN112480257A (en) | 2005-03-23 | 2021-03-12 | 根马布股份公司 | CD38 antibodies for the treatment of multiple myeloma |
| CN101189023B (en) | 2005-03-31 | 2013-01-30 | 通用医疗公司 | Monitoring and modulating hgf/hgfr activity |
| CA2603385C (en) | 2005-04-04 | 2014-07-15 | University Of Florida Research Foundation, Inc. | Desferrithiocin polyether analogues and uses thereof for treating metal overload, oxidative stress, and neoplastic and preneoplastic conditions |
| US20070027428A1 (en) * | 2005-05-03 | 2007-02-01 | Pharmajet, Inc. | Vial system and method for needle-less injector |
| US7699802B2 (en) | 2005-05-03 | 2010-04-20 | Pharmajet, Inc. | Needle-less injector |
| US7618393B2 (en) | 2005-05-03 | 2009-11-17 | Pharmajet, Inc. | Needle-less injector and method of fluid delivery |
| CN101213297B (en) | 2005-05-09 | 2013-02-13 | 小野药品工业株式会社 | Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| LT2460831T (en) | 2005-05-27 | 2016-12-12 | Biogen Ma Inc. | Tweak binding antibodies |
| US20070118093A1 (en) * | 2005-06-20 | 2007-05-24 | Von Muhlen Marcio G | High-speed jet devices for drug delivery |
| GB0513248D0 (en) * | 2005-06-29 | 2005-08-03 | Boc Group Plc | Gas dispenser |
| KR101411165B1 (en) | 2005-07-01 | 2014-06-25 | 메다렉스, 엘.엘.시. | Human monoclonal antibodies to programmed death ligand 1(pd-l1) |
| BRPI0614475B8 (en) * | 2005-08-03 | 2021-05-25 | Fraunhofer Usa Inc | polypeptide, antibody, nucleic acid, vectors, host cell, antibody composition and production processes |
| US20070055200A1 (en) * | 2005-08-10 | 2007-03-08 | Gilbert Scott J | Needle-free jet injection drug delivery device |
| EP1762575A1 (en) * | 2005-09-12 | 2007-03-14 | Ganymed Pharmaceuticals AG | Identification of tumor-associated antigens for diagnosis and therapy |
| WO2007038637A2 (en) | 2005-09-26 | 2007-04-05 | Medarex, Inc. | Human monoclonal antibodies to cd70 |
| CA2625664C (en) | 2005-10-21 | 2016-01-05 | Novartis Ag | Human antibodies against il13 and therapeutic uses |
| EP1790664A1 (en) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
| AU2006321554B2 (en) | 2005-12-08 | 2012-08-02 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to Fucosyl-GM1 and methods for using anti-Fucosyl-GM1 |
| TWI457133B (en) | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | Novel composition |
| US9267937B2 (en) | 2005-12-15 | 2016-02-23 | Massachusetts Institute Of Technology | System for screening particles |
| AR058592A1 (en) | 2005-12-22 | 2008-02-13 | Glaxosmithkline Biolog Sa | VACCINE |
| GB0607088D0 (en) | 2006-04-07 | 2006-05-17 | Glaxosmithkline Biolog Sa | Vaccine |
| US20070166774A1 (en) * | 2006-01-17 | 2007-07-19 | Groman Ernest V | Functional immunoassay |
| US20080161755A1 (en) * | 2006-01-27 | 2008-07-03 | Bioject Inc. | Needle-free injection device and priming system |
| ES2391657T3 (en) | 2006-02-07 | 2012-11-28 | Shire Human Genetic Therapies, Inc. | Stabilized protein compositions that have a free thiol moiety |
| WO2008048344A2 (en) * | 2006-02-13 | 2008-04-24 | Fraunhofer Usa, Inc. | Bacillus anthracis antigens, vaccine compositions, and related methods |
| CN101395174B (en) * | 2006-02-13 | 2014-03-19 | 艾比欧公司 | Hpv antigens, vaccine compositions, and related methods |
| JP2009526526A (en) * | 2006-02-13 | 2009-07-23 | フラウンホーファー ユーエスエー， インコーポレイテッド | Influenza antigens, vaccine compositions, and related methods |
| WO2007106415A2 (en) * | 2006-03-10 | 2007-09-20 | Massachusetts Institute Of Technology | Triggered self-assembly conjugates and nanosystems |
| WO2007111806A2 (en) | 2006-03-23 | 2007-10-04 | Massachusetts Eye And Ear Infirmary | Cyclopentane heptanoic acid compounds for reducing body fat |
| US20080045471A1 (en) * | 2006-03-27 | 2008-02-21 | North Don A | Nucleic Acids For Apoptosis Of Cancer Cells |
| NZ570805A (en) | 2006-03-30 | 2011-10-28 | Glaxosmithkline Biolog Sa | Vaccine comprising Type 5 and Type 8 capsular polysaccharides from Staphyloccocus aureus |
| EP2007435B1 (en) | 2006-03-31 | 2019-12-18 | Massachusetts Institute Of Technology | System for targeted delivery of therapeutic agents |
| US20090325944A1 (en) * | 2006-04-12 | 2009-12-31 | Suzanne Walker Kahne | Methods and Compositions for Modulating Glycosylation |
| AU2007240732B2 (en) * | 2006-04-21 | 2013-07-04 | Amgen, Inc. | Buffering agents for biopharmaceutical formulations |
| CA2652280C (en) | 2006-05-15 | 2014-01-28 | Massachusetts Institute Of Technology | Polymers for functional particles |
| DK2034830T3 (en) | 2006-05-25 | 2014-10-27 | Biogen Idec Inc | ANTI-VLA-1 ANTIBODY FOR TREATMENT OF CASES |
| CN104356230A (en) * | 2006-06-02 | 2015-02-18 | 哈佛大学校长及研究员协会 | Protein surface remodeling |
| WO2007150030A2 (en) | 2006-06-23 | 2007-12-27 | Massachusetts Institute Of Technology | Microfluidic synthesis of organic nanoparticles |
| ES2427924T3 (en) | 2006-06-30 | 2013-11-04 | Merck Sharp & Dohme Corp. | IGFBP2 biomarker |
| JP5605895B2 (en) | 2006-07-04 | 2014-10-15 | ゲンマブ エー／エス | CD20 binding molecule for treating COPD |
| CN105727276A (en) | 2006-07-17 | 2016-07-06 | 葛兰素史密丝克莱恩生物有限公司 | Influenza vaccine |
| ES2396220T3 (en) | 2006-08-11 | 2013-02-20 | Ono Pharmaceutical Co., Ltd. | Monoclonal antibodies against stromal-derived factor 1 (SDF-1) |
| WO2008021367A2 (en) * | 2006-08-11 | 2008-02-21 | President And Fellows Of Harvard College | Moenomycin biosynthesis-related compositions and methods of use thereof |
| US20100061990A1 (en) * | 2006-08-14 | 2010-03-11 | Massachusetts Institute Of Technology | Hemagglutinin Polypeptides, and Reagents and Methods Relating Thereto |
| US20090269342A1 (en) * | 2006-08-14 | 2009-10-29 | Massachusetts Institute Of Technology | Hemagglutinin Polypeptides, and Reagents and Methods Relating Thereto |
| WO2008030611A2 (en) | 2006-09-05 | 2008-03-13 | Medarex, Inc. | Antibodies to bone morphogenic proteins and receptors therefor and methods for their use |
| US7942845B2 (en) * | 2006-09-19 | 2011-05-17 | Bioject, Inc. | Needle-free injector and process for providing serial injections |
| PT2486941T (en) | 2006-10-02 | 2017-05-30 | Squibb & Sons Llc | Human antibodies that bind cxcr4 and uses thereof |
| US7547293B2 (en) | 2006-10-06 | 2009-06-16 | Bioject, Inc. | Triggering mechanism for needle-free injector |
| AU2007307107B2 (en) * | 2006-10-06 | 2011-11-03 | Amgen Inc. | Stable antibody formulations |
| JO3598B1 (en) | 2006-10-10 | 2020-07-05 | Infinity Discovery Inc | Boronic acids and esters as inhibitors of fatty acid amide hydrolase |
| EP2086582B1 (en) | 2006-10-12 | 2012-11-14 | GlaxoSmithKline Biologicals s.a. | Vaccine comprising an oil in water emulsion adjuvant |
| KR101151202B1 (en) | 2006-10-12 | 2012-06-11 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | Vaccine comprising an oil in water emulsion adjuvant |
| EP2068922B1 (en) | 2006-10-19 | 2012-06-27 | CSL Limited | Anti-il-13r alpha 1 antibodies and their uses thereof |
| EP2094247B1 (en) * | 2006-10-20 | 2022-06-29 | Amgen Inc. | Stable polypeptide formulations |
| US8067375B2 (en) | 2006-10-20 | 2011-11-29 | Biogen Idec Ma Inc. | Treatment of demyelinating disorders with soluble lymphotoxin-β-receptor |
| US8618248B2 (en) | 2006-10-31 | 2013-12-31 | President And Fellows Of Harvard College | Phosphopeptide compositions and anti-phosphopeptide antibody compositions and methods of detecting phosphorylated peptides |
| AR063840A1 (en) | 2006-11-15 | 2009-02-25 | Medarex Inc | MONOCLONAL HUMAN ANTIBODIES FOR BTLA AND METHODS OF USE |
| JP5398538B2 (en) | 2006-12-01 | 2014-01-29 | メダレックス・リミテッド・ライアビリティ・カンパニー | Human antibodies that bind to CD22 and uses thereof |
| BRPI0719756A2 (en) | 2006-12-01 | 2014-01-21 | Anterios Inc | Amphiphilic Nanoparticles |
| CA2671850A1 (en) * | 2006-12-08 | 2008-06-19 | Massachusetts Institute Of Technology | Delivery of nanoparticles and/or agents to cells |
| CL2007003622A1 (en) | 2006-12-13 | 2009-08-07 | Medarex Inc | Human anti-cd19 monoclonal antibody; composition comprising it; and tumor cell growth inhibition method. |
| MX2009006277A (en) | 2006-12-14 | 2009-07-24 | Medarex Inc | Human antibodies that bind cd70 and uses thereof. |
| US20080213282A1 (en) * | 2006-12-21 | 2008-09-04 | Jaby Jacob | Formulations |
| KR101810348B1 (en) | 2006-12-26 | 2017-12-18 | 랜티우스 메디컬 이메징, 인크. | Ligands for imaging cardiac innervation |
| US20080171968A1 (en) * | 2007-01-15 | 2008-07-17 | Bioject, Inc. | Methods of administering injectables to a joint with a needle-free injection system |
| WO2008091838A2 (en) | 2007-01-22 | 2008-07-31 | Intelliject, Inc. | Medical injector with compliance tracking and monitoring |
| JP5649825B2 (en) | 2007-01-31 | 2015-01-07 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | Stabilized p53 peptides and methods of use thereof |
| US9217129B2 (en) | 2007-02-09 | 2015-12-22 | Massachusetts Institute Of Technology | Oscillating cell culture bioreactor |
| WO2008100624A2 (en) | 2007-02-16 | 2008-08-21 | Merrimack Pharmaceuticals, Inc. | Antibodies against erbb3 and uses thereof |
| WO2008103997A2 (en) * | 2007-02-23 | 2008-08-28 | Bioject Inc. | Needle-free injection devices and drug delivery systems therefor |
| EP1970384A1 (en) | 2007-03-14 | 2008-09-17 | Ganymed Pharmaceuticals AG | Monoclonal antibodies for treatment of cancer |
| CA2680592C (en) | 2007-03-15 | 2016-07-05 | University Of Florida Research Foundation, Inc. | Desferrithiocin polyether analogues and uses thereof in treating pathological conditions |
| US7960139B2 (en) | 2007-03-23 | 2011-06-14 | Academia Sinica | Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells |
| MX2009009912A (en) | 2007-03-27 | 2010-01-18 | Sea Lane Biotechnologies Llc | Constructs and libraries comprising antibody surrogate light chain sequences. |
| ES2430067T3 (en) | 2007-03-28 | 2013-11-18 | President And Fellows Of Harvard College | Sewn polypeptides |
| WO2008124634A1 (en) | 2007-04-04 | 2008-10-16 | Massachusetts Institute Of Technology | Polymer-encapsulated reverse micelles |
| US20090074828A1 (en) | 2007-04-04 | 2009-03-19 | Massachusetts Institute Of Technology | Poly(amino acid) targeting moieties |
| BRPI0810865A2 (en) * | 2007-04-28 | 2017-05-09 | Fraunhofer Usa Inc | trypanosome antigens, vaccine compositions, and related methods |
| US8747872B2 (en) * | 2007-05-02 | 2014-06-10 | The Regents Of The University Of Michigan | Nanoemulsion therapeutic compositions and methods of using the same |
| GB0708758D0 (en) | 2007-05-04 | 2007-06-13 | Powderject Res Ltd | Particle cassettes and process thereof |
| EP1997832A1 (en) | 2007-05-29 | 2008-12-03 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against Claudin-18 for treatment of cancer |
| CN101801407B (en) | 2007-06-05 | 2013-12-18 | 耶鲁大学 | Inhibitors of receptor tyrosine kinases and methods of use thereof |
| DK2170390T3 (en) | 2007-06-14 | 2019-01-21 | Biogen Ma Inc | NATALIZUMABANTISTIC FORMULATIONS |
| PL2175881T3 (en) * | 2007-06-14 | 2012-12-31 | Crucell Switzerland Ag | Intradermal influenza vaccine |
| WO2008156676A1 (en) | 2007-06-15 | 2008-12-24 | President And Fellows Of Harvard College | Methods and compositions for detecting and modulating o-glycosylation |
| CN101883583B (en) | 2007-06-26 | 2017-05-17 | 葛兰素史密丝克莱恩生物有限公司 | Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates |
| WO2009009759A2 (en) * | 2007-07-11 | 2009-01-15 | Fraunhofer Usa, Inc. | Yersinia pestis antigens, vaccine compositions, and related methods |
| JP5588866B2 (en) | 2007-08-10 | 2014-09-10 | メダレックス エル．エル．シー． | HCO 32 and HCO 27 and related examples |
| EP2190472A2 (en) * | 2007-08-20 | 2010-06-02 | Fraunhofer USA, Inc. | Prophylactic and therapeutic influenza vaccines, antigens, compositions, and methods |
| LT2769729T (en) | 2007-09-04 | 2019-05-10 | Compugen Ltd. | Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics |
| GB0717337D0 (en) | 2007-09-06 | 2007-10-17 | Ucb Pharma Sa | Method of treatment |
| US8604004B2 (en) * | 2007-10-04 | 2013-12-10 | President And Fellows Of Harvard College | Moenomycin analogs, methods of synthesis, and uses thereof |
| TWI489993B (en) | 2007-10-12 | 2015-07-01 | Novartis Ag | Compositions and methods of use for antibodies against sclerostin |
| CN105770878A (en) | 2007-10-12 | 2016-07-20 | 麻省理工学院 | Vaccine Nanotechnology |
| DK2567709T3 (en) | 2007-11-02 | 2018-03-12 | Novartis Ag | Molecules and Methods for Modulating Low-Density Lipoprotein Receptor-Related Protein 6 (LRP6) |
| EP2570137A3 (en) | 2007-11-07 | 2013-08-21 | Celldex Therapeutics, Inc. | Antibodies that bind human dendritic and epithelial cell 205 (DEC-205) |
| US8617099B2 (en) * | 2007-11-26 | 2013-12-31 | Bioject Inc. | Injection device plunger auto-disable |
| US20090137949A1 (en) * | 2007-11-26 | 2009-05-28 | Bioject Inc. | Needle-free injection device with nozzle auto-disable |
| KR20130087632A (en) | 2007-12-17 | 2013-08-06 | 화이자 리미티드 | Treatment of interstitial cystitis |
| EP2231258A1 (en) | 2007-12-21 | 2010-09-29 | Aesthetic Sciences Corporation | Self-contained pressurized injection device |
| KR20100111275A (en) * | 2008-01-03 | 2010-10-14 | 메사츄세츠 인스티튜트 어브 테크놀로지 | Decoy influenza therapies |
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| US20090187135A1 (en) * | 2008-01-18 | 2009-07-23 | Eilaz Babaev | Ultrasonic syringe |
| CN101965398B (en) | 2008-01-22 | 2015-03-18 | 圣保罗州研究奖励基金会 | Peptides, compositions, and uses thereof |
| US20110052501A1 (en) * | 2008-01-31 | 2011-03-03 | Liat Dassa | Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics |
| EP2650017A3 (en) | 2008-02-05 | 2014-01-22 | Bristol-Myers Squibb Company | Alpha 5 - beta 1 antibodies and their uses |
| WO2009100309A2 (en) | 2008-02-08 | 2009-08-13 | Medimmune, Llc | Anti-ifnar1 antibodies with reduced fc ligand affinity |
| TW201000107A (en) * | 2008-04-09 | 2010-01-01 | Infinity Pharmaceuticals Inc | Inhibitors of fatty acid amide hydrolase |
| EP2612680B1 (en) | 2008-04-16 | 2018-05-23 | GlaxoSmithKline Biologicals SA | Vaccine |
| WO2009134808A2 (en) * | 2008-04-28 | 2009-11-05 | President And Fellows Of Harvard College | Supercharged proteins for cell penetration |
| EP2439212B1 (en) | 2008-05-02 | 2016-12-21 | Novartis AG | Improved fibronectin-based binding molecules and uses thereof |
| US8021344B2 (en) | 2008-07-28 | 2011-09-20 | Intelliject, Inc. | Medicament delivery device configured to produce an audible output |
| USD994111S1 (en) | 2008-05-12 | 2023-08-01 | Kaleo, Inc. | Medicament delivery device cover |
| WO2009155025A1 (en) | 2008-05-30 | 2009-12-23 | Dana-Farber Cancer Institute Inc. | Methods of treating a meiotic kinesin-associated disease |
| WO2009150623A1 (en) | 2008-06-13 | 2009-12-17 | Pfizer Inc | Treatment of chronic prostatitis |
| MX2010014079A (en) | 2008-06-20 | 2011-02-22 | Novartis Ag | Immunoglobulins with reduced aggregation. |
| CN105147608B (en) | 2008-06-26 | 2019-12-10 | 安特里奥公司 | Dermal delivery |
| EP2318832B1 (en) | 2008-07-15 | 2013-10-09 | Academia Sinica | Glycan arrays on ptfe-like aluminum coated glass slides and related methods |
| WO2010011313A2 (en) * | 2008-07-23 | 2010-01-28 | President And Fellows Of Harvard College | Ligation of stapled polypeptides |
| CN102159203A (en) * | 2008-07-23 | 2011-08-17 | 麻省理工学院 | Activatiqn of histone deacetylase 1 (hdac1) protects against DNA damage and increases neuronal survival |
| EP3629022A1 (en) | 2008-07-25 | 2020-04-01 | Richard W. Wagner | Protein screening methods |
| AR072999A1 (en) | 2008-08-11 | 2010-10-06 | Medarex Inc | HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE |
| EP2166021A1 (en) * | 2008-09-16 | 2010-03-24 | Ganymed Pharmaceuticals AG | Monoclonal antibodies for treatment of cancer |
| US9901681B2 (en) * | 2008-09-18 | 2018-02-27 | Becton, Dickinson And Company | Medical injector with slidable sleeve activation |
| EP2349209A2 (en) | 2008-09-26 | 2011-08-03 | Nanobio Corporation | Nanoemulsion therapeutic compositions and methods of using the same |
| MX349463B (en) | 2008-09-26 | 2017-07-31 | Univ Emory | Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor. |
| US8734803B2 (en) | 2008-09-28 | 2014-05-27 | Ibio Inc. | Humanized neuraminidase antibody and methods of use thereof |
| US8591905B2 (en) | 2008-10-12 | 2013-11-26 | The Brigham And Women's Hospital, Inc. | Nicotine immunonanotherapeutics |
| US8343498B2 (en) | 2008-10-12 | 2013-01-01 | Massachusetts Institute Of Technology | Adjuvant incorporation in immunonanotherapeutics |
| US8343497B2 (en) * | 2008-10-12 | 2013-01-01 | The Brigham And Women's Hospital, Inc. | Targeting of antigen presenting cells with immunonanotherapeutics |
| US8277812B2 (en) * | 2008-10-12 | 2012-10-02 | Massachusetts Institute Of Technology | Immunonanotherapeutics that provide IgG humoral response without T-cell antigen |
| BR122018013284B1 (en) | 2008-10-29 | 2022-03-03 | Ablynx N.V | FORMULATIONS OF SINGLE DOMAIN ANTIGEN BINDING MOLECULES, THEIR FORMULATION METHOD AND THEIR USE, KIT OR ARTICLE OF MANUFACTURE, AS WELL AS THE METHOD FOR PREPARING A RECONSTITUTED FORMULATION CONTAINING AN SDAB MOLECULE |
| CA2743904A1 (en) | 2008-11-17 | 2010-05-20 | The Regents Of The University Of Michigan | Cancer vaccine compositions and methods of using the same |
| US9545483B2 (en) * | 2008-12-02 | 2017-01-17 | Sanofi-Aventis Deutschland Gmbh | Drive assembly suitable for use in a medication delivery device and medication delivery device |
| CA2744409A1 (en) * | 2008-12-05 | 2010-06-10 | Ams Research Corporation | Devices, systems and methods for delivering fluid to tissue |
| US20110311450A1 (en) | 2008-12-08 | 2011-12-22 | Zurit Levine | Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics |
| WO2010077806A1 (en) | 2008-12-15 | 2010-07-08 | Greenlight Biosciences, Inc. | Methods for control of flux in metabolic pathways |
| WO2010069605A2 (en) | 2008-12-19 | 2010-06-24 | Medirista Biotechnologies Ab | Oxidized cardiolipin as a novel pro-inflammatory factor |
| CA2749877A1 (en) * | 2008-12-22 | 2010-07-01 | Greenlight Biosciences, Inc. | Compositions and methods for the production of a compound |
| KR101769160B1 (en) | 2009-03-05 | 2017-08-17 | 옥스포드 바이오테라퓨틱스 리미티드 | Fully human antibodies specific to cadm1 |
| GB0904540D0 (en) | 2009-03-17 | 2009-04-29 | Biotica Tech Ltd | Novel compounds and methods for their production |
| ES2493916T3 (en) | 2009-04-07 | 2014-09-12 | Infinity Pharmaceuticals, Inc. | Inhibitors of fatty acid amide hydrolase |
| WO2010118159A1 (en) | 2009-04-07 | 2010-10-14 | Infinity Pharmaceuticals, Inc. | Inhibitors of fatty acid amide hydrolase |
| SG175166A1 (en) * | 2009-04-17 | 2011-11-28 | Biogen Idec Inc | Compositions and methods to treat acute myelogenous leukemia |
| CN106188295A (en) | 2009-04-20 | 2016-12-07 | 牛津生物疗法有限公司 | It is specific to the antibody of cadherins 17 |
| NO2424895T3 (en) | 2009-04-27 | 2018-02-03 | ||
| CN102414223A (en) | 2009-04-27 | 2012-04-11 | 诺瓦提斯公司 | Composition and methods of use for therapeutic antibodies specific for the il-12 receptore betal subunit |
| JP2012525146A (en) | 2009-04-28 | 2012-10-22 | プレジデント アンド フェロウズ オブ ハーバード カレッジ | Overcharged protein for cell penetration |
| US8435523B2 (en) | 2009-05-04 | 2013-05-07 | Abbott Research B.V. | Antibodies against nerve growth factor (NGF) with enhanced in vivo stability |
| AU2010249046A1 (en) | 2009-05-13 | 2011-12-01 | Sea Lane Biotechnologies, Llc | Neutralizing molecules to influenza viruses |
| US8765735B2 (en) * | 2009-05-18 | 2014-07-01 | Infinity Pharmaceuticals, Inc. | Isoxazolines as inhibitors of fatty acid amide hydrolase |
| US8927551B2 (en) * | 2009-05-18 | 2015-01-06 | Infinity Pharmaceuticals, Inc. | Isoxazolines as inhibitors of fatty acid amide hydrolase |
| US9149465B2 (en) * | 2009-05-18 | 2015-10-06 | Infinity Pharmaceuticals, Inc. | Isoxazolines as inhibitors of fatty acid amide hydrolase |
| CA2769999C (en) | 2009-06-01 | 2020-02-18 | Shriners Hospitals For Children | A cloned transmembrane receptor for 24-hydroxylated vitamin d compounds and uses thereof |
| WO2010141074A2 (en) | 2009-06-01 | 2010-12-09 | President And Fellows Of Harvard College | O-glcnac transferase inhibitors and uses thereof |
| US8974423B2 (en) * | 2009-06-01 | 2015-03-10 | Sanofi-Aventis Deutschland Gmbh | Resettable drug delivery device |
| CN102458479B (en) | 2009-06-04 | 2016-07-13 | 诺华公司 | The method identifying IgG binding site |
| EP3020412B1 (en) | 2009-06-16 | 2017-10-11 | The Regents of the University of Michigan | An immunogenic composition comprising nanoemulsion inactivated rsv |
| WO2010146511A1 (en) | 2009-06-17 | 2010-12-23 | Pfizer Limited | Treatment of overactive bladder |
| WO2011008260A2 (en) | 2009-07-13 | 2011-01-20 | President And Fellows Of Harvard College | Bifunctional stapled polypeptides and uses thereof |
| KR20120090037A (en) | 2009-07-31 | 2012-08-16 | 메다렉스, 인코포레이티드 | Fully human antibodies to btla |
| US8394922B2 (en) | 2009-08-03 | 2013-03-12 | Medarex, Inc. | Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof |
| GB0913681D0 (en) | 2009-08-05 | 2009-09-16 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| GB0914589D0 (en) | 2009-08-20 | 2009-09-30 | Biotica Tech Ltd | Novel compounds and methods for their production |
| WO2011029823A1 (en) | 2009-09-09 | 2011-03-17 | Novartis Ag | Monoclonal antibody reactive with cd63 when expressed at the surface of degranulated mast cells |
| GB0916630D0 (en) | 2009-09-22 | 2009-11-04 | Secr Defence | Antibody |
| JP2013505300A (en) | 2009-09-22 | 2013-02-14 | エルロン・セラピューティクス・インコーポレイテッド | Peptidomimetic macrocycle |
| EP2483307A1 (en) | 2009-09-29 | 2012-08-08 | Fraunhofer USA, Inc. | Influenza hemagglutinin antibodies, compositions, and related methods |
| GB0917817D0 (en) | 2009-10-12 | 2009-11-25 | Biotica Tech Ltd | Novel compounds and methods for their production |
| GB0917816D0 (en) | 2009-10-12 | 2009-11-25 | Biotica Tech Ltd | Novel compounds and methods for their production |
| US20120231004A1 (en) | 2009-10-13 | 2012-09-13 | Oxford Biotherapeutic Ltd. | Antibodies |
| CA2777242A1 (en) | 2009-10-14 | 2011-04-21 | Merrimack Pharmaceuticals, Inc. | Bispecific binding agents targeting igf-1r and erbb3 signalling and uses thereof |
| WO2011051327A2 (en) | 2009-10-30 | 2011-05-05 | Novartis Ag | Small antibody-like single chain proteins |
| WO2011051466A1 (en) | 2009-11-02 | 2011-05-05 | Novartis Ag | Anti-idiotypic fibronectin-based binding molecules and uses thereof |
| JP2013509869A (en) | 2009-11-05 | 2013-03-21 | ノバルティス アーゲー | Biomarkers for predicting fibrosis progression |
| EP2507265B1 (en) | 2009-12-01 | 2016-05-11 | Compugen Ltd. | Antibody specific for heparanase splice variant T5 and its use. |
| US10087236B2 (en) | 2009-12-02 | 2018-10-02 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
| US11377485B2 (en) | 2009-12-02 | 2022-07-05 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
| CN105125572A (en) | 2009-12-18 | 2015-12-09 | 箭头研究公司 | Organic compositions to treat hsf1-related diseases |
| WO2011076781A1 (en) | 2009-12-22 | 2011-06-30 | Novartis Ag | Tetravalent cd47-antibody constant region fusion protein for use in therapy |
| US9180127B2 (en) | 2009-12-29 | 2015-11-10 | Dana-Farber Cancer Institute, Inc. | Type II Raf kinase inhibitors |
| JP6210685B2 (en) | 2010-01-27 | 2017-10-11 | マサチューセッツ インスティテュート オブ テクノロジー | Engineered polypeptide agents for targeted broad spectrum influenza neutralization |
| WO2011092233A1 (en) | 2010-01-29 | 2011-08-04 | Novartis Ag | Yeast mating to produce high-affinity combinations of fibronectin-based binders |
| RU2569061C2 (en) * | 2010-02-03 | 2015-11-20 | Инфинити Фармасьютикалз, Инк. | Inhibitors of amide-hydrolase of fatty acids |
| CA2789125A1 (en) | 2010-02-10 | 2011-08-18 | Novartis Ag | Methods and compounds for muscle growth |
| EP2544674B1 (en) | 2010-03-08 | 2017-10-25 | Sloan Kettering Institute For Cancer Research | Cdc7 kinase inhibitors and uses thereof |
| GB201003920D0 (en) | 2010-03-09 | 2010-04-21 | Glaxosmithkline Biolog Sa | Method of treatment |
| GB201003922D0 (en) | 2010-03-09 | 2010-04-21 | Glaxosmithkline Biolog Sa | Conjugation process |
| SG183983A1 (en) | 2010-03-17 | 2012-10-30 | Abbott Res Bv | Anti-nerve growth factor (ngf) antibody compositions |
| US9102697B2 (en) | 2010-03-22 | 2015-08-11 | President And Fellows Of Harvard College | Trioxacarcins and uses thereof |
| EP2371864A1 (en) | 2010-03-23 | 2011-10-05 | Ganymed Pharmaceuticals AG | Monoclonal antibodies for treatment of cancer |
| CN107098958B (en) | 2010-03-26 | 2021-11-05 | 达特茅斯大学理事会 | VISTA regulatory T cell mediator protein, VISTA binding agent and uses thereof |
| US10745467B2 (en) | 2010-03-26 | 2020-08-18 | The Trustees Of Dartmouth College | VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders |
| US20150231215A1 (en) | 2012-06-22 | 2015-08-20 | Randolph J. Noelle | VISTA Antagonist and Methods of Use |
| US10338069B2 (en) | 2010-04-12 | 2019-07-02 | Academia Sinica | Glycan arrays for high throughput screening of viruses |
| WO2011130434A2 (en) | 2010-04-13 | 2011-10-20 | Celldex Therapeutics Inc. | Antibodies that bind human cd27 and uses thereof |
| LT2558499T (en) | 2010-04-16 | 2017-07-25 | Biogen Ma Inc. | Anti-vla-4 antibodies |
| EP3431604A1 (en) | 2010-04-23 | 2019-01-23 | Arrowhead Pharmaceuticals, Inc. | Organic compositions to treat beta-enac-related diseases |
| WO2011140254A1 (en) | 2010-05-04 | 2011-11-10 | Adimab, Llc | Antibodies against epidermal growth factor receptor (egfr) and uses thereof |
| WO2011140151A1 (en) | 2010-05-04 | 2011-11-10 | Dyax Corp. | Antibodies against epidermal growth factor receptor (egfr) |
| US8450350B2 (en) | 2010-05-05 | 2013-05-28 | Infinity Pharmaceuticals, Inc. | Triazoles as inhibitors of fatty acid synthase |
| EP2566853B1 (en) | 2010-05-05 | 2017-01-25 | Infinity Pharmaceuticals, Inc. | Tetrazolones as inhibitors of fatty acid synthase |
| JP2013526277A (en) | 2010-05-07 | 2013-06-24 | グリーンライト バイオサイエンシーズ インコーポレーテッド | Controlling flux of metabolic pathways by enzyme relocation |
| TWI592391B (en) | 2010-05-11 | 2017-07-21 | 藍瑟斯醫學影像公司 | Compositions, methods and systems for the synthesis and use of imaging agents |
| US8658603B2 (en) | 2010-06-16 | 2014-02-25 | The Regents Of The University Of Michigan | Compositions and methods for inducing an immune response |
| JP5857043B2 (en) | 2010-06-18 | 2016-02-10 | 大鵬薬品工業株式会社 | PRPK-TPRKB modulator and use thereof |
| US10045911B2 (en) * | 2010-06-25 | 2018-08-14 | Genetronics, Inc. | Intradermal injection device |
| EP3202415B1 (en) | 2010-06-30 | 2021-12-08 | Compugen Ltd. | Fusion protein comprising a c1orf32 polypeptide and one or more domains of an immunoglobulin heavy chain constant region for treatment of multiple sclerosis, rheumatoid arthritis and other autoimmune disorders. |
| CA2804154C (en) | 2010-07-01 | 2021-06-01 | The Texas A&M University System | Perlecan domain v protects, repairs and restores ischemic brain stroke injury and motor function |
| AU2011277983C1 (en) | 2010-07-16 | 2016-09-29 | Ablynx Nv | Modified single domain antigen binding molecules and uses thereof |
| US8822663B2 (en) | 2010-08-06 | 2014-09-02 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| KR20170058446A (en) | 2010-08-13 | 2017-05-26 | 에일러론 테라퓨틱스 인코포레이티드 | Peptidomimetic macrocycles |
| WO2012022734A2 (en) | 2010-08-16 | 2012-02-23 | Medimmune Limited | Anti-icam-1 antibodies and methods of use |
| DK3219796T3 (en) | 2010-08-31 | 2020-12-21 | Greenlight Biosciences Inc | PROCEDURES FOR MONITORING FLOW IN METABOLIC REACTIONS BY PROTEASE MANIPULATION |
| WO2012035518A1 (en) | 2010-09-17 | 2012-03-22 | Compugen Ltd. | Compositions and methods for treatment of drug resistant multiple myeloma |
| US8802110B2 (en) | 2010-09-21 | 2014-08-12 | Massachusetts Institute Of Technology | Influenza treatment and/or characterization, human-adapted HA polypeptides; vaccines |
| WO2012040459A2 (en) | 2010-09-22 | 2012-03-29 | President And Fellows Of Harvard College | Beta-catenin targeting peptides and uses thereof |
| WO2012042480A1 (en) | 2010-09-28 | 2012-04-05 | Kahr Medical Ltd. | Compositions and methods for treatment of hematological malignancies |
| EP3828205A1 (en) | 2010-10-01 | 2021-06-02 | Oxford BioTherapeutics Ltd | Anti-ror1 antibodies |
| WO2012044684A2 (en) | 2010-10-01 | 2012-04-05 | Biogen Idec Ma Inc. | Interferon-beta for use as monotherapy or in combination with other cancer therapies |
| HUE058896T2 (en) | 2010-10-01 | 2022-09-28 | Modernatx Inc | Ribonucleic acids containing n1-methyl-pseudouracils and uses thereof |
| US10226527B2 (en) | 2010-10-04 | 2019-03-12 | Massachusetts Institute Of Technology | Hemagglutinin polypeptides, and reagents and methods relating thereto |
| JP2013543384A (en) | 2010-10-05 | 2013-12-05 | ノバルティス アーゲー | Anti-IL12Rbeta1 antibody and its use in the treatment of autoimmune and inflammatory diseases |
| WO2012064973A2 (en) | 2010-11-10 | 2012-05-18 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| JP6017439B2 (en) | 2010-11-24 | 2016-11-02 | ノバルティス・インターナショナル・ファーマシューティカル・リミテッドＮｏｖａｒｔｉｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｌｔｄ． | Fusion enzyme having N-acetylglucosaminyltransferase activity |
| US10208349B2 (en) | 2011-01-07 | 2019-02-19 | Ucb Biopharma Sprl | Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy |
| GB201100282D0 (en) | 2011-01-07 | 2011-02-23 | Ucb Pharma Sa | Biological methods |
| US8809349B2 (en) | 2011-01-10 | 2014-08-19 | Infinity Pharmaceuticals, Inc. | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
| ES2687494T3 (en) | 2011-01-19 | 2018-10-25 | Topokine Therapeutics, Inc. | Methods and compositions to reduce body fat |
| EP3689331A1 (en) | 2011-01-24 | 2020-08-05 | Anterios, Inc. | Nanoparticle compositions, formulations thereof, and uses thereof |
| US20120328549A1 (en) | 2011-01-24 | 2012-12-27 | Anterios, Inc. | Oil compositions |
| TR201905477T4 (en) | 2011-01-24 | 2019-05-21 | Anterios Inc | Nano-particle compositions. |
| US9173999B2 (en) | 2011-01-26 | 2015-11-03 | Kaleo, Inc. | Devices and methods for delivering medicaments from a multi-chamber container |
| US8627816B2 (en) | 2011-02-28 | 2014-01-14 | Intelliject, Inc. | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
| US8939943B2 (en) | 2011-01-26 | 2015-01-27 | Kaleo, Inc. | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
| SG193258A1 (en) | 2011-03-03 | 2013-10-30 | Tersus Pharmaceuticals Llc | COMPOSITIONS AND METHODS COMPRISING C16:1n7-PALMITOLEATE |
| WO2012119989A2 (en) | 2011-03-04 | 2012-09-13 | Oryzon Genomics, S.A. | Methods and antibodies for the diagnosis and treatment of cancer |
| GB201103836D0 (en) | 2011-03-07 | 2011-04-20 | Glaxosmithkline Biolog Sa | Conjugation process |
| WO2012135615A2 (en) | 2011-03-30 | 2012-10-04 | Brown University | Enopeptins, uses thereof, and methods of synthesis thereto |
| US8710200B2 (en) | 2011-03-31 | 2014-04-29 | Moderna Therapeutics, Inc. | Engineered nucleic acids encoding a modified erythropoietin and their expression |
| CN103596974B (en) | 2011-04-15 | 2016-08-31 | 卡姆普根有限公司 | Polypeptide and polynucleotide and for treating immunity related disorder and the purposes of cancer |
| US20140072622A1 (en) | 2011-05-17 | 2014-03-13 | Glaxosmithkline Biologicals S.A. | Vaccine against streptococcus pneumoniae |
| US8691231B2 (en) | 2011-06-03 | 2014-04-08 | Merrimack Pharmaceuticals, Inc. | Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies |
| BR112013031762A2 (en) | 2011-06-16 | 2016-09-13 | Novartis Ag | soluble proteins for use as therapeutics |
| EP2723384B1 (en) | 2011-06-22 | 2018-08-29 | The General Hospital Corporation | Treatment of proteinopathies |
| EP2726508B1 (en) | 2011-06-28 | 2017-08-09 | Oxford BioTherapeutics Ltd | Antibodies to adp-ribosyl cyclase 2 |
| EP2726503B1 (en) | 2011-06-30 | 2019-09-04 | Compugen Ltd. | Polypeptides and uses thereof for treatment of autoimmune disorders and infection |
| JP6472999B2 (en) | 2011-07-01 | 2019-02-20 | ノバルティス アーゲー | Methods for treating metabolic disorders |
| CN103930422A (en) | 2011-07-19 | 2014-07-16 | 无限药品股份有限公司 | Heterocyclic compounds and uses thereof |
| JP6027611B2 (en) | 2011-07-19 | 2016-11-16 | インフィニティー ファーマシューティカルズ， インコーポレイテッド | Heterocyclic compounds and uses thereof |
| ES2719266T3 (en) | 2011-07-22 | 2019-07-09 | Massachusetts Inst Technology | Histone deacetylase class I activators (HDACS), and uses thereof |
| EP2736928B1 (en) | 2011-07-28 | 2019-01-09 | i2 Pharmaceuticals, Inc. | Sur-binding proteins against erbb3 |
| US9408972B2 (en) | 2011-08-02 | 2016-08-09 | Pharmajet, Inc. | Needle-free injection device |
| AU2012302197B2 (en) | 2011-08-29 | 2016-01-07 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
| EP3521432A1 (en) | 2011-09-02 | 2019-08-07 | Arrowhead Pharmaceuticals, Inc. | Organic compositions to treat hsf1-related diseases |
| JP2014526250A (en) | 2011-09-09 | 2014-10-06 | グリーンライト バイオサイエンシーズ インコーポレーテッド | Cell-free preparation of carbapenem |
| CA3123737A1 (en) | 2011-09-09 | 2013-03-14 | Lantheus Medical Imaging, Inc. | Compositions, methods, and systems for the synthesis and use of imaging agents |
| EP3384938A1 (en) | 2011-09-12 | 2018-10-10 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| AU2013201121A1 (en) | 2011-09-20 | 2013-04-04 | Vical Incorporated | Synergistic anti-tumor efficacy using alloantigen combination immunotherapy |
| EP2758437B1 (en) | 2011-09-22 | 2020-06-03 | Amgen Inc. | Cd27l antigen binding proteins |
| US9630979B2 (en) | 2011-09-29 | 2017-04-25 | Infinity Pharmaceuticals, Inc. | Inhibitors of monoacylglycerol lipase and methods of their use |
| RS62993B1 (en) | 2011-10-03 | 2022-03-31 | Modernatx Inc | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| RU2639523C2 (en) | 2011-10-18 | 2017-12-21 | Эйлерон Терапьютикс, Инк. | Peptidomimetic macrocycles and their application |
| WO2013074986A1 (en) | 2011-11-17 | 2013-05-23 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-jun-n-terminal kinase (jnk) |
| GB201119999D0 (en) | 2011-11-20 | 2012-01-04 | Glaxosmithkline Biolog Sa | Vaccine |
| GB201120000D0 (en) | 2011-11-20 | 2012-01-04 | Glaxosmithkline Biolog Sa | Vaccine |
| WO2013090315A1 (en) | 2011-12-13 | 2013-06-20 | Pharmajet Inc. | Needle-free intradermal injection device |
| US9255665B2 (en) | 2011-12-15 | 2016-02-09 | Socpra Sciences Et Genie S.E.C. | Mechanism for puncturing a gas cartridge |
| WO2013090750A1 (en) | 2011-12-16 | 2013-06-20 | University Of Florida Research Foundation, Inc. | Uses of 4'-desferrithiocin analogs |
| CN104114572A (en) | 2011-12-16 | 2014-10-22 | 现代治疗公司 | Modified nucleoside, nucleotide, and nucleic acid compositions |
| US8426471B1 (en) | 2011-12-19 | 2013-04-23 | Topokine Therapeutics, Inc. | Methods and compositions for reducing body fat and adipocytes |
| US9975956B2 (en) | 2011-12-22 | 2018-05-22 | I2 Pharmaceuticals, Inc. | Surrogate binding proteins which bind DR4 and/or DR5 |
| GB201122305D0 (en) | 2011-12-23 | 2012-02-01 | Biotica Tech Ltd | Novel compound |
| EP3358000A3 (en) | 2012-01-05 | 2018-12-19 | Glykos Finland Oy | Protease deficient filamentous fungal cells and methods of use thereof |
| JP6158833B2 (en) | 2012-01-09 | 2017-07-05 | アローヘッド ファーマシューティカルズ インコーポレイテッド | Organic composition for treating beta-catenin related diseases |
| JP2015512616A (en) | 2012-02-01 | 2015-04-30 | コンピュゲン エルティーディー． | C1ORF32 antibody and its use for the treatment of cancer |
| AR089972A1 (en) | 2012-02-13 | 2014-10-01 | Bristol Myers Squibb Co | ENEDIINO COMPOUNDS, CONJUGATES OF THESE AND THEIR USES AND METHODS |
| CA2864120A1 (en) | 2012-02-15 | 2013-08-22 | Aileron Therapeutics, Inc. | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles |
| CA2862038C (en) | 2012-02-15 | 2021-05-25 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
| WO2013142796A2 (en) | 2012-03-23 | 2013-09-26 | Bristol-Myers Squibb Company | Methods of treatments using ctla4 antibodies |
| WO2013144758A1 (en) | 2012-03-27 | 2013-10-03 | Novartis Ag | Treatment of fibrosis |
| US10106833B2 (en) | 2012-04-06 | 2018-10-23 | President And Fellows Of Harvard College | Methods and compounds for identifying glycosyltransferase inhibitors |
| US9273084B2 (en) | 2012-04-06 | 2016-03-01 | President And Fellows Of Harvard College | Moenomycin analogs, methods of synthesis, and uses thereof |
| WO2013152279A1 (en) | 2012-04-06 | 2013-10-10 | President And Fellows Of Harvard College | Chemoenzymatic methods for synthesizing moenomycin analogs |
| US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| US10130714B2 (en) | 2012-04-14 | 2018-11-20 | Academia Sinica | Enhanced anti-influenza agents conjugated with anti-inflammatory activity |
| US9181572B2 (en) | 2012-04-20 | 2015-11-10 | Abbvie, Inc. | Methods to modulate lysine variant distribution |
| EP2841098A4 (en) | 2012-04-23 | 2016-03-02 | Allertein Therapeutics Llc | Nanoparticles for treatment of allergy |
| WO2013167153A1 (en) | 2012-05-09 | 2013-11-14 | Ganymed Pharmaceuticals Ag | Antibodies useful in cancer diagnosis |
| US9969794B2 (en) | 2012-05-10 | 2018-05-15 | Visterra, Inc. | HA binding agents |
| SG11201406769RA (en) | 2012-05-10 | 2014-11-27 | Massachusetts Inst Technology | Agents for influenza neutralization |
| US9399672B2 (en) | 2012-05-17 | 2016-07-26 | The United States Of America, As Represented By The Secretary Department Of Health And Human Services | Hepatitis C virus neutralizing antibody |
| UY34813A (en) | 2012-05-18 | 2013-11-29 | Amgen Inc | ANTIGEN UNION PROTEINS DIRECTED AGAINST ST2 RECEIVER |
| US9522235B2 (en) | 2012-05-22 | 2016-12-20 | Kaleo, Inc. | Devices and methods for delivering medicaments from a multi-chamber container |
| DK2852610T3 (en) | 2012-05-23 | 2018-09-03 | Glykos Finland Oy | PRODUCTION OF FUCOSYLED GLYCOPROTEIN |
| US9249182B2 (en) | 2012-05-24 | 2016-02-02 | Abbvie, Inc. | Purification of antibodies using hydrophobic interaction chromatography |
| US9890215B2 (en) | 2012-06-22 | 2018-02-13 | King's College London | Vista modulators for diagnosis and treatment of cancer |
| AR091649A1 (en) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | OPTIMIZATION OF ANTIBODIES THAT FIX THE LYMPHOCYTE ACTIVATION GEN 3 (LAG-3) AND ITS USES |
| AU2013301312A1 (en) | 2012-08-06 | 2015-03-19 | Glaxosmithkline Biologicals S.A. | Method for eliciting in infants an immune response against RSV and B. pertussis |
| US20140037680A1 (en) | 2012-08-06 | 2014-02-06 | Glaxosmithkline Biologicals, S.A. | Novel method |
| AU2013203000B9 (en) | 2012-08-10 | 2017-02-02 | Lantheus Medical Imaging, Inc. | Compositions, methods, and systems for the synthesis and use of imaging agents |
| US9914956B2 (en) | 2012-08-18 | 2018-03-13 | Academia Sinica | Cell-permeable probes for identification and imaging of sialidases |
| CA2884704C (en) | 2012-09-07 | 2023-04-04 | Randolph J. Noelle | Vista modulators for diagnosis and treatment of cancer |
| DK2920197T3 (en) | 2012-09-26 | 2021-05-31 | Harvard College | PROLINE-LOCKED STOPPED PEPTIDES AND USES THEREOF |
| WO2014055564A1 (en) | 2012-10-01 | 2014-04-10 | President And Fellows Of Harvard College | Stabilized polypeptide insulin receptor modulators |
| PT2909204T (en) | 2012-10-12 | 2019-03-21 | Dana Farber Cancer Inst Inc | Gsk3 inhibitors and methods of use thereof |
| EP2909194A1 (en) | 2012-10-18 | 2015-08-26 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| US9758522B2 (en) | 2012-10-19 | 2017-09-12 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
| WO2014063054A1 (en) | 2012-10-19 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof |
| WO2014066443A1 (en) | 2012-10-23 | 2014-05-01 | Emory University | Gm-csf and il-4 conjugates, compositions, and methods related thereto |
| BR112015009229B1 (en) | 2012-10-24 | 2021-07-20 | Platelet Targeted Therapeutics, Llc | COMPOSITION TARGETING THE EXPRESSION OF GENES FOR PLATELETS, USE OF A STEM CELL COMPRISING SUCH COMPOSITION TO TREAT HEMOPHILIA AND IN VITRO OR EX VIVO METHOD TO GENERATE A MODIFIED STEM CELL |
| WO2014065822A1 (en) | 2012-10-26 | 2014-05-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hepatitis c virus neutralizing epitopes, antibodies, and methods |
| JP6526563B2 (en) | 2012-11-01 | 2019-06-05 | エイルロン セラピューティクス，インコーポレイテッド | Disubstituted amino acids and methods for their preparation and use |
| RS58023B2 (en) | 2012-11-01 | 2021-12-31 | Infinity Pharmaceuticals Inc | Treatment of cancers using pi3 kinase isoform modulators |
| US9567301B2 (en) | 2012-11-02 | 2017-02-14 | Dana-Farber Cancer Institute, Inc. | Pyrrol-1-yl benzoic acid derivatives useful as myc inhibitors |
| US20150313825A1 (en) | 2012-11-21 | 2015-11-05 | Topokine Therapeutics, Inc. | Methods and compositions for locally increasing body fat |
| JP6408478B2 (en) | 2012-11-26 | 2018-10-17 | プレジデント アンド フェローズ オブ ハーバード カレッジ | Trioxacalcin, trioxacalcin-antibody complex and use thereof |
| EP4074834A1 (en) | 2012-11-26 | 2022-10-19 | ModernaTX, Inc. | Terminally modified rna |
| AU2013359419B2 (en) | 2012-12-10 | 2018-03-15 | Biogen Ma Inc. | Anti-blood dendritic cell antigen 2 antibodies and uses thereof |
| LT2935320T (en) | 2012-12-18 | 2019-11-11 | Novartis Ag | Stabilized insulin-like growth factor polypeptides |
| WO2014100695A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| CA2894130A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof |
| CA2899363A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| PT2935222T (en) | 2012-12-21 | 2018-12-10 | Epizyme Inc | Prmt5 inhibitors and uses thereof |
| AU2013370241B2 (en) | 2012-12-27 | 2018-02-15 | Kaleo, Inc. | Devices, systems and methods for locating and interacting with medicament delivery systems |
| JP2016504050A (en) | 2013-01-17 | 2016-02-12 | モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | Signal sensor polynucleotide for modification of cell phenotype |
| JO3519B1 (en) | 2013-01-25 | 2020-07-05 | Amgen Inc | Antibody constructs for CDH19 and CD3 |
| EP2948478B1 (en) | 2013-01-25 | 2019-04-03 | Amgen Inc. | Antibodies targeting cdh19 for melanoma |
| CA2898633C (en) | 2013-02-07 | 2021-07-13 | Massachusetts Institute Of Technology | Human adaptation of h5 influenza |
| ES2959258T3 (en) | 2013-02-07 | 2024-02-22 | Childrens Medical Center | Protein antigens that provide protection against pneumococcal colonization and/or disease |
| SG11201505330QA (en) | 2013-02-08 | 2015-08-28 | Novartis Ag | Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders |
| WO2015198217A2 (en) | 2013-02-08 | 2015-12-30 | Novartis Ag | Compositions and methods for long-acting antibodies targeting il-17 |
| SG11201506243XA (en) | 2013-02-14 | 2015-09-29 | Bristol Myers Squibb Co | Tubulysin compounds, methods of making and use |
| WO2014133855A1 (en) | 2013-02-28 | 2014-09-04 | Caprion Proteomics Inc. | Tuberculosis biomarkers and uses thereof |
| SG10201700952XA (en) | 2013-03-13 | 2017-04-27 | Harvard College | Stapled and stitched polypeptides and uses thereof |
| EP2968391A1 (en) | 2013-03-13 | 2016-01-20 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
| US9546203B2 (en) | 2013-03-14 | 2017-01-17 | Amgen Inc. | Aglycosylated Fc-containing polypeptides with cysteine substitutions |
| WO2014159554A1 (en) | 2013-03-14 | 2014-10-02 | Abbvie Inc. | Low acidic species compositions and methods for producing the same using displacement chromatography |
| BR112015017307A2 (en) | 2013-03-14 | 2017-11-21 | Abbvie Inc | compositions of low acid species and methods for their production and use |
| WO2014143739A2 (en) | 2013-03-15 | 2014-09-18 | Biogen Idec Ma Inc. | Anti-alpha v beta 6 antibodies and uses thereof |
| US9308236B2 (en) | 2013-03-15 | 2016-04-12 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions |
| WO2014151386A1 (en) | 2013-03-15 | 2014-09-25 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
| ES2753950T3 (en) | 2013-03-15 | 2020-04-15 | Amgen Res Munich Gmbh | Single-chain binding molecules comprising N-terminus ABP |
| WO2014144466A1 (en) | 2013-03-15 | 2014-09-18 | Biogen Idec Ma Inc. | Anti-alpha v beta 6 antibodies and uses thereof |
| US9505849B2 (en) | 2013-03-15 | 2016-11-29 | Amgen Research (Munich) Gmbh | Antibody constructs for influenza M2 and CD3 |
| CN105392801A (en) | 2013-03-15 | 2016-03-09 | 比奥根Ma公司 | Treatment and prevention of acute kidney injury using anti-alpha v beta 5 antibodies |
| CA2907915C (en) | 2013-04-03 | 2023-03-07 | Allertein Therapeutics, Llc | Immunomodulatory nanoparticle compositions comprising a plurality of nanoparticles comprising biodegradable or biocompatible polymers and hydrophilic and hydrophobic cellular components |
| AU2014248014B2 (en) | 2013-04-04 | 2018-11-08 | President And Fellows Of Harvard College | Macrolides and methods of their preparation and use |
| EP2983659B1 (en) | 2013-04-09 | 2019-11-20 | Massachusetts Institute of Technology | Drug delivery polymer and uses thereof |
| US10301359B2 (en) | 2013-04-30 | 2019-05-28 | Massachusetts Institute Of Technology | Human adaptation of H3 influenza |
| US9315472B2 (en) | 2013-05-01 | 2016-04-19 | Massachusetts Institute Of Technology | 1,3,5-triazinane-2,4,6-trione derivatives and uses thereof |
| NO2753788T3 (en) | 2013-05-10 | 2018-06-16 | ||
| AU2014273946B2 (en) | 2013-05-30 | 2020-03-12 | Infinity Pharmaceuticals, Inc. | Treatment of cancers using PI3 kinase isoform modulators |
| EA201592285A1 (en) | 2013-05-30 | 2016-05-31 | Байоджен Ма Инк. | ANTIGENSYCLING PROTEINS TO ONCOSTATIN M RECEPTOR |
| WO2014197723A2 (en) | 2013-06-05 | 2014-12-11 | Massachusetts Institute Of Technology | Human adaptation of h7 ha |
| AU2014278231B2 (en) | 2013-06-11 | 2017-05-25 | KALA BIO, Inc. | Urea derivatives and uses thereof |
| US10227390B2 (en) | 2013-06-14 | 2019-03-12 | President And Fellows Of Harvard College | Stabilized polypeptide insulin receptor modulators |
| EP3013365B1 (en) | 2013-06-26 | 2019-06-05 | Academia Sinica | Rm2 antigens and use thereof |
| ES2909438T3 (en) | 2013-06-26 | 2022-05-06 | Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Gesundheit & Umwelt Gmbh | Enantiomer (S) of mepacine as a paracaspase (MALT1) inhibitor to treat cancer |
| WO2014210564A1 (en) | 2013-06-27 | 2014-12-31 | Academia Sinica | Glycan conjugates and use thereof |
| KR20160034379A (en) | 2013-07-25 | 2016-03-29 | 다나-파버 캔서 인스티튜트 인크. | Inhibitors of transcription factors and uses thereof |
| EP3030671B1 (en) | 2013-08-05 | 2018-10-03 | Greenlight Biosciences, Inc. | Engineered proteins with a protease cleavage site |
| AU2014304545A1 (en) | 2013-08-05 | 2016-02-25 | Glaxosmithkline Biologicals S.A. | Combination immunogenic compositions |
| US9782476B2 (en) | 2013-09-06 | 2017-10-10 | Academia Sinica | Human iNKT cell activation using glycolipids with altered glycosyl groups |
| AR097648A1 (en) | 2013-09-13 | 2016-04-06 | Amgen Inc | COMBINATION OF EPIGENETIC FACTORS AND BIESPECTIVE COMPOUNDS THAT HAVE LIKE DIANA CD33 AND CD3 IN THE TREATMENT OF MYELOID LEUKEMIA |
| WO2015050959A1 (en) | 2013-10-01 | 2015-04-09 | Yale University | Anti-kit antibodies and methods of use thereof |
| US20160271265A1 (en) | 2013-10-02 | 2016-09-22 | Novartis Ag | Insulin-like growth factor mimetics for use in therapy |
| US9751888B2 (en) | 2013-10-04 | 2017-09-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| JP6466924B2 (en) | 2013-10-04 | 2019-02-06 | インフィニティー ファーマシューティカルズ， インコーポレイテッド | Heterocyclic compounds and uses thereof |
| US20160243224A1 (en) | 2013-10-04 | 2016-08-25 | Biogen Ma Inc. | Tweak antagonists for treating lupus nephritis and muscle atrophy |
| AU2014333563B9 (en) | 2013-10-11 | 2020-04-02 | Oxford Biotherapeutics Ltd | Conjugated antibodies against LY75 for the treatment of cancer |
| US9982009B2 (en) | 2013-10-15 | 2018-05-29 | Massachusetts Institute Of Technology | Methods for treating polycystic kidney disease and polycystic liver disease |
| US9902986B2 (en) | 2013-10-16 | 2018-02-27 | Massachusetts Institute Of Technology | Enterobactin conjugates and uses thereof |
| WO2015057939A1 (en) | 2013-10-18 | 2015-04-23 | Biogen Idec Ma Inc. | Anti-s1p4 antibodies and uses thereof |
| CA2927917C (en) | 2013-10-18 | 2022-08-09 | Syros Pharmaceuticals, Inc. | Heteroaromatic compounds useful for the treatment of proliferative diseases |
| AU2014337044A1 (en) | 2013-10-18 | 2016-05-05 | Dana-Farber Cancer Institute, Inc. | Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7) |
| US20160244452A1 (en) | 2013-10-21 | 2016-08-25 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| CN106061261B (en) | 2013-11-01 | 2018-04-24 | 卡拉制药公司 | Crystal form of therapeutic compounds and application thereof |
| JP6306700B2 (en) | 2013-11-01 | 2018-04-04 | ユニバーシティ オブ オスロＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｏｓｌｏ | Modified albumin and use thereof |
| US9993541B2 (en) | 2013-11-13 | 2018-06-12 | University Of Oslo | Outer membrane vesicles and uses thereof |
| WO2015071763A2 (en) | 2013-11-15 | 2015-05-21 | Oslo Universitetssykehus Hf | Ctl peptide epitopes and antigen-specific t cells, methods for their discovery, and uses thereof |
| UY35874A (en) | 2013-12-12 | 2015-07-31 | Novartis Ag | A PROCESS FOR THE PREPARATION OF A COMPOSITION OF PEGILATED PROTEINS |
| US10106607B2 (en) | 2013-12-20 | 2018-10-23 | Intervet Inc. | Caninized antibodies |
| TWI670283B (en) | 2013-12-23 | 2019-09-01 | 美商建南德克公司 | Antibodies and methods of use |
| HRP20220748T1 (en) | 2013-12-24 | 2022-09-02 | Janssen Pharmaceutica Nv | Anti-vista antibodies and fragments |
| MY180383A (en) | 2013-12-24 | 2020-11-28 | Harvard College | Cortistatin analogues and syntheses and uses thereof |
| US11014987B2 (en) | 2013-12-24 | 2021-05-25 | Janssen Pharmaceutics Nv | Anti-vista antibodies and fragments, uses thereof, and methods of identifying same |
| JP2017507118A (en) | 2014-01-16 | 2017-03-16 | アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ | Compositions and methods for the treatment and detection of cancer |
| US10150818B2 (en) | 2014-01-16 | 2018-12-11 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
| EP3099693A4 (en) | 2014-01-31 | 2017-08-16 | Dana-Farber Cancer Institute, Inc. | Uses of diazepane derivatives |
| AU2015226911B2 (en) | 2014-03-07 | 2018-03-01 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Non-narcotic CRMP2 peptides targeting sodium channels for chronic pain |
| DK3119397T3 (en) | 2014-03-19 | 2022-03-28 | Infinity Pharmaceuticals Inc | Heterocyclic compounds for use in the treatment of PI3K-gamma-mediated disorders |
| TWI687428B (en) | 2014-03-27 | 2020-03-11 | 中央研究院 | Reactive labelling compounds and uses thereof |
| WO2015149016A2 (en) | 2014-03-28 | 2015-10-01 | University Of Washington Through Its Center For Commercialization | Breast and ovarian cancer vaccines |
| WO2015164604A1 (en) | 2014-04-23 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged janus kinase inhibitors and uses thereof |
| WO2015164614A1 (en) | 2014-04-23 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Janus kinase inhibitors and uses thereof |
| WO2015168079A1 (en) | 2014-04-29 | 2015-11-05 | Infinity Pharmaceuticals, Inc. | Pyrimidine or pyridine derivatives useful as pi3k inhibitors |
| WO2015168380A1 (en) | 2014-04-30 | 2015-11-05 | Massachusetts Institute Of Technology | Siderophore-based immunization against gram-negative bacteria |
| US10533039B2 (en) | 2014-05-21 | 2020-01-14 | President And Fellows Of Harvard College | Ras inhibitory peptides and uses thereof |
| US10118969B2 (en) | 2014-05-27 | 2018-11-06 | Academia Sinica | Compositions and methods relating to universal glycoforms for enhanced antibody efficacy |
| CA2950415A1 (en) | 2014-05-27 | 2015-12-03 | Academia Sinica | Anti-cd20 glycoantibodies and uses thereof |
| KR102512592B1 (en) | 2014-05-27 | 2023-03-21 | 아카데미아 시니카 | Anti-her2 glycoantibodies and uses thereof |
| EP3149045B1 (en) | 2014-05-27 | 2023-01-18 | Academia Sinica | Compositions and methods relating to universal glycoforms for enhanced antibody efficacy |
| KR102494193B1 (en) | 2014-05-28 | 2023-01-31 | 아카데미아 시니카 | Anti-tnf-alpha glycoantibodies and uses thereof |
| SI3151921T1 (en) | 2014-06-06 | 2019-12-31 | Bristol-Myers Squibb Company | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof |
| CA2951885C (en) | 2014-06-11 | 2023-07-04 | Kathy A. Green | Use of vista agonists and antagonists to suppress or enhance humoral immunity |
| WO2015189425A1 (en) | 2014-06-13 | 2015-12-17 | Glaxosmithkline Biologicals Sa | Immunogenic combinations |
| EA034691B1 (en) | 2014-06-19 | 2020-03-06 | Ариад Фармасьютикалз, Инк. | Heteroaryl compounds for kinase inhibition |
| US10188661B2 (en) | 2014-06-27 | 2019-01-29 | Topokine Therapeutics, Inc. | Topical dosage regimen |
| US9840479B2 (en) | 2014-07-02 | 2017-12-12 | Massachusetts Institute Of Technology | Polyamine-fatty acid derived lipidoids and uses thereof |
| US20170226552A1 (en) | 2014-07-03 | 2017-08-10 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using cobalt |
| WO2016007764A1 (en) | 2014-07-09 | 2016-01-14 | Abbvie Inc. | Methods for modulating the glycosylation profile of recombinant proteins using non-commonly used sugars |
| US9517307B2 (en) | 2014-07-18 | 2016-12-13 | Kaleo, Inc. | Devices and methods for delivering opioid antagonists including formulations for naloxone |
| US10759836B2 (en) | 2014-07-18 | 2020-09-01 | University Of Washington | Cancer vaccine compositions and methods of use thereof |
| WO2016016859A1 (en) | 2014-07-31 | 2016-02-04 | Amgen Research (Munich) Gmbh | Optimized cross-species specific bispecific single chain antibody constructs |
| AR101669A1 (en) | 2014-07-31 | 2017-01-04 | Amgen Res (Munich) Gmbh | ANTIBODY CONSTRUCTS FOR CDH19 AND CD3 |
| TW201609811A (en) | 2014-07-31 | 2016-03-16 | 安美基研究（慕尼黑）公司 | Bispecific single chain antibody construct with enhanced tissue distribution |
| WO2016025331A1 (en) | 2014-08-11 | 2016-02-18 | University Of Massachusetts | Anti-ospa antibodies and methods of use |
| US10736966B2 (en) | 2014-08-12 | 2020-08-11 | Massachusetts Institute Of Technology | Brush-poly (glycoamidoamine)-lipids and uses thereof |
| JO3663B1 (en) | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | Anti-lag3 antibodies and antigen-binding fragments |
| PE20170289A1 (en) | 2014-08-19 | 2017-04-05 | Merck Sharp & Dohme | ANTI TIGIT ANTIBODIES |
| US20170275344A1 (en) | 2014-08-26 | 2017-09-28 | Compugen Ltd. | Polypeptides and uses thereof as a drug for treatment of autoimmune disorders |
| EP2993174A1 (en) | 2014-09-08 | 2016-03-09 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH | Pyrazolopyridine derivatives and their use in therapy |
| KR102422375B1 (en) | 2014-09-08 | 2022-07-18 | 아카데미아 시니카 | HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS |
| MX2017003797A (en) | 2014-09-24 | 2017-06-15 | Aileron Therapeutics Inc | Peptidomimetic macrocycles and uses thereof. |
| CA2961029A1 (en) | 2014-09-24 | 2016-03-31 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and formulations thereof |
| CA2963470A1 (en) | 2014-10-03 | 2016-04-07 | Massachusetts Institute Of Technology | Antibodies that bind ebola glycoprotein and uses thereof |
| WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| US9732119B2 (en) | 2014-10-10 | 2017-08-15 | Bristol-Myers Squibb Company | Immunomodulators |
| EP4112076A1 (en) | 2014-10-10 | 2023-01-04 | The Regents of The University of Michigan | Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease |
| KR20210142781A (en) | 2014-10-21 | 2021-11-25 | 다케다 야쿠힌 고교 가부시키가이샤 | Crystalline forms of 5-chloro-n4-[2-(dimethylphosphoryl)phenyl]-n2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]pyrimidine-2,4-diamine |
| US20180015101A1 (en) | 2014-10-28 | 2018-01-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Compositions and methods for antigen-specific tolerance |
| AU2015252119A1 (en) | 2014-11-07 | 2016-05-26 | Takeda Vaccines, Inc. | Hand, foot, and mouth vaccines and methods of manufacture and use thereof |
| MA40920A (en) | 2014-11-07 | 2017-09-12 | Takeda Vaccines Inc | VACCINES OF THE HAND, FOOT AND MOUTH, AND METHODS OF MANUFACTURING AND USE THEREOF |
| WO2016077125A1 (en) | 2014-11-10 | 2016-05-19 | Moderna Therapeutics, Inc. | Alternative nucleic acid molecules containing reduced uracil content and uses thereof |
| WO2016075137A1 (en) | 2014-11-10 | 2016-05-19 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Spiropyrazine derivatives as inhibitors of non-apoptotic regulated cell-death |
| US10077287B2 (en) | 2014-11-10 | 2018-09-18 | Bristol-Myers Squibb Company | Tubulysin analogs and methods of making and use |
| US9856292B2 (en) | 2014-11-14 | 2018-01-02 | Bristol-Myers Squibb Company | Immunomodulators |
| DK3221346T3 (en) | 2014-11-21 | 2020-10-12 | Bristol Myers Squibb Co | ANTIBODIES INCLUDING MODIFIED CONSTANT AREAS OF THE HEAVY CHAIN |
| HUE050596T2 (en) | 2014-11-21 | 2020-12-28 | Bristol Myers Squibb Co | Antibodies against cd73 and uses thereof |
| US10253045B2 (en) | 2014-11-26 | 2019-04-09 | Kala Pharmaceuticals, Inc. | Crystalline forms of a therapeutic compound and uses thereof |
| EP3227341A1 (en) | 2014-12-02 | 2017-10-11 | CeMM - Forschungszentrum für Molekulare Medizin GmbH | Anti-mutant calreticulin antibodies and their use in the diagnosis and therapy of myeloid malignancies |
| WO2016090347A1 (en) | 2014-12-05 | 2016-06-09 | Immunext, Inc. | Identification of vsig8 as the putative vista receptor and its use thereof to produce vista/vsig8 modulators |
| WO2016094710A1 (en) | 2014-12-10 | 2016-06-16 | Kala Pharmaceuticals, Inc. | 1 -amino-triazolo(1,5-a)pyridine-substituted urea derivative and uses thereof |
| US9861680B2 (en) | 2014-12-18 | 2018-01-09 | Bristol-Myers Squibb Company | Immunomodulators |
| JP6738348B2 (en) | 2014-12-19 | 2020-08-12 | リジェネサンス ベスローテン フェンノートシャップ | Antibodies that bind to human C6 and uses thereof |
| AU2015369707B2 (en) | 2014-12-23 | 2020-07-23 | Sloan-Kettering Institute For Cancer Research | Polymorph of granaticin B |
| AU2015369683C1 (en) | 2014-12-23 | 2024-06-20 | Bristol-Myers Squibb Company | Antibodies to TIGIT |
| CA2972239A1 (en) | 2014-12-23 | 2016-06-30 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| JP6863897B2 (en) | 2015-01-09 | 2021-04-21 | アダルタ・リミテッド | CXCR4 binding molecule |
| WO2016115201A1 (en) | 2015-01-14 | 2016-07-21 | Bristol-Myers Squibb Company | Heteroarylene-bridged benzodiazepine dimers, conjugates thereof, and methods of making and using |
| US10495645B2 (en) | 2015-01-16 | 2019-12-03 | Academia Sinica | Cancer markers and methods of use thereof |
| US9975965B2 (en) | 2015-01-16 | 2018-05-22 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
| EP3248005B1 (en) | 2015-01-24 | 2020-12-09 | Academia Sinica | Novel glycan conjugates and methods of use thereof |
| US20160222060A1 (en) | 2015-02-04 | 2016-08-04 | Bristol-Myers Squibb Company | Immunomodulators |
| WO2016127052A1 (en) | 2015-02-05 | 2016-08-11 | Bristol-Myers Squibb Company | Cxcl11 and smica as predictive biomarkers for efficacy of anti-ctla4 immunotherapy |
| EP4226937A3 (en) | 2015-03-05 | 2023-09-27 | Northwestern University | Non-neuroinvasive viruses and uses thereof |
| WO2016144773A1 (en) | 2015-03-06 | 2016-09-15 | Abbvie Inc. | Arabinosylated glycoproteins |
| EP3268037B1 (en) | 2015-03-09 | 2022-08-31 | Celldex Therapeutics, Inc. | Cd27 agonists |
| US9809625B2 (en) | 2015-03-18 | 2017-11-07 | Bristol-Myers Squibb Company | Immunomodulators |
| CN107614003A (en) | 2015-03-20 | 2018-01-19 | 艾瑞朗医疗公司 | Peptidomimetic macrocyclic compound and application thereof |
| AU2016235054B2 (en) | 2015-03-24 | 2020-07-16 | Kaleo, Inc. | Devices and methods for delivering a lyophilized medicament |
| EP3273966B1 (en) | 2015-03-27 | 2023-05-03 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
| CN107614682B (en) | 2015-03-30 | 2021-11-09 | 绿光生物科技股份有限公司 | Cell-free production of ribonucleic acids |
| RU2736732C2 (en) | 2015-04-02 | 2020-11-19 | Интервет Интернэшнл Б.В. | Antibodies to canine interleukin-4 alpha receptor |
| IL283764B2 (en) | 2015-04-10 | 2024-01-01 | Amgen Inc | Interleukin-2 muteins for the expansion of t-regulatory cells |
| CA2979826A1 (en) | 2015-04-10 | 2016-10-13 | Ruth Brack-Werner | Pyrone derivatives for use in therapy |
| HUE061730T2 (en) | 2015-04-17 | 2023-08-28 | Amgen Res Munich Gmbh | Bispecific antibody constructs for cdh3 and cd3 |
| AU2016255770A1 (en) | 2015-04-27 | 2017-11-16 | University Of Florida Research Foundation, Incorporated | Metabolically programmed metal chelators and uses thereof |
| AU2016254215A1 (en) | 2015-04-30 | 2017-10-26 | President And Fellows Of Harvard College | Anti-aP2 antibodies and antigen binding agents to treat metabolic disorders |
| WO2016178591A2 (en) | 2015-05-05 | 2016-11-10 | Gene Predit, Sa | Genetic markers and treatment of male obesity |
| CN107849142B (en) | 2015-05-15 | 2022-04-26 | 综合医院公司 | Antagonistic anti-tumor necrosis factor receptor superfamily antibodies |
| US10568852B2 (en) | 2015-05-22 | 2020-02-25 | Helmholtz Zentrum Munchen - Deutsches Forschungszentrum Fur Gesundheit Und Umwelt (Gmbh) | Combination compositions and their use in methods for treating obesity and obesity-related disorders |
| US10316097B2 (en) | 2015-05-27 | 2019-06-11 | Ucb Biopharma Sprl | Method for the treatment of epilepsy, epileptogenesis, seizures or convulsions by an anti-colony-stimulating factor 1 receptor (CSF-1R) antibody |
| AU2016276963C1 (en) | 2015-06-12 | 2021-08-05 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| PL3310764T3 (en) | 2015-06-19 | 2023-11-06 | Massachusetts Institute Of Technology | Alkenyl substituted 2,5-piperazinediones and their use in compositions for delivering an agent to a subject or cell |
| DK3313882T3 (en) | 2015-06-24 | 2020-05-11 | Janssen Pharmaceutica Nv | Anti-VISTA antibodies and fragments |
| JOP20200312A1 (en) | 2015-06-26 | 2017-06-16 | Novartis Ag | Factor xi antibodies and methods of use |
| BR112017028353A2 (en) | 2015-06-29 | 2018-09-04 | The Rockfeller University | cd40 antibodies with enhanced agonist activity |
| CN107835700A (en) | 2015-06-30 | 2018-03-23 | Kaleo公司 | For the automatic injector for the medicament being applied in pre-filled syringe |
| WO2017004548A1 (en) | 2015-07-01 | 2017-01-05 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
| AU2016291846B2 (en) | 2015-07-13 | 2022-05-26 | Compugen Ltd. | HIDE1 Compositions and Methods |
| TWI793062B (en) | 2015-07-31 | 2023-02-21 | 德商安美基研究（慕尼黑）公司 | Antibody constructs for dll3 and cd3 |
| TWI829617B (en) | 2015-07-31 | 2024-01-21 | 德商安美基研究（慕尼黑）公司 | Antibody constructs for flt3 and cd3 |
| TWI717375B (en) | 2015-07-31 | 2021-02-01 | 德商安美基研究（慕尼黑）公司 | Antibody constructs for cd70 and cd3 |
| TWI796283B (en) | 2015-07-31 | 2023-03-21 | 德商安美基研究（慕尼黑）公司 | Antibody constructs for msln and cd3 |
| US10369572B2 (en) | 2015-07-31 | 2019-08-06 | Point Of Care Diagnostics, Llc | Reagent dispensing apparatus |
| TWI744242B (en) | 2015-07-31 | 2021-11-01 | 德商安美基研究（慕尼黑）公司 | Antibody constructs for egfrviii and cd3 |
| JO3620B1 (en) | 2015-08-05 | 2020-08-27 | Amgen Res Munich Gmbh | Immune-checkpoint inhibitors for use in the treatment of blood-borne cancers cancers |
| WO2017044858A2 (en) | 2015-09-09 | 2017-03-16 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
| US10023613B2 (en) | 2015-09-10 | 2018-07-17 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles as modulators of MCL-1 |
| SI3350157T1 (en) | 2015-09-17 | 2022-04-29 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| PL3350333T3 (en) | 2015-09-17 | 2022-03-07 | Modernatx, Inc. | Polynucleotides containing a stabilizing tail region |
| RU2638457C2 (en) | 2015-09-28 | 2017-12-13 | Общество С Ограниченной Ответственностью "Онкомакс" | Antibodies specifically binding type 1 receptor of fibroblast growth factor, antibodies application for oncological disease treatment, method for antibodies production |
| EP3355914B1 (en) | 2015-09-29 | 2024-03-06 | The General Hospital Corporation | A composition comprising bcg for reducing cholesterol. |
| SG10202101510XA (en) | 2015-09-30 | 2021-03-30 | Rhythm Pharmaceuticals Inc | Method of treating melanocortin-4 receptor pathway-associated disorders |
| EP3355882A1 (en) | 2015-10-01 | 2018-08-08 | Kythera Biopharmaceuticals, Inc. | Compositions comprising a statin for use in methods of adipolysis |
| GB201518684D0 (en) | 2015-10-21 | 2015-12-02 | Glaxosmithkline Biolog Sa | Vaccine |
| JO3555B1 (en) | 2015-10-29 | 2020-07-05 | Merck Sharp & Dohme | Antibody neutralizing human respiratory syncytial virus |
| CN108602884B (en) | 2015-11-08 | 2024-06-25 | 豪夫迈·罗氏有限公司 | Method for screening multispecific antibodies |
| WO2017083627A1 (en) | 2015-11-13 | 2017-05-18 | Visterra, Inc. | Compositions and methods for treating and preventing influenza |
| MX2018006072A (en) | 2015-11-19 | 2018-08-01 | Squibb Bristol Myers Co | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof. |
| AR108824A1 (en) | 2015-11-21 | 2018-10-03 | Fundacio Privada Inst De Recerca De La Sida Caixa Irsicaixa | DERIVATIVES OF ANTIBODIES AGAINST HIV WITH DUAL ANTIVIRAL AND IMMUNOMODULATORY ACTIVITY |
| EP3383903A1 (en) | 2015-11-30 | 2018-10-10 | Bristol-Myers Squibb Company | Anti human ip-10 antibodies and their uses |
| FI3383920T3 (en) | 2015-11-30 | 2024-04-10 | Univ California | Tumor-specific payload delivery and immune activation using a human antibody targeting a highly specific tumor cell surface antigen |
| JP7114465B2 (en) | 2015-12-22 | 2022-08-08 | モデルナティエックス インコーポレイテッド | Compounds and compositions for intracellular delivery of drugs |
| KR20180104036A (en) | 2016-01-22 | 2018-09-19 | 머크 샤프 앤드 돔 코포레이션 | Anti-coagulation factor XI antibody |
| TWI797073B (en) | 2016-01-25 | 2023-04-01 | 德商安美基研究（慕尼黑）公司 | Pharmaceutical composition comprising bispecific antibody constructs |
| EA039859B1 (en) | 2016-02-03 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Bispecific antibody constructs binding egfrviii and cd3 |
| CR20180420A (en) | 2016-02-03 | 2018-12-05 | Amgen Inc | BIESPECTIFIC ANTIBODY CONSTRUCTS FOR BCMA AND CD3 THAT ARE LINKED TO T-CELLS |
| SI3411404T1 (en) | 2016-02-03 | 2023-01-31 | Amgen Research (Munich) Gmbh | Psma and cd3 bispecific t cell engaging antibody constructs |
| US10899836B2 (en) | 2016-02-12 | 2021-01-26 | Janssen Pharmaceutica Nv | Method of identifying anti-VISTA antibodies |
| SG11201805941WA (en) | 2016-02-17 | 2018-09-27 | Novartis Ag | Tgfbeta 2 antibodies |
| AU2017222564A1 (en) | 2016-02-24 | 2018-09-06 | Visterra, Inc. | Formulations of antibody molecules to influenza virus |
| US10143746B2 (en) | 2016-03-04 | 2018-12-04 | Bristol-Myers Squibb Company | Immunomodulators |
| US20190284293A1 (en) | 2016-03-04 | 2019-09-19 | Bristol-Myers Squibb Company | Combination therapy with anti-cd73 antibodies |
| EP3423489A1 (en) | 2016-03-04 | 2019-01-09 | The Rockefeller University | Antibodies to cd40 with enhanced agonist activity |
| JP2019515876A (en) | 2016-03-08 | 2019-06-13 | アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ | Methods for module synthesis of N-glycans and their arrays |
| WO2017161116A1 (en) | 2016-03-17 | 2017-09-21 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors |
| US10358463B2 (en) | 2016-04-05 | 2019-07-23 | Bristol-Myers Squibb Company | Immunomodulators |
| CA3020312A1 (en) | 2016-04-06 | 2017-10-12 | Greenlight Biosciences, Inc. | Cell-free production of ribonucleic acid |
| US20210017281A1 (en) | 2016-04-15 | 2021-01-21 | Immunext, Inc. | Anti-human vista antibodies and use thereof |
| EP3445385A4 (en) | 2016-04-18 | 2019-11-20 | The Trustees of Columbia University in the City of New York | Therapeutic targets involved in the progression of nonalcoholic steatohepatitis (nash) |
| CN109071665B (en) | 2016-04-18 | 2022-11-01 | 塞德斯医疗公司 | Agonistic antibodies that bind human CD40 and uses thereof |
| JOP20170091B1 (en) | 2016-04-19 | 2021-08-17 | Amgen Res Munich Gmbh | Administration of a bispecific construct binding to CD33 and CD3 for use in a method for the treatment of myeloid leukemia |
| CA3019588A1 (en) | 2016-04-20 | 2017-10-26 | Merck Sharp & Dohme Corp. | Cmv neutralizing antigen binding proteins |
| AU2017251983B2 (en) | 2016-04-22 | 2023-07-20 | BioNTech SE | Methods for providing single-stranded RNA |
| CN109071623B (en) | 2016-05-04 | 2022-05-27 | 美国安进公司 | Interleukin-2 muteins for expansion of T regulatory cells |
| KR102417687B1 (en) | 2016-05-09 | 2022-07-07 | 브리스톨-마이어스 스큅 컴퍼니 | TL1A antibodies and uses thereof |
| WO2017201390A1 (en) | 2016-05-19 | 2017-11-23 | The Regents Of The University Of Michigan | Novel adjuvant compositions |
| TW201802121A (en) | 2016-05-25 | 2018-01-16 | 諾華公司 | Reversal binding agents for anti-factor XI/XIa antibodies and uses thereof |
| BR112018075078A2 (en) | 2016-06-03 | 2019-03-06 | Sanofi Pasteur Inc. | modification of manipulated influenza hemagglutinin polypeptides |
| US10105449B2 (en) | 2016-06-07 | 2018-10-23 | Massachusetts Institute Of Technology | Drug delivery polymers and uses thereof |
| US10919914B2 (en) | 2016-06-08 | 2021-02-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| TWI802193B (en) | 2016-06-14 | 2023-05-11 | 美商默沙東有限責任公司 | Anti-coagulation factor xi antibodies |
| WO2017218704A1 (en) | 2016-06-14 | 2017-12-21 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| US20180002417A1 (en) | 2016-06-15 | 2018-01-04 | Celimmune Llc | Methods and Compositions for the Treatment of Celiac Disease, Non-Celiac Gluten Sensitivity, and Refractory Celiac Disease |
| GB201610599D0 (en) | 2016-06-17 | 2016-08-03 | Glaxosmithkline Biologicals Sa | Immunogenic Composition |
| TWI780057B (en) | 2016-07-14 | 2022-10-11 | 美商必治妥美雅史谷比公司 | Antibodies against tim3 and uses thereof |
| NL2017267B1 (en) | 2016-07-29 | 2018-02-01 | Aduro Biotech Holdings Europe B V | Anti-pd-1 antibodies |
| NL2017270B1 (en) | 2016-08-02 | 2018-02-09 | Aduro Biotech Holdings Europe B V | New anti-hCTLA-4 antibodies |
| EP3494141A4 (en) | 2016-08-03 | 2020-04-08 | Bio-Techne Corporation | Identification of vsig3/vista as a novel immune checkpoint and use thereof for immunotherapy |
| CA3031797A1 (en) | 2016-08-05 | 2018-02-08 | Sanofi Pasteur, Inc. | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| SG11201900794PA (en) | 2016-08-05 | 2019-02-27 | Sanofi Pasteur Inc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| CN109641911B (en) | 2016-08-19 | 2023-02-21 | 百时美施贵宝公司 | seco-cyclopropylpyrroloindole compounds and antibody-drug conjugates thereof and methods of making and using |
| CN109963868B (en) | 2016-08-22 | 2023-11-14 | 醣基生医股份有限公司 | Antibodies, binding fragments, and methods of use |
| WO2018035710A1 (en) | 2016-08-23 | 2018-03-01 | Akeso Biopharma, Inc. | Anti-ctla4 antibodies |
| WO2018044970A1 (en) | 2016-08-31 | 2018-03-08 | University Of Rochester | Human monoclonal antibodies to human endogenous retrovirus k envelope (herv-k) and uses thereof |
| JOP20190055A1 (en) | 2016-09-26 | 2019-03-24 | Merck Sharp & Dohme | Anti-cd27 antibodies |
| EP3305781A1 (en) | 2016-10-07 | 2018-04-11 | Deutsches Krebsforschungszentrum | Chemical substances which inhibit the enzymatic activity of human kallikrein-related peptidase 6 (klk6) |
| AU2017343778A1 (en) | 2016-10-13 | 2019-05-02 | Massachusetts Institute Of Technology | Antibodies that bind Zika virus envelope protein and uses thereof |
| US20190263926A1 (en) | 2016-10-28 | 2019-08-29 | Astute Medical, Inc. | Use of Antibodies to TIMP-2 for the Improvement of Renal Function |
| CN110267971B (en) | 2016-11-07 | 2023-12-19 | 百时美施贵宝公司 | Immunomodulators |
| WO2018089540A1 (en) | 2016-11-08 | 2018-05-17 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| CA3043277A1 (en) | 2016-11-11 | 2018-05-17 | The Regents Of The University Of California | Anti-cd46 antibodies and methods of use |
| CA3043131A1 (en) | 2016-11-18 | 2018-05-24 | Neurovive Pharmaceutical Ab | Use of sanglifehrin macrocyclic analogues as anticancer compounds |
| WO2018096396A1 (en) | 2016-11-22 | 2018-05-31 | University Of Oslo | Albumin variants and uses thereof |
| WO2018106738A1 (en) | 2016-12-05 | 2018-06-14 | Massachusetts Institute Of Technology | Brush-arm star polymers, conjugates and particles, and uses thereof |
| JP2020502218A (en) | 2016-12-21 | 2020-01-23 | メレオ バイオファーマ ３ リミテッド | Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta |
| AU2017381433A1 (en) | 2016-12-21 | 2019-07-04 | Mereo Biopharma 3 Limited | Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta |
| IL308980A (en) | 2016-12-23 | 2024-01-01 | Novartis Ag | Factor xi antibodies and methods of use |
| JP7014797B2 (en) | 2016-12-23 | 2022-02-01 | カレオ，インコーポレイテッド | Drug delivery devices and methods for delivering drugs to babies and children |
| KR102597943B1 (en) | 2017-01-05 | 2023-11-06 | 카 메디컬 리미티드 | PD1-41BBL fusion protein and methods of using the same |
| CN110573522B (en) | 2017-01-05 | 2023-09-19 | 卡尔医学有限公司 | SIRP alpha-41 BBL fusion proteins and methods of use thereof |
| WO2018129451A2 (en) | 2017-01-09 | 2018-07-12 | Merrimack Pharmaceuticals, Inc. | Anti-fgfr antibodies and methods of use |
| EP3570906A4 (en) | 2017-01-17 | 2020-10-21 | Kaleo, Inc. | Medicament delivery devices with wireless connectivity and event detection |
| EP3572429A4 (en) | 2017-01-23 | 2021-04-07 | Suzhou Alphamab Co., Ltd | Pd-l1 binding polypeptide or composite |
| WO2018140510A1 (en) | 2017-01-25 | 2018-08-02 | Biogen Ma Inc. | Compositions and methods for treatment of stroke and other cns disorders |
| CN108392700B (en) * | 2017-02-02 | 2020-12-22 | 黄国伦 | Pressurized gas injection apparatus and method |
| JOP20190189A1 (en) | 2017-02-02 | 2019-08-01 | Amgen Res Munich Gmbh | Low ph pharmaceutical composition comprising t cell engaging antibody constructs |
| GB201702144D0 (en) | 2017-02-09 | 2017-03-29 | Annexin Pharmaceuticals Ab | Therapeutic compositions |
| AU2018219317A1 (en) | 2017-02-10 | 2019-09-26 | Mount Tam Therapeutics, Inc. | Rapamycin analog |
| SG11201906947SA (en) | 2017-02-17 | 2019-08-27 | Bristol Myers Squibb Co | Antibodies to alpha-synuclein and uses thereof |
| GB201703876D0 (en) | 2017-03-10 | 2017-04-26 | Berlin-Chemie Ag | Pharmaceutical combinations |
| DK3596041T3 (en) | 2017-03-15 | 2023-01-23 | Modernatx Inc | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS |
| US11969506B2 (en) | 2017-03-15 | 2024-04-30 | Modernatx, Inc. | Lipid nanoparticle formulation |
| US11555031B2 (en) | 2017-03-20 | 2023-01-17 | The Broad Institute, Inc. | Compounds and methods for regulating insulin secretion |
| CN110958882B (en) | 2017-04-05 | 2023-08-29 | 布罗德研究所股份有限公司 | Tricyclic compounds as glycogen synthase kinase 3 (GSK 3) inhibitors and uses thereof |
| TWI796329B (en) | 2017-04-07 | 2023-03-21 | 美商默沙東有限責任公司 | Anti-ilt4 antibodies and antigen-binding fragments |
| TWI788340B (en) | 2017-04-07 | 2023-01-01 | 美商必治妥美雅史谷比公司 | Anti-icos agonist antibodies and uses thereof |
| CN118267470A (en) | 2017-04-13 | 2024-07-02 | 赛罗帕私人有限公司 | Anti-SIRP alpha antibodies |
| AR111773A1 (en) | 2017-05-05 | 2019-08-21 | Amgen Inc | PHARMACEUTICAL COMPOSITION THAT INCLUDES CONSTRUCTS OF BISPECTIFIC ANTIBODIES FOR STORAGE AND ADMINISTRATION |
| WO2018207023A2 (en) | 2017-05-10 | 2018-11-15 | Albajuna Therapeutics, S.L. | Fc-fusion protein derivatives with high dual hiv antiviral and immunomodulatory activity |
| CN111094335B (en) | 2017-05-15 | 2022-08-23 | 罗切斯特大学 | Broadly neutralizing anti-influenza monoclonal antibodies and uses thereof |
| CN116333129A (en) | 2017-05-25 | 2023-06-27 | 百时美施贵宝公司 | Antibodies comprising modified heavy chain constant regions |
| WO2018232120A1 (en) | 2017-06-14 | 2018-12-20 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
| US11066445B2 (en) | 2017-06-23 | 2021-07-20 | Bristol-Myers Squibb Company | Immunomodulators acting as antagonists of PD-1 |
| ES2967001T3 (en) | 2017-06-23 | 2024-04-25 | Affinivax Inc | Immunogenic compositions |
| JP2020524527A (en) | 2017-06-23 | 2020-08-20 | スージョウ ボジュホワ バイオメディカル デクノロジー カンパニー リミテッドＳｕｚｈｏｕ Ｂｏｊｕｈｕａ Ｂｉｏｍｅｄｉｃａｌ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏ． Ｌｔｄ | Monoclonal antibodies targeting human tumor stem cells and uses thereof |
| WO2019013789A1 (en) | 2017-07-12 | 2019-01-17 | Curza Global, Llc | Antimicrobial compounds |
| WO2019013790A1 (en) | 2017-07-12 | 2019-01-17 | Curza Global, Llc | Antimicrobial compounds and uses thereof |
| BR112020003498A2 (en) | 2017-08-22 | 2020-08-25 | Biogen Ma, Inc. | pharmaceutical compositions and dosage regimens that contain anti-alpha (v) beta (6) antibodies |
| GB2584009B (en) | 2017-08-28 | 2022-03-23 | Revagenix Inc | Aminoglycosides and uses thereof |
| US11744801B2 (en) | 2017-08-31 | 2023-09-05 | Modernatx, Inc. | Methods of making lipid nanoparticles |
| US12005112B2 (en) | 2017-09-07 | 2024-06-11 | University Of Oslo | Vaccine molecules |
| US20220118076A1 (en) | 2017-09-07 | 2022-04-21 | University Of Oslo | Vaccine molecules |
| EP3692053A1 (en) | 2017-10-03 | 2020-08-12 | Bristol-Myers Squibb Company | Immunomodulators |
| WO2019070901A1 (en) | 2017-10-04 | 2019-04-11 | Amgen Inc. | Transthyretin immunoglobulin fusions |
| WO2019075090A1 (en) | 2017-10-10 | 2019-04-18 | Tilos Therapeutics, Inc. | Anti-lap antibodies and uses thereof |
| MX2020003841A (en) | 2017-10-11 | 2020-11-06 | Greenlight Biosciences Inc | Methods and compositions for nucleoside triphosphate and ribonucleic acid production. |
| JP7035299B2 (en) | 2017-10-26 | 2022-03-15 | イミューンオンコ バイオファーマシューティカルズ （シャンハイ） カンパニー リミテッド | New recombinant fusion proteins, as well as their preparation and use |
| KR20200074214A (en) | 2017-11-01 | 2020-06-24 | 브리스톨-마이어스 스큅 컴퍼니 | Anti-stimulatory antibody for use in treating cancer |
| MY193736A (en) | 2017-11-03 | 2022-10-27 | Takeda Vaccines Inc | Method for inactivating zika virus and for determining the completeness of inactivation |
| SG11202004426SA (en) | 2017-11-17 | 2020-06-29 | Merck Sharp & Dohme | Antibodies specific for immunoglobulin-like transcript 3 (ilt3) and uses thereof |
| WO2019109079A1 (en) | 2017-12-01 | 2019-06-06 | North Carolina State University | Fibrin particles and methods of making the same |
| EA202091422A1 (en) | 2017-12-11 | 2020-08-28 | Эмджен Инк. | METHOD FOR CONTINUOUS PRODUCTION OF PRODUCTS BASED ON BISPECIFIC ANTIBODIES |
| WO2019123375A1 (en) | 2017-12-21 | 2019-06-27 | Gliapharm Sa | Compositions and methods of treatment for neurological disorders comprising motor neuron diseases |
| GB201721582D0 (en) | 2017-12-21 | 2018-02-07 | Glaxosmithkline Biologicals Sa | S aureus antigens and immunogenic compositions |
| GB201721576D0 (en) | 2017-12-21 | 2018-02-07 | Glaxosmithkline Biologicals Sa | Hla antigens and glycoconjugates thereof |
| CN111788186A (en) | 2017-12-21 | 2020-10-16 | 格利亚制药股份公司 | Compositions and methods for treating neurological disorders including dementia |
| JP7284759B2 (en) | 2017-12-27 | 2023-05-31 | ブリストル－マイヤーズ スクイブ カンパニー | ANTI-CD40 ANTIBODY AND USES THEREOF |
| UY38041A (en) | 2017-12-29 | 2019-06-28 | Amgen Inc | CONSTRUCTION OF BIESPECFIC ANTIBODY DIRECTED TO MUC17 AND CD3 |
| KR20200108870A (en) | 2018-01-12 | 2020-09-21 | 브리스톨-마이어스 스큅 컴퍼니 | Antibodies to TIM3 and uses thereof |
| WO2019148412A1 (en) | 2018-02-01 | 2019-08-08 | Merck Sharp & Dohme Corp. | Anti-pd-1/lag3 bispecific antibodies |
| US11787857B2 (en) | 2018-02-02 | 2023-10-17 | Bio-Techne Corporation | Compounds that modulate the interaction of VISTA and VSIG3 and methods of making and using |
| EP3749363A1 (en) | 2018-02-08 | 2020-12-16 | Amgen Inc. | Low ph pharmaceutical antibody formulation |
| NL2020520B1 (en) | 2018-03-02 | 2019-09-12 | Labo Bio Medical Invest B V | Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders |
| US20210363172A1 (en) | 2018-03-15 | 2021-11-25 | Biontech Rna Pharmaceuticals Gmbh | 5'-cap-trinucleotide- or higher oligonucleotide compounds and their use in stabilizing rna, expressing proteins in therapy |
| MX2020009861A (en) | 2018-03-23 | 2020-10-08 | Bristol Myers Squibb Co | Antibodies against mica and/or micb and uses thereof. |
| MA52190A (en) | 2018-04-02 | 2021-02-17 | Bristol Myers Squibb Co | ANTI-TREM-1 ANTIBODIES AND ASSOCIATED USES |
| WO2019194858A1 (en) | 2018-04-03 | 2019-10-10 | Achaogen, Inc. | Modular synthesis of aminoglycosides |
| US20210169969A1 (en) | 2018-04-06 | 2021-06-10 | Leonardus H.T. Van Der Ploeg | Compositions for treating kidney disease |
| CN112218657A (en) | 2018-04-12 | 2021-01-12 | 百时美施贵宝公司 | Anti-cancer combination therapy of CD73 antagonist antibody and PD-1/PD-L1 axis antagonist antibody |
| US20210198374A1 (en) | 2018-04-17 | 2021-07-01 | Celldex Therapeutics, Inc. | Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs |
| EP3781206A2 (en) | 2018-04-20 | 2021-02-24 | iOmx Therapeutics AG | A 5-thiazolecarboxamide kinase inhibitor and uses thereof |
| CA3096703A1 (en) | 2018-05-03 | 2019-11-07 | University Of Rochester | Anti-influenza neuraminidase monoclonal antibodies and uses thereof |
| SG11202011667WA (en) | 2018-05-25 | 2020-12-30 | Primmune Therapeutics Inc | Tlr7 agonists |
| CN112867394A (en) | 2018-06-04 | 2021-05-28 | 马萨诸塞州渤健公司 | anti-VLA-4 antibodies with reduced effector function |
| GB201809746D0 (en) | 2018-06-14 | 2018-08-01 | Berlin Chemie Ag | Pharmaceutical combinations |
| JP2021527693A (en) | 2018-06-21 | 2021-10-14 | ユマニティ セラピューティクス，インコーポレーテッド | Compositions and Methods for the Treatment and Prevention of Neurological Disorders |
| AU2019301316A1 (en) | 2018-07-11 | 2021-02-18 | Kahr Medical Ltd. | Sirpalpha-4-1BBL variant fusion protein and methods of use thereof |
| WO2020018433A1 (en) | 2018-07-16 | 2020-01-23 | Kaleo, Inc. | Medicament delivery devices with wireless connectivity and compliance detection |
| US20210301017A1 (en) | 2018-07-30 | 2021-09-30 | Amgen Research (Munich) Gmbh | Prolonged administration of a bispecific antibody construct binding to cd33 and cd3 |
| CA3105729A1 (en) | 2018-07-31 | 2020-02-06 | Amgen Research (Munich) Gmbh | Dosing regimen for bcma-cd3 bispecific antibodies |
| JP7412409B2 (en) | 2018-07-31 | 2024-01-12 | アムジェン インコーポレイテッド | Pharmaceutical formulations of masked antibodies |
| MA53330A (en) | 2018-08-03 | 2021-06-09 | Amgen Inc | ANTIBODY CONSTRUCTIONS FOR CLDN18.2 AND CD3 |
| WO2020029982A1 (en) | 2018-08-08 | 2020-02-13 | Immuneonco Biopharmaceuticals (Shanghai) Co., Ltd | Recombinant bifunctional protein targeting cd47 and her2 |
| WO2020049208A1 (en) | 2018-09-09 | 2020-03-12 | Fundacio Privada Institut De Recerca De La Sida - Caixa | Aurora kinase as target for treating, preventing or curing hiv infection or aids |
| CA3153959A1 (en) | 2018-09-18 | 2020-03-26 | Merrimack Pharmaceuticals, Inc. | Anti-tnfr2 antibodies and uses thereof |
| CA3113436A1 (en) | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| US20210378980A1 (en) | 2018-09-20 | 2021-12-09 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
| EP3863722A2 (en) | 2018-10-10 | 2021-08-18 | Tilos Theapeutics, Inc. | Anti-lap antibody variants and uses thereof |
| AU2019356564A1 (en) | 2018-10-11 | 2021-04-29 | Amgen Inc. | Downstream processing of bispecific antibody constructs |
| WO2020084005A1 (en) | 2018-10-23 | 2020-04-30 | Myelopro Diagnostics And Research Gmbh | Compounds targeting mutant calreticulin |
| EP3643713A1 (en) | 2018-10-23 | 2020-04-29 | iOmx Therapeutics AG | Heterocyclic kinase inhibitors and uses thereof |
| US11827670B2 (en) | 2018-11-09 | 2023-11-28 | University Of Massachusetts | Anti-CfaE antibodies and methods of use |
| WO2020102501A1 (en) | 2018-11-16 | 2020-05-22 | Bristol-Myers Squibb Company | Anti-nkg2a antibodies and uses thereof |
| CN113348177A (en) | 2018-11-28 | 2021-09-03 | 百时美施贵宝公司 | Antibodies comprising modified heavy chain constant regions |
| US20220098310A1 (en) | 2018-12-06 | 2022-03-31 | Alexion Pharmaceuticals, Inc. | Anti-alk2 antibodies and uses thereof |
| CA3123024A1 (en) | 2018-12-18 | 2020-06-25 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for enhancing body weight and lean muscle mass using antagonists against leptin receptor, gdf8 and activin a |
| WO2020128863A1 (en) | 2018-12-19 | 2020-06-25 | Novartis Ag | Anti-tnf-alpha antibodies |
| WO2020132378A2 (en) | 2018-12-22 | 2020-06-25 | Gliapharm Sa | Compositions and methods of treatment for neurological disorders comprising depression |
| WO2020144535A1 (en) | 2019-01-08 | 2020-07-16 | Aduro Biotech Holdings, Europe B.V. | Methods and compositions for treatment of multiple myeloma |
| JP2022518230A (en) | 2019-01-16 | 2022-03-14 | カーザ グローバル， エルエルシー | Antibacterial compounds and methods |
| US20230159491A1 (en) | 2019-01-16 | 2023-05-25 | Curza Global, Llc | Antimicrobial Compounds and Methods |
| CN109762067B (en) | 2019-01-17 | 2020-02-28 | 北京天广实生物技术股份有限公司 | Antibodies that bind human Claudin18.2 and uses thereof |
| KR102643707B1 (en) | 2019-01-22 | 2024-03-04 | 에오비안 파마슈티컬스, 인크. | MTORC modulators and their uses |
| JP2022522985A (en) | 2019-01-22 | 2022-04-21 | ジェネンテック， インコーポレイテッド | Immunoglobulin A antibody, and method of production and use |
| PE20212305A1 (en) | 2019-01-22 | 2021-12-10 | Bristol Myers Squibb Co | ANTIBODIES AGAINST IL-7R ALPHA SUBUNIT AND USES OF THESE |
| WO2020160397A1 (en) | 2019-01-31 | 2020-08-06 | Modernatx, Inc. | Methods of preparing lipid nanoparticles |
| WO2020168466A1 (en) | 2019-02-19 | 2020-08-27 | Stemirna Therapeutics Co., Ltd. | Modified nucleoside and synthetic methods thereof |
| WO2020180712A1 (en) | 2019-03-01 | 2020-09-10 | Merrimack Pharmaceuticals, Inc. | Anti-tnfr2 antibodies and uses thereof |
| EP3938395A1 (en) | 2019-03-11 | 2022-01-19 | Biogen MA Inc. | Pharmaceutical compositions containing anti-lingo-1 antibodies |
| JP2022521819A (en) | 2019-03-25 | 2022-04-12 | ビステラ， インコーポレイテッド | Compositions and Methods for Treating and Preventing Influenza |
| JP2022527372A (en) | 2019-04-08 | 2022-06-01 | バイオジェン・エムエイ・インコーポレイテッド | Anti-integrin antibodies and their use |
| EP3972694A1 (en) | 2019-05-21 | 2022-03-30 | Bristol-Myers Squibb Company | Immunomodulators |
| MA56205A (en) | 2019-06-11 | 2022-04-20 | Regeneron Pharma | ANTI-PCRV ANTIBODIES WHICH BIND TO PCRV, COMPOSITIONS COMPRISING ANTI-PCRV ANTIBODIES, AND METHODS OF USE THEREOF |
| TW202045711A (en) | 2019-06-13 | 2020-12-16 | 美商安進公司 | Automated biomass-based perfusion control in the manufacturing of biologics |
| US20220324924A1 (en) | 2019-07-08 | 2022-10-13 | Amgen Inc. | Multispecific transthyretin immunoglobulin fusions |
| EP3997114A1 (en) | 2019-07-11 | 2022-05-18 | KAHR Medical Ltd. | Heterodimers and methods of use thereof |
| CN114174536A (en) | 2019-07-15 | 2022-03-11 | 百时美施贵宝公司 | anti-TREM-1 antibodies and uses thereof |
| CN114174337A (en) | 2019-07-15 | 2022-03-11 | 英特维特国际股份有限公司 | Caninized antibodies against canine CTLA-4 |
| AU2020312687A1 (en) | 2019-07-15 | 2022-01-27 | Intervet International B.V. | Caninized antibodies to human and canine CTLA-4 |
| CN114144435B (en) | 2019-07-15 | 2024-06-25 | 百时美施贵宝公司 | Antibodies against human TREM-1 and uses thereof |
| AU2020319876A1 (en) | 2019-07-31 | 2022-02-24 | Modernatx, Inc. | Compositions and methods for delivery of RNA interference agents to immune cells |
| CA3148824A1 (en) | 2019-07-31 | 2021-02-04 | Sanofi Pasteur Inc. | Multivalent pneumococcal polysaccharide-protein conjugate compositions and methods of using the same |
| US11167087B2 (en) | 2019-08-09 | 2021-11-09 | Kaleo, Inc. | Devices and methods for delivery of substances within a prefilled syringe |
| JP2022544236A (en) | 2019-08-13 | 2022-10-17 | アムジエン・インコーポレーテツド | Interleukin-2 muteins for proliferation of regulatory T cells |
| US20220340643A1 (en) | 2019-09-13 | 2022-10-27 | Rutgers, The State University Of New Jersey | Aav-compatible laminin-linker polymerization proteins |
| CN114555627A (en) | 2019-10-30 | 2022-05-27 | 百时美施贵宝公司 | Immune modulator |
| EP3819007B1 (en) | 2019-11-11 | 2024-07-10 | Amgen Research (Munich) GmbH | Dosing regimen for anti-bcma agents |
| CA3156683A1 (en) | 2019-11-13 | 2021-05-20 | Amgen Inc. | Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules |
| CN115297930A (en) | 2019-11-13 | 2022-11-04 | 库扎环球有限责任公司 | Antimicrobial compounds and methods |
| EP4061818B1 (en) | 2019-11-19 | 2023-12-06 | Bristol-Myers Squibb Company | Macrocyclic peptides as pd-l1 inhibitors and immunomodulators for the treatment of cancer and infectious diseases |
| IL293804A (en) | 2019-12-11 | 2022-08-01 | Visterra Inc | Anti-hemagglutinin (ha) antibody molecules, compositions comprising same and uses thereof |
| CA3162705A1 (en) | 2019-12-17 | 2021-06-24 | Amgen Inc. | Dual interleukin-2 /tnf receptor agonist for use in therapy |
| CA3161496A1 (en) | 2019-12-20 | 2021-06-24 | Mohamad Morsey | Bispecific caninized antibodies for treating atopic dermatitis |
| WO2021123089A1 (en) | 2019-12-20 | 2021-06-24 | Intervet International B.V. | Antibodies to canine interleukin-4 receptor alpha |
| CA3164129A1 (en) | 2019-12-20 | 2021-06-24 | Amgen Inc. | Mesothelin-targeted cd40 agonistic multispecific antibody constructs for the treatment of solid tumors |
| EP4087849B1 (en) | 2020-01-06 | 2023-12-27 | Bristol-Myers Squibb Company | Macrocyclic peptides as pd-l1 inhibitors and immunomodulators for the treatment of cancer and infectious diseases |
| CN114929728A (en) | 2020-01-06 | 2022-08-19 | 百时美施贵宝公司 | Immunomodulator |
| CN110818795B (en) | 2020-01-10 | 2020-04-24 | 上海复宏汉霖生物技术股份有限公司 | anti-TIGIT antibodies and methods of use |
| WO2021150824A1 (en) | 2020-01-22 | 2021-07-29 | Amgen Research (Munich) Gmbh | Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof |
| BR112022014970A2 (en) | 2020-01-31 | 2022-09-20 | Modernatx Inc | METHODS TO PREPARE LIPID NANOPARTICLES |
| JP2023515223A (en) | 2020-02-27 | 2023-04-12 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド | Antibodies that bind to IL4R and uses thereof |
| US11642407B2 (en) | 2020-02-28 | 2023-05-09 | Massachusetts Institute Of Technology | Identification of variable influenza residues and uses thereof |
| JP2023516459A (en) | 2020-03-09 | 2023-04-19 | ブリストル－マイヤーズ スクイブ カンパニー | ANTIBODY TO CD40 WITH ENHANCED AGONISTIC ACTIVITY |
| EP4121442A1 (en) | 2020-03-16 | 2023-01-25 | Bristol-Myers Squibb Company | Immunomodulators |
| AU2021240028A1 (en) | 2020-03-19 | 2022-09-15 | Amgen Inc. | Antibodies against mucin 17 and uses thereof |
| US20230151059A1 (en) | 2020-03-30 | 2023-05-18 | Bristol-Myers Squibb Company | Immunomodulators |
| JP2023519930A (en) | 2020-04-01 | 2023-05-15 | ユニバーシティ オブ ロチェスター | Monoclonal Antibodies Against Hemagglutinin (HA) and Neuraminidase (NA) of Influenza H3N2 Virus |
| WO2021207449A1 (en) | 2020-04-09 | 2021-10-14 | Merck Sharp & Dohme Corp. | Affinity matured anti-lap antibodies and uses thereof |
| EP3901151A1 (en) | 2020-04-21 | 2021-10-27 | iOmx Therapeutics AG | Halogenated-heteroaryl and other heterocyclic kinase inhibitors, and uses thereof |
| EP4139341A1 (en) | 2020-04-21 | 2023-03-01 | Regeneron Pharmaceuticals, Inc. | Il-2 variants with reduced binding to il-2 receptor alpha and uses thereof |
| WO2021219731A2 (en) | 2020-04-28 | 2021-11-04 | Iomx Therapeutics Ag | Bicyclic kinase inhibitors and uses thereof |
| US11634477B2 (en) | 2020-04-28 | 2023-04-25 | The Rockefeller University | Neutralizing anti-SARS-CoV-2 antibodies and methods of use thereof |
| CN115461080A (en) | 2020-04-29 | 2022-12-09 | 安进公司 | Pharmaceutical formulations |
| JP2023524444A (en) | 2020-04-29 | 2023-06-12 | アムジェン インコーポレイテッド | Pharmaceutical formulation |
| US20230183354A1 (en) | 2020-04-30 | 2023-06-15 | Sairopa B.V. | Anti-cd103 antibodies |
| KR20230008790A (en) | 2020-05-08 | 2023-01-16 | 브리스톨-마이어스 스큅 컴퍼니 | immunomodulator |
| WO2021231729A1 (en) | 2020-05-13 | 2021-11-18 | Sanofi | Adjuvanted stabilized stem hemagglutinin nanoparticles and methods of using the same to induce broadly neutralizing antibodies against influenza |
| WO2021231732A1 (en) | 2020-05-15 | 2021-11-18 | Bristol-Myers Squibb Company | Antibodies to garp |
| CA3183756A1 (en) | 2020-05-19 | 2021-11-25 | Amgen Inc. | Mageb2 binding constructs |
| WO2021237109A1 (en) | 2020-05-22 | 2021-11-25 | Trailhead Biosystems Inc. | Combination therapy for treatment of viral infections |
| JP2023527972A (en) | 2020-05-29 | 2023-07-03 | アムジエン・インコーポレーテツド | Reduced Adverse Effect Administration of Bispecific Constructs that Bind CD33 and CD3 |
| US20240148889A1 (en) | 2020-06-11 | 2024-05-09 | President And Fellows Of Harvard College | Stabilized trioxacarcin antibody drug conjugates and uses thereof |
| FR3112939B1 (en) | 2020-07-31 | 2024-01-05 | Univ Montpellier | Universal cell therapy product and its use |
| US11484604B2 (en) | 2020-08-07 | 2022-11-01 | Fortis Therapeutics, Inc. | Immunoconjugates targeting CD46 and methods of use thereof |
| WO2022046651A1 (en) | 2020-08-24 | 2022-03-03 | Amgen Inc. | Pharmaceutical formulation comprising a bite, bispecific antibody, and methionine |
| WO2022072797A1 (en) | 2020-10-02 | 2022-04-07 | Bristol-Myers Squibb Company | Macrocyclic peptide boronate immunomodulators |
| EP4225775A1 (en) | 2020-10-08 | 2023-08-16 | Bristol-Myers Squibb Company | Dimeric milla immunomodulators |
| EP4225774A1 (en) | 2020-10-09 | 2023-08-16 | Bristol-Myers Squibb Company | Macrocyclic immunomodulators |
| CN116348488A (en) | 2020-10-15 | 2023-06-27 | 英特维特国际股份有限公司 | Caninized rat antibody of canine interleukin-31 receptor alpha |
| US20230390296A1 (en) | 2020-10-30 | 2023-12-07 | Keio University | Novel treatment and prevention of sarcopenia-related diseases |
| EP4238979A1 (en) | 2020-10-30 | 2023-09-06 | Xeno-Interface Inc. | Beta-strand type crosslinked peptide |
| JP2023548878A (en) | 2020-11-04 | 2023-11-21 | ザ ロックフェラー ユニバーシティー | Neutralizing anti-SARS-COV-2 antibody |
| KR20230098335A (en) | 2020-11-06 | 2023-07-03 | 암젠 인크 | Antigen binding domains with reduced clipping ratio |
| CN116323671A (en) | 2020-11-06 | 2023-06-23 | 安进公司 | Multi-targeting bispecific antigen binding molecules with increased selectivity |
| CA3199976A1 (en) | 2020-11-06 | 2022-05-12 | Amgen Research (Munich) Gmbh | Polypeptide constructs selectively binding to cldn6 and cd3 |
| TW202225188A (en) | 2020-11-06 | 2022-07-01 | 德商安美基研究（慕尼黑）公司 | Polypeptide constructs binding to cd3 |
| WO2022103781A1 (en) | 2020-11-10 | 2022-05-19 | Amgen Inc. | Methods for administering a bcma x cd3 binding molecule |
| JP2023547947A (en) | 2020-11-11 | 2023-11-14 | ビオンテック・ソシエタス・エウロパエア | Monoclonal antibodies against programmed cell death-1 protein and their use in medicine |
| AR124267A1 (en) | 2020-12-09 | 2023-03-01 | Genentech Inc | HIGH THROUGH METHODS FOR PREPARING LIPID NANOPARTICLES AND THEIR USES |
| CN114685669A (en) | 2020-12-30 | 2022-07-01 | 和铂医药(苏州)有限公司 | Antibodies that bind TROP2 and uses thereof |
| US20220227844A1 (en) | 2021-01-15 | 2022-07-21 | The Rockefeller University | Neutralizing anti-sars-cov-2 antibodies |
| WO2022192176A1 (en) | 2021-03-09 | 2022-09-15 | Massachusetts Institute Of Technology | Branched poly(-amino esters) for the delivery of nucleic acids |
| JP2024510207A (en) | 2021-03-12 | 2024-03-06 | ブリストル－マイヤーズ スクイブ カンパニー | KRAS inhibitor |
| EP4305038A1 (en) | 2021-03-12 | 2024-01-17 | Bristol-Myers Squibb Company | Kras g12d inhibitors |
| KR20230160321A (en) | 2021-03-24 | 2023-11-23 | 브리스톨-마이어스 스큅 컴퍼니 | immunomodulator |
| AU2022253269A1 (en) | 2021-04-09 | 2023-11-23 | Celldex Therapeutics, Inc. | Antibodies against ilt4, bispecific anti-ilt4/pd-l1 antibody and uses thereof |
| WO2022221284A2 (en) | 2021-04-12 | 2022-10-20 | Bristol-Myers Squibb Company | Cyclic peptide immunomodulators |
| US20240207354A1 (en) | 2021-05-06 | 2024-06-27 | Amgen Inc. | Etelcalcetide formulations |
| CA3217180A1 (en) | 2021-05-06 | 2022-11-10 | Amgen Research (Munich) Gmbh | Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases |
| EP4334343A2 (en) | 2021-05-06 | 2024-03-13 | The Rockefeller University | Neutralizing anti-sars- cov-2 antibodies and methods of use thereof |
| KR20240017813A (en) | 2021-05-10 | 2024-02-08 | 이슘 리서치 디벨롭먼트 컴퍼니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. | Pharmaceutical composition for treating neurological diseases |
| EP4346882A1 (en) | 2021-05-26 | 2024-04-10 | Oxford BioTherapeutics Ltd | Pharmaceutical combination comprising an anti-cd205 antibody and an immune checkpoint inhibitor |
| TW202313065A (en) | 2021-05-28 | 2023-04-01 | 美商季卡尼醫療公司 | Compounds for treating genetic diseases |
| EP4351553A1 (en) | 2021-06-09 | 2024-04-17 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH | Novel anti-fibrotic drugs |
| KR20240019236A (en) | 2021-06-09 | 2024-02-14 | 브리스톨-마이어스 스큅 컴퍼니 | Cyclic peptide immunomodulator |
| IL308847A (en) | 2021-06-30 | 2024-01-01 | Amgen Inc | Method of reconstituting lyophilized formulation |
| KR20240034211A (en) | 2021-07-12 | 2024-03-13 | 브리스톨-마이어스 스큅 컴퍼니 | Macrocyclic immunomodulators |
| CN117940445A (en) | 2021-07-19 | 2024-04-26 | 百时美施贵宝公司 | Macrocyclic immunomodulators |
| AU2022316209A1 (en) | 2021-07-20 | 2024-02-22 | Regeneron Pharmaceuticals, Inc. | Butyrophilin-like 2 agents for treating inflammatory disorders |
| EP4384534A1 (en) | 2021-08-11 | 2024-06-19 | Sanofi Pasteur, Inc. | Truncated influenza neuraminidase and methods of using the same |
| CA3227716A1 (en) | 2021-08-20 | 2023-02-23 | Intervet International B.V. | Antibodies and igg fusion proteins with an extended half-life |
| AU2022331810A1 (en) | 2021-08-20 | 2024-02-29 | Intervet International B.V. | Fusion proteins for treating atopic dermatitis |
| US20230233667A1 (en) | 2021-09-08 | 2023-07-27 | Affinivax, Inc. | Coronavirus vaccine |
| CN113773401B (en) | 2021-09-15 | 2023-06-20 | 宜明昂科生物医药技术（上海）股份有限公司 | Recombinant fusion protein targeting CD47 and PD-L1 and preparation and application thereof |
| WO2023059857A1 (en) | 2021-10-08 | 2023-04-13 | Sanofi Pasteur Inc. | Multivalent influenza vaccines |
| CN113754769B (en) | 2021-10-13 | 2023-06-06 | 宜明昂科生物医药技术（上海）股份有限公司 | CD 70-targeting antibodies, their preparation and use |
| CN113831412B (en) | 2021-10-13 | 2023-06-20 | 宜明昂科生物医药技术（上海）股份有限公司 | Antibodies targeting CD24, their preparation and use |
| CN113956363B (en) | 2021-10-13 | 2023-03-31 | 宜明昂科生物医药技术（上海）股份有限公司 | Recombinant fusion protein targeting CD47 and CD24 and preparation and application thereof |
| AU2022364888A1 (en) | 2021-10-14 | 2024-05-30 | Latticon (Suzhou) Biopharmaceuticals Co., Ltd. | Novel antibody-cytokine fusion protein, preparation method therefor and use thereof |
| WO2023069994A1 (en) | 2021-10-20 | 2023-04-27 | Bristol-Myers Squibb Company | Immunomodulators |
| CA3233696A1 (en) | 2021-11-03 | 2023-05-11 | Joachim Koch | Bispecific cd16a binders |
| CA3237018A1 (en) | 2021-11-03 | 2023-05-11 | Joachim Koch | Bispecific cd16a binders |
| CA3237134A1 (en) | 2021-11-05 | 2023-05-11 | Timothy ALEFANTIS | Multivalent influenza vaccines comprising recombinant hemagglutinin and neuraminidase and methods of using the same |
| CA3237139A1 (en) | 2021-11-05 | 2023-05-11 | Sanofi | Hybrid multivalent influenza vaccines comprising hemagglutinin and neuraminidase and methods of using the same |
| WO2023077521A1 (en) | 2021-11-08 | 2023-05-11 | Celldex Therapeutics, Inc | Anti-ilt4 and anti-pd-1 bispecific constructs |
| WO2023089314A1 (en) | 2021-11-18 | 2023-05-25 | Oxford Biotherapeutics Limited | Pharmaceutical combinations |
| WO2023096904A2 (en) | 2021-11-24 | 2023-06-01 | President And Fellows Of Harvard College | C-16 modified trioxacarcins, antibody drug conjugates, and uses thereof |
| WO2023102507A1 (en) | 2021-12-03 | 2023-06-08 | Bristol-Myers Squibb Company | Macrocyclic immunomodulators |
| WO2023105281A1 (en) | 2021-12-11 | 2023-06-15 | Fundaciò Privada Institut De Recerca De La Sida-Caixa | Soluble tigit recombinant proteins |
| WO2023114884A2 (en) | 2021-12-15 | 2023-06-22 | Interius Biotherapeutics, Inc. | Pseudotyped viral particles, compositions comprising the same, and uses thereof |
| CA3239826A1 (en) | 2021-12-16 | 2023-06-22 | Mohamad Morsey | Caninized antibodies to canine interleukin-31 receptor alpha ii |
| AU2022409611A1 (en) | 2021-12-16 | 2024-07-04 | Intervet International B.V. | Caninized antibodies to human ngf |
| WO2023114889A1 (en) | 2021-12-16 | 2023-06-22 | Modernatx, Inc. | Processes for preparing lipid nanoparticles |
| CA3240585A1 (en) | 2021-12-17 | 2023-06-22 | Wenfeng Xu | Anti-ox40 antibodies, multispecific antibodies and methods of use |
| AU2022411573A1 (en) | 2021-12-17 | 2024-06-27 | Shanghai Henlius Biologics Co., Ltd. | Anti-ox40 antibodies and methods of use |
| AU2022426799A1 (en) | 2021-12-30 | 2024-06-20 | Curza Global, Llc | Antimicrobial compounds and methods |
| WO2023147399A1 (en) | 2022-01-27 | 2023-08-03 | The Rockefeller University | Broadly neutralizing anti-sars-cov-2 antibodies targeting the n-terminal domain of the spike protein and methods of use thereof |
| WO2023144206A1 (en) | 2022-01-27 | 2023-08-03 | Sanofi Pasteur | Modified vero cells and methods of using the same for virus production |
| WO2023166488A1 (en) | 2022-03-04 | 2023-09-07 | Revagenix, Inc. | Broad spectrum aminoglycosides and uses thereof |
| WO2023177577A1 (en) | 2022-03-14 | 2023-09-21 | Sanofi Pasteur Inc. | Machine-learning techniques in protein design for vaccine generation |
| WO2023175171A1 (en) | 2022-03-18 | 2023-09-21 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Bk polyomavirus antibodies and uses thereof |
| WO2023192873A1 (en) | 2022-03-28 | 2023-10-05 | Bristol-Myers Squibb Company | Macrocyclic immunomodulators |
| WO2023193002A1 (en) | 2022-04-01 | 2023-10-05 | Modernatx, Inc. | Cross mixers for lipid nanoparticle production, and methods of operating the same |
| EP4257132A1 (en) | 2022-04-08 | 2023-10-11 | iOmx Therapeutics AG | Sik3 inhibitors for treating diseases resistant to death receptor signalling |
| EP4257609A1 (en) | 2022-04-08 | 2023-10-11 | iOmx Therapeutics AG | Combination therapies based on pd-1 inhibitors and sik3 inhibitors |
| WO2023212559A1 (en) | 2022-04-26 | 2023-11-02 | Amgen Inc. | Lyophilization method |
| US11932693B2 (en) | 2022-05-12 | 2024-03-19 | BioNTech SE | Monoclonal antibodies directed against programmed death-1 protein and their use in medicine |
| WO2023218027A1 (en) | 2022-05-12 | 2023-11-16 | Amgen Research (Munich) Gmbh | Multichain multitargeting bispecific antigen-binding molecules of increased selectivity |
| GB202207263D0 (en) | 2022-05-18 | 2022-06-29 | Annexin Pharmaceuticals Ab | Therapeutic compositions |
| WO2023225661A1 (en) | 2022-05-20 | 2023-11-23 | Bristol-Myers Squibb Company | Macrocyclic immunomodulators |
| WO2023235380A1 (en) | 2022-06-01 | 2023-12-07 | Zikani Therapeutics, Inc. | Macrolides for treating genetic diseases |
| US20240067662A1 (en) | 2022-06-10 | 2024-02-29 | Bristol-Myers Squibb Company | Kras inhibitors |
| WO2023240189A1 (en) | 2022-06-10 | 2023-12-14 | Bristol-Myers Squibb Company | Tetrahydropyrido 3,4-d pyrimidine derivatives as kras inhibitors |
| WO2023250513A1 (en) | 2022-06-24 | 2023-12-28 | Zikani Therapeutics, Inc. | 13-membered macrolide compounds for treating diseases mediated by abnormal protein translation |
| WO2024026475A1 (en) | 2022-07-29 | 2024-02-01 | Modernatx, Inc. | Compositions for delivery to hematopoietic stem and progenitor cells (hspcs) and related uses |
| WO2024026487A1 (en) | 2022-07-29 | 2024-02-01 | Modernatx, Inc. | Lipid nanoparticle compositions comprising phospholipid derivatives and related uses |
| WO2024026482A1 (en) | 2022-07-29 | 2024-02-01 | Modernatx, Inc. | Lipid nanoparticle compositions comprising surface lipid derivatives and related uses |
| WO2024036270A1 (en) | 2022-08-11 | 2024-02-15 | Bristol-Myers Squibb Company | Kras inhibitors |
| US20240199584A1 (en) | 2022-08-16 | 2024-06-20 | Bristol-Myers Squibb Company | Kras inhibitors |
| WO2024049994A1 (en) | 2022-09-01 | 2024-03-07 | Zikani Therapeutics, Inc. | Treatment of familial adenomatous polyopsis using a 13-membered macrolide |
| WO2024054926A1 (en) | 2022-09-07 | 2024-03-14 | Bristol-Myers Squibb Company | Kras g12d inhibitors |
| WO2024059472A1 (en) | 2022-09-12 | 2024-03-21 | Bristol-Myers Squibb Company | Macrocyclic immunomodulators |
| WO2024059675A2 (en) | 2022-09-14 | 2024-03-21 | Amgen Inc. | Bispecific molecule stabilizing composition |
| WO2024091918A2 (en) | 2022-10-25 | 2024-05-02 | Modernatx, Inc. | Methods of lipid nanoparticle production in cross-mixers |
| WO2024115713A1 (en) | 2022-11-30 | 2024-06-06 | The Trustees Of The University Of Pennsylvania | Brisc deubiquitinating enzyme inhibitors |
| WO2024121380A1 (en) | 2022-12-08 | 2024-06-13 | Pierre Fabre Medicament | Vaccinal composition and adjuvant |
| GB202219154D0 (en) | 2022-12-19 | 2023-02-01 | Metacurum Biotech Ab | Antibodies and uses thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2737946A (en) * | 1949-09-01 | 1956-03-13 | Jr George N Hein | Hypodermic injection apparatus |
| US2764977A (en) * | 1951-05-24 | 1956-10-02 | Becton Dickinson Co | Hypodermic injection mechanism |
| US3115133A (en) * | 1962-05-15 | 1963-12-24 | Morando Emilio Donald | Needleless prefilled disposable hypodermic injector |
| US3403679A (en) * | 1964-12-11 | 1968-10-01 | Secr Defence Brit | Hypodermic injection apparatus with a secondary capsule-collapsing means |
| US3688765A (en) * | 1969-10-03 | 1972-09-05 | Jack S Gasaway | Hypodermic injection device |
| US3695266A (en) * | 1970-06-18 | 1972-10-03 | Maurice G Lussier | Needleless sequential dosing syringe |
| US3853125A (en) * | 1971-10-05 | 1974-12-10 | W Clark | Disposable needleless injector |
| US3802430A (en) * | 1972-06-30 | 1974-04-09 | L Arnold | Disposable pyrotechnically powered injector |
| US4089334A (en) * | 1976-10-07 | 1978-05-16 | Schwebel Paul R | Pyrotechnically powered needleless injector |
| US4329988A (en) * | 1980-12-23 | 1982-05-18 | Survival Technology, Inc. | Plural injection assembly |
| US4403989A (en) * | 1981-09-14 | 1983-09-13 | Syntex (U.S.A.) Inc. | Injection device |
-
1985
- 1985-03-25 US US06/715,930 patent/US4596556A/en not_active Expired - Fee Related
-
1986
- 1986-01-23 CA CA000500154A patent/CA1232807A/en not_active Expired
- 1986-01-23 EP EP86300442A patent/EP0197625A1/en not_active Withdrawn
- 1986-03-11 JP JP61051627A patent/JPS61268265A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US4596556A (en) | 1986-06-24 |
| EP0197625A1 (en) | 1986-10-15 |
| CA1232807A (en) | 1988-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS61268265A (en) | Syringe apparatus | |
| US9737670B2 (en) | Intradermal injector | |
| US7744582B2 (en) | Needle assisted jet injector | |
| US6530903B2 (en) | Safety syringe | |
| JP4755547B2 (en) | Wet / dry automatic injection device | |
| EP0802809B1 (en) | Medical injection system comprising a gas spring | |
| EP1833532B1 (en) | Safety syringe | |
| USRE35986E (en) | Multiple chamber automatic injector | |
| JP4917538B2 (en) | Disposable pneumatic safety syringe with retractable needle | |
| DK169309B1 (en) | Automatic injection device | |
| US5697917A (en) | Nozzle assembly with adjustable plunger travel gap | |
| WO1994009839A1 (en) | Automatic two-chamber injector | |
| WO1997031664A1 (en) | Frangible plunger for nozzle assembly | |
| NZ556682A (en) | Safety syringe |